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Mucosal delivery of recombinant adenovirus serotype 5 (rAd5)-based vaccine 
preparations are appealing for vaccine development in terms of lowering toxicity induced 
by high viral loads and substantial liver accumulation following systemic injection of the 
vaccine.  However, this mode of delivery is currently under-developed due to the 
relatively low T-cell mediated immune responses generated against the encoded 
transgene.  The first study described in this thesis demonstrated that sublingual 
immunization induces rapid migration of MHCII+, CD11C+ antigen presenting cells to 
the delivery site and elicit antigen-specific T and B cell-mediated immune responses in 
naïve mice and those with pre-existing immunity (PEI) to Ad5 at a level higher than that 
achieved after oral immunization.  More importantly, this strategy improved protection of 
animals with PEI to Ad in contrast to poor protection after IM injection.  The second 
study was designed to establish a method for inducing PEI that most accurately reflects 
natural infection in rodents and identifies the immunologic parameters elicited by rAd5-
based Ebola vaccine necessary for protection against lethal infection.  When 
immunization occurred by the same route in which PEI was induced, the antigen-specific 
 vii 
multifunctional CD8+ T cell and antibody responses were significantly reduced.  This 
correlated with poor survival after challenge with a lethal dose of Ebola Zaire in rodents.  
The data suggests that 1) establishment of PEI by the same route used for immunization 
is the most stringent test for a novel formulation designed to be effective in those with 
PEI to Ad5, and 2) for a formulation to be effective in those with PEI, it must be capable 
of restoring antigen-specific multifunctional CD8+ T cell and antibody responses, 
compromised by PEI.  The third study screened novel formulations for their ability to 
improve in vitro transduction efficiency and immunogenicity and efficacy in vivo in the 
presence of anti-Ad5 neutralizing antibodies. Formulations consisting of 
pharmaceutically acceptable, non-immunogenic excipients that can prime the arms of 
immune response compromised by PEI improved survival after lethal challenge with 
Ebola Zaire challenge for rAd5-based Ebola vaccine in rodents with PEI.  Taken 
together, these studies provide insight on how to reconstitute necessary immune 
responses in vaccine protocols by establishing a reliable PEI model in rodents, testing 
routes of administration, and formulations of the rAd5-based Ebola vaccine.
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 1 
CHAPTER ONE 
INTRODUCTION  
1.1 Ebola Virus Infection and Therapeutics/Vaccine Development 
Ebola virus (EBOV) is a highly virulent pathogen causing severe hemorrhagic 
fever with a high case fatality rate in humans, non-human primates (NHPs) and rodent 
models of infection.  An increase in unpredictable, lethal outbreaks, documented 
accidental laboratory exposures and the possible use of Ebola as a bioweapon emphasize 
the need for effective therapeutics and vaccines against this pathogen.  Recently, two 
Investigational New Drug (IND) allowances from the FDA have approved phase I 
clinical trials in terms of EBOV therapeutics, 1) anti-sense phosphorodiamidate morphino 
oligomers (PMOs: AVI-6002, AVI-6003, Sarepta Therapeutics), and 2) lipid-
nanoparticle/small interfering RNA (TKM-Ebola, LNP/siRNA, Tekmira 
Pharmaceuticals).  Unfortunately, these candidates require multiple doses to achieve 
therapeutic efficacy, which is not ideal with regard to patient compliance and outbreak 
scenarios. Recombinant adenovirus (rAd)-based vectors have been identified as a potent 
vaccine candidate by affording both pre- and post-exposure protection against the various 
isolates of EBOV.  However, prevalent pre-existing immunity (PEI) in general 
populations is the major barrier that limits immunogenicity and clinical utility of the 
vaccine.  These concerns have fueled a quest for even better treatment or vaccination 
strategies.  Here, we summarize 1) recent advances in post-exposure therapeutics and 
vaccines and emerging trends for prevention of lethal EBOV-mediated hemorrhagic 
fever, 2) the biology of adenovirus, factors limiting the utility of rAd-based vector and 
strategies to overcome the limitations for successful rAd5-based vaccine development.  
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1.1.1 Biology of Ebola virus  
Ebola virus (EBOV) is a filamentous, negative-stranded RNA virus of the Filoviridae 
family that causes a severe, often fatal viral hemorrhagic fever in humans and non-human 
primates (NHPs) [1].  The single-stranded, negative sense 18.9 kb RNA genome encodes 
seven structural proteins and two non-structural proteins as shown in Figure 1.1A.  The 
central core of the virion is composed of the ribonucleoprotein (RNP) complex, which 
consists of the genomic RNA molecule encapsulated by the nucleoprotein (NP) linked to 
the inner matrix proteins virion protein (VP) 30 and VP35 and the RNA-dependent RNA 
polymerase (L; Figure 1.1B).  This complex is involved in transcription and virus 
replication [2-4].  Matrix proteins VP40 and VP24 are linked to the RNP complex at the 
inner surface of the lipid bilayer of the viral envelope, and are also involved in viral 
nucleocapsid formation, viral budding, assembly, and host range determination [5-10].  
Ebola glycoproteins are disposed throughout the viral envelope derived from the host 
cells.  These proteins are organized as trimeric spikes, consisting of two fragments 
(extracellular protein, GP1, and membrane-anchored protein, GP2) linked by disulfide 
bonds [4, 11-13].  GP binds preferentially to endothelial and monocytic cells via GP1.  
This process has been shown to disrupt endothelial cells and cause EBOV pathogenesis 
by a 17 amino acid domain in GP that resembles an immunosuppressive motif in 
retroviral envelope proteins [14-20]. The non-structural sGP is generated from non-edited 
GP mRNA at the C-termini through proteolysis by furin and is released from cells in 
large quantity early in infection [21, 22].  Δ-peptide is also generated from the same 
mRNA species proteolytically processed by a signalase at the N-termini [23].  sGP shares 
neutralizing epitopes with the envelope trimer spike GP [24].  This would suggest that 
sGP may be a decoy produced by the virus to bind circulating neutralizing antibodies 
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(NABs) and may explain why passive transfer of human anti-Ebola monoclonal 
neutralizing antibodies to non-human primates has failed to protect animals against lethal 
infection [25, 26]. 
Ebola infection in humans generally occurs through direct contact with mucosal 
surfaces, skin abrasions or contaminated needles [27].  Peripheral antigen presenting cells 
(APCs) such as macrophages and dendritic cells (DCs) are major targets of EBOV 
infection, which serve as carriers for virus dissemination and systemic infection including 
secondary lymphoid organs, liver, endothelial cells, fibroblasts and epithelial cells [28-
31].  EBOV infection of monocytes and macrophages induces massive production of pro-
inflammatory cytokines and chemokines including interleukin (IL)-1β, 2, 6, 8 and 10; 
tumor necrosis factor (TNF)-α; monocyte chemo-attractant protein (MCP)-1; regulated 
on activation normal T cell expressed and secreted (RANTES); reactive and nitrogen 
oxygen species (ROS and NO, respectively) [29, 32-34].  This cytokine storm contributes 
to the pathogenesis at the late stage of disease by recruiting APCs towards infected 
tissues, inducing coagulopathy while increasing endothelial permeability and vascular 
leakage (TNF-α, NO, Figure 1.2).  In addition, the anti-viral interferon type I response is 
blocked by VP24 and 35 which prevent nuclear accumulation of signal transducer and 
activator 1 (STAT1) and impede the activity of interferon regulatory factor (IRF)-3 and 7. 
[35, 36]  Also, VP24 inhibit the type I IFN response by blocking p38 MAP kinase 
pathway in a JAK-STAT pathway independent manner and VP35 interfere activation of 
dsRNA dependent protein kinase [37].  Even if the immune system was functioning at an 
optimal level during infection, EBOV prevents up-regulation of major histocompatibility 
complex (MHC) molecules and antigen presentation to T cells despite entering immature 
DCs through typical C-type lectins (DC-SIGN) or other surface receptors [38, 39].    
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Figure 1.1. The Ebola Virus. A. Schematic Representation of the Zaire EBOV 
(ZEBOV) Genome. B. Configuration of the ZEBOV Particle.  The non-segmented 
negative-stranded RNA genome contains seven structural proteins (NP, VP24, VP30, 
VP35, VP40, L, GP) and two non-structural proteins (soluble GP: sGP, small sGP: 
ssGP).  The central core of EBOV is composed of RNP complex in association of 
genomic RNA with NP, VP30, VP35 and L protein.  The rod-shaped virus is 80 nm in 
diameter.  The number and length of the genomes incorporated into a single virus capsid 
during replication and assembly dictates the length of the virion, ranging from 1,028 to 
1,978 nm. (Adapted from Swiss Institute of Bioinformatics)  
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Figure 1.2 Ebola virus pathogenesis	  	  Virus spreads from the initial infection site (small 
lesions) to regional lymph nodes, liver, and spleen, endothelial cells, fibroblasts and 
epithelial cells.  EBOV infects a variety of cell types including macrophages and myeloid 
dendritic cells and substantial loss of lymphocyte apoptosis with the aid of soluble factors 
released from monocytes and macrophages [1-3]. The systemic virus spread and 
replication, the general dysregulation of the host immune response, the coagulation 
abnormalities, the impairment of the vascular system, and hypotension all together finally 
result in shock and multi-organ failure.  (Adapted from Feldmann H., and Geisbert T.W., 
[40]).  
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Over the last 35 years, numerous Ebola outbreaks have been recorded.  The 
EBOV was first identified during simultaneous outbreaks in 1976 by two species, Zaire 
(EBOV) and Sudan (SUDV), with high case fatality rates (EBOV: 60~90%, SUDV: 
40~60%).  Since then, additional species have been isolated: Reston (RESTV) [41], Tai 
Forest (TAFV) [42] and Bundigbugyo (BDBV) [43].  RESTV, discovered in 1989 in 
cynomolgus macaques imported into the US from the Philippines, is the only strain that 
has not been associated with human disease [41, 44-47].  Although they have been 
limited to parts of Central Africa, the number of outbreaks and associated fatalities have 
slowly increased overtime.  This coupled with documented reports that Ebola can be 
transmitted via the aerosol route in non-human primates have raised significant concerns 
over its possible use as a biological weapon [40, 48, 49], makes the virus a NIAID 
Category A Priority Pathogen and restricts experiments using all Ebola species to 
biosafety level (BSL)-4 containment laboratories  
(http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx).  There is 
generally a 2~21 day incubation period before symptoms of EBOV-induced hemorrhagic 
fever are noted.  They initially manifest as non-specific flu-like symptoms (malaise, 
chills, fever) and rapidly progress to severe nausea, diarrhea, shortness of breath, 
hypotension, bleeding and coma [50].  Vascular injury due to endothelial cell damage, 
hepatocyte necrosis caused by virus replication, coagulation disorders and uncontrolled 
cytokine/chemokine secretion by infected monocytes and macrophages contribute to 
EBOV-induced hemorrhagic shock and eventual death of the patient [51-53].  Although, 
EBOV is the focus of many research programs around the world, effective vaccines or 
therapeutic regiments to combat this deadly pathogen are currently unavailable for human 
use despite the fact that novel cutting edge interdisciplinary approaches have accelerated 
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identification of therapeutic targets and promising molecular candidates currently in pre-
clinical testing. 
1.2 Development of antivirals as novel targets for treatments 
Despite the fact that EBOV has been identified as the cause of many lethal 
outbreaks of hemorrhagic fever for more than three decades, current treatment options for 
infected individuals are limited.  Crude approaches like administration of convalescent 
serum from infected survivors [54] or equine anti-Ebola immunoglobulin with interferon 
[55] have been successfully used to reduce the severity of infection in laboratory settings.  
Even though each person that received these preparations survived, the mechanism for 
protection is not clear since the composition of each product was complex and one 
specific component could not reproducibly be linked to survival.  For example, it was 
initially thought that anti-Ebola IgG was responsible for protection of 8 patients with 
EBOV HF who survived after they were given whole blood know to contain anti-EBOV 
IgG [56].  Although this association seemed logical and straightforward, it has not been 
successfully reproduced in a controlled laboratory setting.  In a study conducted by 
Jahrling et al., naïve rhesus macaques given convalescent-phase whole blood from 3 
macaques that survived ZEBOV infection developed notable serum anti-EBOV IgG 
antibody titers [57].  This, however, was not sufficient to control virus replication and 
disease in these animals progressed in a manner similar to that seen in untreated 
macaques.  The efficacy of passive transfer of immunity to EBOV infection using a 
highly characterized human monoclonal anti-Ebola neutralizing antibody (KZ52) has 
been evaluated in GP and NHPs (Table 1.2) [25].  Even though this antibody had 
reported IC50 of 0.5~2 μg/ml in in vitro and in vivo systems, administration of a dose of 
25 mg/kg 1 hour after ZEBOV challenge conferred only partial protection (9 of 15) in 
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guinea pigs and failed to control virus replication and protect NHPs even when the dose 
was increased to 50 mg/kg. More recently, it was found that several doses of a species-
matched polycolonal anti-Ebola GP antibody given after exposure to ZEBOV could 
effectively protect NHP from lethal infection.  Additional detailed molecular studies 
revealed that monoclonal neutralizing antibodies interact with Ebola GP at different sites 
of the protein and during different stages of infection and that polyclonal antibodies or 
combinations of monoclonal isolates are most effective in pre- and post- challenge 
scenarios in vivo [58-61].  Once it was clear that direct transfer of immunity from 
infected survivors was an unreliable approach to combat Ebola infection, large multi-
center collaborative projects were developed to screen libraries of well characterized and 
novel compounds to identify cellular proteins responsible for virus entry as well as small 
molecules that could effectively prevent virus replication, stimulate the immune response 
and treat symptoms of infection.  Compounds that have currently been evaluated in 
rodents and NHPs are summarized in Table 1.1 and 1.2, respectively. 
1.2.1 Small molecule inhibitors of virus entry and endosomal escape 
Virus entry is an essential step in the virus life cycle and is often an attractive 
target for therapy since inhibition of this process blocks replication at an early stage, 
significantly reducing the chance for the virus to evolve and develop drug resistance. 
High-throughput cell-based screening (HTS) assays performed in tandem with 
recombinant Ebola expressing green fluorescent protein or recombinant pseudotyped 
viruses coated with EBOV GP that do not require high-level containment have been used 
to identify many proteins that enhance filovirus entry [58]. This approach in combination  
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Table 1.1. Summary of anti-viral compounds tested in rodents 
 
 
    Therapeutic targets 
Prophylactic 
efficacy  Therapeutic efficacy Concerns References 
FGI-103, 104 and 
106 Unknown 
Yes 
FGI-106: 2 ~ 
5 mg/kg BW* 
(single dose) 
Yes 
FGI-103: 10 mg/kg BW*, 
(single dose) 
FGI-104: 10 mg/kg BW*/day 
(11 times), 
FGI-106: 5 mg/kg BW*  
(3 times) 
Multiple dose 
required [62-64] 
NSC62914 
Reactive 
oxygen species 
(ROS) 
Partial 
protection 
2 mg/kg BW* 
(3 times)  
Partial protection 
2 ~ 5 mg/kg BW* (3 times) 
Multiple dose 
required [65] 
Small interfering 
RNAs (siRNA) 
L polymerase + 
VP24 + VP35  Not tested 
Yes 
0.75 ~ 1 mg/kg BW*  
(7 times) 
Multiple dose 
required [66] 
Phosphorodiamid
ate morphino 
oligo nucleotides 
(PMOs) 
VP24+VP35; L 
polymerase + 
VP24 + VP35 
Yes 
5-50 µg  
(twice) 
Yes 
12.5 ~ 100 mg 
 (11 times) 
Multiple dose 
required [67, 68] 
Monoclonal 
neutralizing 
Antibodies 
(NABs) 
Ebola Virion 
(KZ52) Not tested 
Yes 
50 mg/kg BW* 
(single dose) 
Multiple dose 
required [26] 
Triple 
monoclonal 
antibody cocktail 
Ebola GP 
Yes 
100 µg  
(single dose) 
Yes 
100 µg  
(single dose) 
must be used 
early 
before/after 
exposure. 
[60] 
S-adenosyl-L-
homocysteine 
hydrolase 
inhibitors 
S-adenosyl-L-
homocysteine 
hydrolase 
Yes 
Ca-C3Ado: 80 
mg/kg BW*, 
(single dose) 
C-NpcA: 1 
mg/kg BW* 
(single dose) 
Yes 
Ca-C3Ado: 80 mg/kg BW*, 
(3 times) 
C-NpcA: 1 mg/kg BW* 
(3 times) 
Manipulation 
of host immune 
system 
[69, 70] 
*: BW: body weight 
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Table 1.2. Summary of anti-viral compounds tested in NHPs 
 
 
    Therapeutic targets 
Prophylactic 
efficacy  Therapeutic efficacy Concerns References 
Recombinant 
human activated 
protein C 
(rhAPC) 
Abnormal 
coagulation Not tested 
Partial protection 
2 mg/m2/h (i.v. 
infusion) until day 7 
post-exposure 
Low efficacy, 
manipulation of 
coagulant pathway 
[71] 
Recombinant 
nematode 
anticoagulant 
protein C2 
(rNAPC2) 
Factor VIIa: 
tissue factor 
complex 
Not tested 
Partial protection 
30 µg/kg BW*/day 
until day 14 post-
exposure 
Low efficacy, 
manipulation of 
coagulant pathway 
[72] 
Small interfering 
RNAs (siRNA) 
L polymerase + 
VP24 + VP35  Not tested 
Yes 
2 mg/kg BW* 
 (7 times) 
Multiple dose 
required [73] 
Phosphorodiamid
ate morphino 
oligo nucleotides 
(PMOs) 
VP24+VP35; L 
polymerase + 
VP24 + VP35 
Not tested 
Yes 
12.5 ~ 200 mg 
 (11 times) 
Multiple dose 
required [68] 
Monoclonal 
neutralizing 
Antibodies 
(NABs) 
Ebola Virion 
(KZ52) No No No efficacy [25, 26] 
Triple 
monoclonal 
antibody cocktail 
Ebola GP Not tested 
Full protection 24H, 
Partial Protection 
48H, 
25 mg/kg BW*×  
3 doses 
Multiple doses 
required, must be 
used early after 
exposure.  
[59] 
*: BW: body weight 
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with structural analysis of EBOV GP, has successfully identified novel small molecules 
that may be useful therapeutics for EBOV hemorrhagic fever.  A benzodiazepine 
derivative (compound 7) was identified from HTS of small-molecule compound libraries 
utilizing the pseudotyped Ebola viruses (HIV/EBOV-GP) [74].  Computational crystal 
structure analysis of EBOV GP was used to illustrate that compound 7, could fit within 
the hydrophobic pocket between the GP1 and GP2 subunits and interfere with virus entry 
at the early stage of EBOV infection (Figure 1.4A) [74].  This compound is now under 
further development for testing in several in vivo models of infection.  
Ebola must also closely interact with multiple host proteins for endosomal escape, 
replication, assembly, budding and release processes.  HTS approaches have identified a 
compound derived from benzylpiperazine adamantane diamide(2-((3r,5r,7r)-adamantan-
1-yl)-N-(2-(4-benzylpiperazin-1-yl)-2-oxoethyl)acetamide), known as compound 3.47, 
that binds to Niemann-Pick C1 (NPC1), an endo/lysosomal cholesterol transporter 
protein that is responsible for lipid storage, mediates NPC disease, and inhibits EBOV 
infection in vitro [75].  In a similar manner, efforts to characterize EBOV-host protein 
interactions identified two novel molecules: EBOV Δ-peptide conjugated to the Fc region 
of a human IgG1 antibody and the endosome targeting C-peptide derived from native C-
terminal heptad repeat regions of EBOV GP2 conjugated to the arginine rich sequence of 
HIV-1 Tat as promising candidates to prevent virus release from the endosome (Figure 
1.4A) [76].  In a somewhat opposing manner, Spargers and colleagues identified several 
host proteins (HSPA-5, RPL18) by liquid chromatography-linked tandem mass 
spectrometry that were key in Ebola replication and confirmed their findings by using 
small interfering RNA sequences (siRNA) to target host protein expression [77].  These 
sequences as well as the other compounds mentioned here are currently under evaluation 
in animal models of infection. 
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Cellular protease inhibitors have also been considered as potential anti-viral 
compounds for EBOV hemorrhagic fevers.  This strategy is based upon the fact that 
EBOV GP is processed by endosomal cysteine proteases; Cathepsin, CatB and CatL [78-
80].  Addition of cysteine protease inhibitors E64 and CA074 in culture media effectively 
blocked cellular cathepsins and suppressed EBOV replication and virus-induced 
cytopathic effects in vitro [78].  These compounds demonstrated anti-viral activity 
against many other viruses (Marburg, Rift Valley fever, Lassa, VEE) in vitro and 
protected mice from challenge with mouse-adapted EBOV when given as prophylaxis 
(80%) or post-exposure (50%) therapy. 
 
1.2.2 Compounds that block virus replication 
For many viruses, the RNA-dependent RNA polymerase has traditionally been a 
logical target to block transcription or replication and limit virus infection (Figure 1.3B).  
In this regards, ribavirin, a common anti-viral drug that destroy infectivity of many RNA 
viruses including influenza, poliovirus and filoviruses by exerting mutation frequencies 
in the RNA genome called “error catastrophe” and has been used to treat viral 
hemorrhagic fever [79, 81].  Despite its success in treating HF, ribavirin did not control 
EBOV replication and failed to protect animals from lethal challenge upon EBOV 
infection.  An alternative to this approach is to block virus transcription and/or replication 
with antisense oligonucleotides complementary to sequences in the EBOV genome or 
within the polymerase complex (Figure 1.3B) [66, 73].  Geisbert and colleagues have 
identified siRNAs that specifically bind to sequences within the EBOV polymerase L 
(EK-1), VP24 (VP-24-1160) and VP35 (VP-35-855) regions [73].  When these 
compounds were combined and formulated as stable nucleic acid-lipid particles  
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Figure 1.3 Common targets of small molecules for treatment of Ebola infection.  A. 
Cellular entry and endosomal escape.  Early attempts to mitigate the progress of Ebola 
infection involved administration of serum collected from convalescent survivors 
(humans and primates) and monoclonal antibodies specific for Ebola glycoprotein to 
prevent virus entry into cellular targets.  HTS have identified several compounds that are 
effective in preventing endosomal escape of the virus particle.  Development of silencing 
technologies that make these proteins inaccessible to prevent release of virus particles 
from the endosome.  B. Virus replication. Compounds that have demonstrated efficacy 
in stopping Ebola replication target the replication complex (VP35 and the L polymerase) 
as well as VP 40 and 24, which play a role in cellular transport and virus budding. 
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(SNALPs) and given to NHPs in 4 separate doses of 2 mg/kg each intravenously, 66% of 
the population survived lethal challenge with EBOV.  A 7 dose regimen effectively 
halted virus replication with a moderate increase in serum aspartate aminotransferase 
levels noted.  All animals given this regimen survived challenge [73]. 
In a similar approach, c-Abl1 and related tyrosine kinases, known to affect 
replication of certain DNA viruses and bacteria, were evaluated for their role in EBOV 
replication.  A series of silencing studies revealed that c-Abl1 phosphorylates the VP40 
protein, which is necessary for transport of the nucleocapsid complex to the cell 
membrane and release of complete virions from the cell [82].  Blocking this process with 
compounds have been approved for the treatment of leukemia in humans such as imatinib 
(known as Gleevec) and nilotinib (known as Tasigna) that target this enzyme 
significantly limited the amount of infectious virions released in culture medium [82].  
Use of compounds that target host gene products rather than the virus itself in larger 
models of EBOV infection may identify an approach that will prevent the development of 
escape mutants that are drug-resistant over time. 
Another therapeutic platform designed to prevent EBOV replication is a synthetic 
antisense oligonucleotide analog that is designed to interfere with translational processes 
by forming base-pair duplexes with specific RNA sequences [67, 68, 83, 84].  
Administration of positively charged EBOV-specific PMOs (AVI-6002) targeting mRNA 
sequences within the VP24 and VP35 regions 30-60 minutes after EBOV infection 
suppressed virus replication and subsequent inflammatory responses and fully protected 5 
of 8 macaques [84].  Post-exposure administration of Marburg virus-specific PMOs 
(AVI-6003) targeting MARV VP24, 35 and L protein also fully protected NHPs from 
lethal challenge [84].  Although these results clearly represent major advancements in the 
development of small molecule therapeutics for filovirus hemorrhagic fever, additional 
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studies must be performed to accurately define the timeframes within which they offer 
post-exposure protection before they can be considered for use in post-exposure 
therapeutic regimens. 
High throughput screening systems have also aided in identifying three small 
molecule inhibitors of EBOV infection: FGI-103 [64], FGI-104 [63] and FGI-106 (Table 
1.1) [62].  These compounds have provided 80~100% protection in mice challenged with 
EBOV.  Although the mechanisms of anti-viral activity of FGI-103 and FGI-104 are not 
completely understood [63, 64], the broad activity of FGI-106 against Ebola, Marburg, 
Rift Valley fever, Dengue, HIV and hepatitis C viruses suggests that this compound 
targets a host cellular pathway that is involved in and common to the replication of many 
different viruses [62]. 
 
1.2.3 Compounds to treat the symptoms of hemorrhagic fevers: Inflammatory 
modulators  
To date, non-adapted strains of EBOV have been found to only induce 
hemorrhagic fevers in humans and non-human primates [85, 86].  Although this species-
specific restriction has been problematic since adapted strains are required for modeling 
disease in rodents [87], they have been pivotal in identifying ways to augment the 
immune response and block virus replication.  For example, severe combined 
immunodeficient (SCID), IFN-α/β receptor knockouts and immune-competent mice 
treated with anti-mouse IFN-α/β antibodies succumb to non-adapted (wild-type) EBOV 
infection [88].  In a separate series of studies, treatment with s-adenosyl-homocysteine 
(SAH) hydrolase inhibitors, 3-deazaadenosine (c3-NpcA) [70] and carbocyclic 3-
dezaadenosine (C-c3Ado) [69], which inhibit replication of a variety DNA and RNA 
viruses, fully protected immune-competent mice during lethal infection with mouse-
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adapted-EBOV.  Further investigation revealed that the protective effect could be 
completely ablated by co-administration of SAH hydrolase inhibitors and anti-mouse 
IFN-α/β antibody [88].  Although these results strongly suggest that resistance and/or 
susceptibility to wild type ZEBOV infection is mediated by the type I IFN response, re-
invigoration of the anti-viral response in this manner has not been effective in rhesus 
macaques [89], baboons [90] and African green monkeys [91].  This might be improved 
by using species-specific interferons.  Further evaluation of this approach has yet to be 
performed. 
In a recent effort to identify novel therapeutics to treat and mitigate the 
pathological symptoms associated with filovirus hemorrhagic fevers, compound 
NSC62914, an antioxidant that acts as a scavenger of reactive oxygen species (ROS) was 
found to inhibit replication of EBOV, Marburg, Lassa and Rift Valley Fever viruses in 
vitro [65].  Although the role of ROS in the pathogenesis of filovirus infection is yet to be 
determined, this compound protected mice from lethal challenge with EBOV.  This was 
significant, given that other known antioxidants have had no impact on EBOV infection.  
It also suggests that NSC62914 and other compounds with antioxidant properties may 
preserve other cell signaling pathways common to many viruses that are arrested during 
EBOV infection. 
 
1.2.4 Compounds to treat the symptoms of hemorrhagic fevers: Coagulation 
modulators  
 Overproduction of pro-coagulant tissue factors during Ebola infection facilitate 
coagulation disorders that progress to multi-organ failure, often indicated by decreased 
serum protein C in the circulation [72].  One promising approach is to alter coagulation 
through the tissue factor pathway by administering a factor VIIa/tissue factor inhibitor 
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(recombinant nematode anticoagulant protein c2: rNAPc2) [92] or by activating the 
natural anticoagulant protein C pathway with recombinant activated protein C (rhAPC) 
[71].  Although, these compounds significantly decreased production of pro-
inflammatory cytokines and extended the mean time to death with respect to non-treated 
controls, they have not markedly improved survival.  
 
1.3 Ebola virus proteins as targets for vaccines 
The first Ebola vaccine consisted of whole virions inactivated by heat, formalin 
and gamma-irradiation.  This preparation was largely ineffective in NHPs [81, 93-95].  
Since then, over-expression of genes that encode EBOV proteins has been the primary 
approach to vaccine development.  The rationale behind this approach was to induce the 
body to produce enough protein sufficient to elicit potent anti-viral T and B cell 
responses that would confer protection against EBOV (Figure 1.4).  Recent studies 
suggest that induction of a B cell-mediated immune response alone is not sufficient for 
protection, but should be combined with sufficient activation of antigen-specific CD8+ T 
cell responses [96-99].  Because Ebola GP was known to play a key role in virus entry 
and facilitate cell death and vascular permeability in the latter stages of infection, most of 
the early recombinant vaccine platforms centered around overexpression of GP alone or 
in combination with NP and other VPs. A variety of viral and non-viral vectors were used 
to deliver genes for these antigens and encourage strong B and T cell mediated immune 
responses (Table 1.3 & 1.4)  
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Figure 1.4 Generalized approach to Ebola vaccine development.   Current vaccine 
platforms under development for clinical testing involve overexpression of Ebola 
glycoprotein and/or nucleoprotein.  This is accomplished through administration of 
replication deficient recombinant adenoviruses or plasmid vectors (Panel A) that 
transduce various cellular targets to make large amounts of the Ebola antigens that enter 
the circulation (Panel B).  Other platforms use attenuated recombinant viruses, such as 
VSV or HPIV3, that contain Ebola glycoprotein on the surface, and can replicate in 
cellular targets (Panel B).  These particles, like the glycoprotein and nucleoprotein made 
from cells transduced with adenovirus or plasmid, are taken up and processed by 
macrophages and dendritic cells (Panel C) to generate strong anti-viral immunity to 
EBOV (Panel D). 
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Table 1.3 Ebola vaccine platforms currently tested in rodents 
 
Platform Targets in vaccine 
Prophylactic 
efficacy  
Therapeutic 
efficacy Concerns References 
Recombinant 
adenovirus serotype 
5 (rAd5) 
GP, GP+NP 
Yes 
1 × 104 IFU* ~ 5 × 
1010 VP 
Yes 
5 × 107 IFU* 
Pre-existing 
immunity [100-104] 
DNA vaccines GP, NP Yes 5 – 25 µg (3 times) Not tested 
Multiple dose 
required [105, 106] 
DNA/rAd5 
(Prime/Boost) GP+NP 
Yes 
DNA: 100 µg (3 
times)/ 
rAd5: 1 × 108 PFU 
Not tested 
Boost 
immunization 
required, pre-
existing 
immunity 
[107, 108] 
Vesicular stomatitis 
virus (VSV) GP 
Yes 
2 × 104 PFU 
Yes 
2 × 105 PFU 
Safety 
(replication 
competent) 
[109-111] 
Human 
parainfluenza virus 
type 3 (HPIV-3) 
GP, GP+NP Yes 2 × 105 ~ 4 × 106 PFU Not tested 
Safety 
(Replication 
competent) 
[112, 113] 
Venezuelan Equine 
Encephalitis virus 
(VEE) replicon 
GP Yes 1 × 106 FFU Not tested 
Boost 
immunization 
required 
[114] 
Virus-like particles 
(VLPs) 
GP+NP+VP
40 
Yes 
10 µg  
(3 times) 
Not tested 
Boost 
immunization 
required 
[115] 
Replication-
deficient ZEBOV 
Whole 
virion 
Yes 
1 × 106 ~ 1× 107 FFU 
(twice) 
Not tested 
Safety, boost 
immunization 
required 
[116] 
 
*: Ratio between infectious unit and total virus particle used in this study was 1:200; IFU: 
infectious unit; VP: total number of virus particles; PFU: plaque forming units; PU: 
particle units; TCID50: 50% tissue culture infective dose; FFU: focus forming units; 
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Table 1.4 Ebola vaccine platforms currently tested in non-human primates 
 
Platform Targets in vaccine 
Prophylactic 
efficacy  
Therapeutic 
efficacy Concerns References 
Recombinant 
adenovirus serotype 
5 (rAd5) 
GP, GP+NP Yes, 1 ×1010 ~ 2 × 1012 VP Not tested 
Pre-existing 
immunity [98, 107] 
DNA/rAd5 
(Prime/Boost) GP+NP 
Yes 
DNA: 4 mg  
(3 times)/ 
rAd5: 1 × 1010 PFU,  
    1 × 1010 PU 
Not tested 
Boost 
immunization 
required, pre-
existing 
immunity 
[107, 108] 
Vesicular stomatitis 
virus (VSV) GP 
Yes 
1 × 107 PFU 
Yes 
2 × 107 PFU 
Safety 
(replication 
competent) 
[109, 118-
122] 
Human 
parainfluenza virus 
type 3 (HPIV-3) 
GP, GP+NP 
Yes 
4 × 106 TCID50 
(single dose), 
2 × 106 TCID50 
(Prime/boost) 
Not tested 
Boost 
immunization 
required, Safety 
(Replication 
competent) 
[123] 
Venezuelan Equine 
Encephalitis virus 
(VEE) replicon 
GP Yes 1 × 107 FFU Not tested 
Boost 
immunization 
required 
[114] 
Virus-like particles 
(VLPs) 
GP+NP+VP
40 
Yes 
250 µg  
(3 times) 
Not tested 
Boost 
immunization 
required 
[124] 
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1.3.1. Recombinant adenovirus and plasmid DNA-based vaccines   
The first vaccine platform that successfully protected NHPs from lethal EBOV 
challenge was a recombinant adenovirus serotype 5 (rAd5) vector expressing EBOV GP 
[108].  A single intramuscular (IM) injection of adenovirus after 3 consecutive priming 
doses of plasmid DNA encoding EBOV GP and NP, SUDV GP and Tai Forest GP fully 
protected primates against EBOV challenge [108]. This combinatorial approach, DNA 
prime/rAd5 boost, greatly improved circulating anti-GP antibody levels and generated 
notable antigen-specific CD4+ and CD8+ T cell proliferative responses in cynomolgus 
macaques [108].  The high level of transgene expression and the inherent adjuvant 
properties of the adenovirus capsid were fully appreciated in subsequent studies in which 
a single IM injection of the virus alone could protect animals from lethal challenge [107].  
Further refinements of the rAd5-based vaccine platform made by Richardson et al. 
involved optimizing the GP expression cassette so that more antigen was produced and 
stronger antigen-specific immune responses achieved with a lower dose of vaccine [104].  
This approach was so successful that a single IM injection of the re-engineered vaccine 
30 minutes after exposure to a lethal dose of ZEBOV fully protected mice, suggesting 
that this platform might be useful for both prophylaxis and post-exposure applications. 
Despite these promising results, the efficacy of this vaccine is still blunted by 
prior exposure to adenovirus serotype 5 (Ad5), which may significantly limit its clinical 
utility for immunization [100, 125].  Anti-Ad5 NAB levels in the general public vary 
according to geographical location.  In the United States, approximately 30-60% of the 
population has high levels of anti-adenovirus antibodies while 40-80% of those in Europe 
and Asia contain similar levels of NAB.  The highest levels recorded to date are found in 
sub-Saharan Africa (80-100% positive) [126].  Increasing the vaccination dose can 
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override pre-existing immunity (PEI) and achieve notable antigen expression.  This 
approach, however, is not desirable since high doses of adenovirus particles can 
precipitate severe, toxic inflammatory responses in humans [127].  Another strategy to 
circumvent PEI to Ad5 involves immunization with rare adenovirus serotypes of human, 
porcine, bovine or chimpanzee origin [102, 103, 127, 128].  This has been effective since 
anti-Ad5 NABs do not completely cross-react with and neutralize these viruses.  Use of 
these viruses in vaccine platforms has successfully protected NHPs with PEI to Ad5 from 
lethal EBOV challenge without clinical signs of disease (Table 1.4) [128]. Mucosal 
administration of the vector also been shown to bypass PEI [100, 101].  Although this 
route of immunization generally induces lower systemic EBOV GP-specific T cell 
responses, it induces strong local T and B cell responses not impaired by PEI that affords 
full protection in rodent models of disease (Table 1.3) [100, 101].  Despite these very 
legitimate concerns, a phase I clinical trial has been conducted in thirty-one healthy 
adults [129].  Results indicate that the rAd5-based EBOV vaccine is capable of inducing 
antigen-specific T cell and antibody responses without significant side effects. 
1.3.2 Live attenuated virus-based vaccines  
Another promising vaccine platform involves the use of live, attenuated 
recombinant viruses containing EBOV GP within their native virus capsid structure.  One 
particular candidate, recombinant vesicular stomatitis virus (VSV) in which wild-type 
VSV glycoprotein was replaced with EBOV-GP demonstrated attenuated growth kinetics 
and tropism of EBOV in vitro [110].  A single dose of the vector given by the IM, 
intranasal (IN) or oral route completely protected mice, guinea pigs and NHPs from lethal 
challenge in the absence of any clinical symptoms or viremia (Table 1.3) [122].  In 
contrast, administration of a γ-irradiated, inactive form of the vector did not protect 
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animals, suggesting that replication is a critical component of the potency of this vaccine 
[121].  This vector is the most promising therapeutic option for post-exposure therapy to 
date since a single intraperitoneal dose 24 hours after lethal EBOV infection fully 
protected mice [109, 118, 120].  Fifty percent of guinea pigs also survived lethal 
challenge when given the vector in a similar manner 24 hours after exposure [56].  Fifty 
percent survival was noted when rhesus macaques were given the vector 20~30 min after 
lethal challenge [109].  These animals did develop notable clinical signs of disease (fever, 
lymphocytopenia) on day 6, but had low-level serum viremia that resolved 10 days later 
[109].  High levels of serum EBOV GP-specific IgG NAB and relatively low IgM 
responses were also found in survivors immunized with this platform.   
Although more than 80 NHPs have been given this vaccine without notable 
toxicity [130], progress of the VSV-based vaccine platform to the clinic has been delayed 
by concerns associated with the safety of this system.  To resolve this issue, the vector 
was first evaluated in immune-compromised mice lacking functional B and T cell 
responses [111] and NHPs infected with simian/human immunodeficiency virus (SHIV) 
[119].  Administration of the vector to NOD-SCID mice at a dose that was 10 times that 
previously given to healthy mice was well tolerated [111].  Four of six vaccinated SHIV 
infected NHPs survived EBOV challenge without vaccine induced toxicity despite the 
fact that a relatively high vaccine dose (1×107 PFU) was given to each animal [119].  In 
an effort to address concerns associated with neurotoxicity of the VSV vector in healthy 
subjects, 21 NHPs were given either wild type VSV or recombinant VSVs containing 
either EBOV or Marburg GP on the surface by intrathalamic injection [131].  Results 
from this study clearly indicate that recombinant VSV filovirus vaccines lack 
neurovirulence properties associated with the wild type vector.  An important observation 
made during this study was that, even though animals given the recombinant vaccine 
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containing Ebola GP did not elicit notable neurovirulence throughout the course of the 
study, the recombinant virus was detected in mucosal swabs indicating that it could leave 
the central nervous system by an unknown mechanism.  This vaccine was first used in 
humans when a laboratory scientist was exposed to EBOV in a BSL-4 laboratory through 
an accidental needle-stick [132].  The VSV vaccine was given 48 hours after exposure.  
The patient developed a mild fever and myalgia 12 hours after injection. Other laboratory 
parameters (blood chemistry, coagulation and hematology) remained normal.  Although 
EBOV infection could not be confirmed through serological testing, the technician 
remains healthy to this day with no detectable viremia noted. 
Recombinant human parainfluenza virus 3 (HPIV3) containing EBOV GP alone 
(HPIV3/EboGP) or together with nucleoprotein (HPIV3/EboGP-NP) in its capsid has 
also been developed as a live-attenuated vaccine platform. Each of these constructs have 
conferred complete protection in guinea pigs and NHPs after EBOV challenge (Table 
1.3) [113, 133].  Much like adenovirus, HPIV-3 is a common respiratory virus, making 
PEI to the vector in humans a major limitation of this platform. To address this issue, 
Bukreyev and colleagues developed a chimeric HPIV-3 vector expressing EBOV GP as 
the sole surface protein to circumvent impact of PEI on vaccine potency [112].  This 
vector, HPIV3/ΔF-HN/EboGP, is resistant to HPIV-3-specific NABs in vitro and a single 
intranasal dose (4×106 PFU) protected guinea pigs from ZEBOV infection [112] (Table 
1.3).  Additional studies in animals given the vaccine in the presence of PEI to HPIV-3 
and evaluation of toxicity of the vaccine in NHPs are needed to evaluate the clinical 
utility of this platform more precisely. 
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1.4 Future directions for successful EBOV prophylaxis and treatment 
Although there is a clear need for effective regimens for prevention and protection 
against EBOV-mediated hemorrhagic fevers, many significant hurdles have limited the 
ability of promising candidates to reach those in need of them.  One of the primary 
reasons for the modest progress made in this area over the last two decades is the fact that 
the virus can only be handled in maximum-containment laboratories (biosafety level 
(BSL)-4).  Significant progress in the development of high throughput systems that allow 
rapid screening of potential anti-viral compounds at a much lower containment level 
(BSL-2) and the use of RNA interference technology to confirm these findings has led to 
the discovery of several novel compounds that have demonstrated protective efficacy in 
animal models of infection (Figure 1.5) [64, 68, 72].  As this approach will significantly 
accelerate the discovery of new therapeutics to combat Ebola, it will also heighten the 
need for studies directed at testing in larger animal models, as data obtained from rodents 
may not accurately reflect the pharmacological and toxicological responses of humans.   
1.4.1 Requirement of multivalent EBOV vaccines 
Although many of the vaccine platforms under development have protected NHPs 
against lethal EBOV infection and, in some cases, entered phase I clinical testing [165], 
each contain antigenic sequences from one specific strain of EBOV.  Because each strain 
of EBOV is known to be antigenically distinct [165], development of multivalent 
vaccines capable of conferring protection against several strains of filoviruses would be 
practical since outbreaks are sporadic and difficult to predict as illustrated by recent 
simultaneous outbreaks caused by two different strains of EBOV.  
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Figure 1.5 Integration of technologies necessary for successful development of 
highly effective preventive and therapeutic agents to combat Ebola.  Structural and 
computational biology in combination with high-throughput screening technologies have 
started to facilitate rational and rapid screening of agents for their potency against Ebola.  
Compounds identified for clinical testing require administration of many doses over a 
significant period of time, which will not be practical economically and during in 
outbreaks.  Thus, there is an obvious need for collaboration with formulation scientists to 
improve serum half-life, anti-viral activity and physical stability of candidates at ambient 
temperatures.  Careful collection and analysis of data obtained from both survivors and 
non-survivors during outbreaks and clinical testing of compounds and subsequent 
identification of gene signatures associated with protection from infection is also vital for 
finding additional targets for new vaccines and anti-viral agents. 
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While a rAd5-based vector expressing both SUDV and EBOV GP and several 
different VSV-based vectors expressing GPs from SUDV, EBOV and MARV have been 
constructed, they have successfully protected a limited number of animals after lethal 
challenge with several different EBOV strains [166-168].  This multivalent approach is 
currently extremely labor intensive and limited by the cloning capacity of recombinant 
viral vectors.  Development of a mosaic antigen that contains protein fragments of 
potential T-cell epitopes from multiple EBOV strains may be a good alternative strategy 
to overcome these issues.  This concept has recently been illustrated with a recombinant 
viral vector expressing multivalent mosaic proteins that could elicit strong antigen-
specific CD8+ T cell responses against several model antigens [166-168].  Even though 
the protective efficacy of this strategy has not yet been demonstrated in infectious disease 
models, recent studies that highlight the importance of CD8+ T cell response in conferring 
immune protection against EBOV infection in NHPs support this approach in developing 
multivalent EBOV vaccines [98].  As technology for production of protein-based 
vaccines progresses, large scale production of these novel antigens in combination with 
immunization scaffolds to ease purification and augment the immune response will be 
possible as recently demonstrated with the production of a potent EBOV GP immune 
complex vaccine in N. benthamiana [169]. 
1.4.2 Formulation development  
It is also important to note that most of the recently discovered compounds have 
limited serum half-lives and poor bioavailability in target tissues, making administration 
of high doses in multiple dosing regimens necessary to achieve an optimal therapeutic 
effect [64, 65, 67, 68, 77, 84].  In addition, it is clear that the success of therapeutics or 
vaccines is influenced by the physical nature of the antigen and the chosen delivery 
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system.  Development of formulations that can stabilize or alter the physical 
characteristics of the antigen and its delivery system is an active area of investigation.  
Thus, focused efforts in formulation development will be key to improve the efficacy and 
reduce the toxicity of these compounds and to move them toward single dose regimens 
that are easy to administer in outbreak and post-exposure scenarios.  Half-life and 
bioavailability can be greatly extended through formulations that maintain their structural 
integrity and protect them from nucleases and other degradative enzymes in vivo during 
long-term storage [134, 135].   
 
Mucoadhesives/Absorption enhancers: Mucoadhesives increase attraction to the 
mucosal cell surface and prolong residence time by reducing mucociliary clearance 
(MCC), which removes foreign particulates such as allergens, bacteria and viruses before 
they reach their target tissues.  Mucoadhesives can be divided into three categories [136].  
The first group includes hydrophilic polymers that adhere to the mucus layer through 
hydrogen bonds.  Examples of this type include sodium alginate, sodium 
carboxymethylcellulose, hydroxypropyl methylcellulose, and carbopol.  The second 
group consists of cationic polymers that interact with the negatively charged mucin by 
ionic or hydrogen bonds like chitosan and its derivatives.  The third group consists of 
thiolated polymers that contain free sulfhydryls groups, which can form very strong 
covalent bonds [137].  Vaccine formulations that contain a mucoadhesive agent have 
generally increased antibody responses with respect to the unformulated vaccine 
preparation [138].  In addition to slowing down the clearance process of vaccines, 
another critical factor that must also be taken into account is ensuring absorption or 
transport across the mucosal epithelium.  Thus absorption enhancers are commonly 
included in preparations designed for mucosal delivery of vaccines due to their ability to 
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facilitate transcellular or paracellular transport of drugs.  Absorption enhancers fall into 
several categories; surfactants, bile salts and their derivatives, phospholipids, 
cyclodextrins, cationic polymers, and lipids.  Some also act as mucoadhesives, as in the 
case of chitosan and its derivatives due to their ability to increase residence time as well 
as interrupt tight junctions allowing access beyond the epithelial barrier [139, 140]. 
 
Lipid based carriers: Another group of extensively studied carrier systems with 
immunomodulation and targeting potential include lipid-based carriers.  Liposomes have 
been studied as vaccine carriers for over 30 years [141, 142] and have been shown to 
boost mucosal immunity against delivered antigens [143, 144].  Liposomes have also 
been shown to preferentially induce Th1 type responses [304], including strengthening 
antigen-specific lymphocyte proliferation [145], and increasing the number of interferon-
γ secreting cells [146-148], and the magnitude of CTL responses [145, 149-151].  The 
addition of adjuvants such as TLR ligands (CpG DNA, lipopolysaccharides) [152-154], 
or incorporation of cytokines [146] in these preparations have also significantly improved 
antigen-specific immune responses.  In order to be effective these agents must either be 
contained within the liposome or present in the final formulation of the vaccine.  Since 
the liposome is not limited to a set size or composition they offer significant flexibility 
for incorporation in a vaccine platform.  Prime-boost immunization strategies with these 
preparations have also notably increased immune responses at both the mucosal and 
systemic levels [146].  However, they are versatile carriers that do not have a set size or 
composition, so there is sufficient flexibility inherent in liposomes that may allow for 
successful vaccination strategies. 
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Entrapment and encapsulation: Preparations that allow continuous release of drug over 
extended periods of time also improve the half-life of drugs with poor bioavailability 
profiles [155].  Formulations that minimize the overall surface charge associated with 
therapeutic compounds also improve bioavailability by improving interaction with target 
tissues and organs [156].  The underlying concept of “entrapment and encapsulation” that 
serves as the basis for each of these strategies has been widely used for several decades in 
the field of pharmaceutical science [157, 158].  Thus, many biodegradable polymeric 
micro/nano-particle systems, hyaluronic acid based-hydrogels and lipid-based delivery 
systems have received regulatory approval for human use and could easily be combined 
with any of the platforms currently under clinical development.   For example, intranasal 
administration of antigens incorporated into poly(lactic-co-glycolic acid (PLGA)) matrix 
has been shown to increase antibody responses to parainfluenza virus subunits [159], 
Bordetella bronchiseptica dermonecrotoxin [160], hepatitis B soluble antigen [161], and 
recombinant HIV proteins [162] in mice.  Particles composed of mucoadhesive polymers 
are quite effective antigen carriers, as chitosan or tri-methyl chitosan nanoparticles have 
been shown to increase serum antibody levels against cholera toxoid in rats, and superior 
IgG and sIgA antibody responses against influenza [163, 164]. 
 
From what we have summarized here, it is clear that different vaccine platforms 
and the route of immunization can induce different types of immune responses. Although 
the exact correlates of protection for EBOV in humans are not known, we believe that 
systems vaccinology approaches employing microarrays, mass spectrometry-based 
proteomics, metabolomics and computational modeling will help define the immune 
responses necessary for protection and allow for further refinement of current vaccine 
platforms with formulations that foster specific types of antigen-specific immune 
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responses and the discovery of new vaccine targets [170, 171].  Development of 
multivalent vaccines or anti-viral drugs that have protective efficacy against more than 
one Ebola strain would be quite useful in the field when the strain responsible for an 
outbreak may not initially be known [62-64].  It is also important to note that each 
candidate for post-exposure therapy mentioned above has shown protective efficacy in 
animals treated very soon (30~60 minutes) after EBOV infection.  Therefore, the use of 
these compounds may be limited to accidental laboratory exposures.  Additional focus 
must be placed on post-exposure treatments for those that have progressed to 
symptomatic illness. Studies evaluating gene expression profiles during active EBOV 
infection will be a valuable tool in working toward this goal, however, facilities and 
reagents to support them are still limited. 
 
1.5 Adenovirus 
1.5.1 Biology of Adenovirus 
Recombinant adenovirus (Ad) vectors were initially developed for treatment of 
genetic disease. Since their discovery, 53 immunologically distinct serotypes of human 
adenoviruses have been identified which are divided into 7 subgroups (A-G) [172].  
These non-enveloped viruses contain a 26 ~ 45 kb double stranded DNA (dsDNA) 
genome flanked by two inverted terminal repeats (ITRs) situated at each end of molecule.  
The virus genome consists of a series of early genes (E1a, E1b, E2a, E2b, E3 and E4), 
which are transcribed prior to DNA replication (Figure 1.6A).  E1, E2, and E4 gene 
products have regulatory functions that allow for transcription and translation of the late 
genes (L1 - L5) and are indispensable for viral replication [173-175]. E3 gene products 
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allow the virus to subvert the immune response by manipulating antigen presentation, 
cytokine and apoptosis pathways and are not needed for viral replication [176].  Late 
genes, transcribed after DNA replication, encode proteins involved in the production and 
assembly of the native structural capsid components [177]. 
The Ad capsid is an icosahedron with 20 faces in the shape of equillaterial 
triangles [178].  Each icosahedron contains 12 copies of hexon trimers. The fiber 
proteins, which also form trimers, are inserted at the 12 vertices into the penton base 
(Figure 1.7). The hexon, the most abundant of the capsid proteins, has a shaft that is 
highly conserved between different serotypes of Ads, and a tower that contains a number 
of loops that bear regions of variability between different serotypes [179].  Most 
neutralizing antibodies to Ad are directed against the variable hexon loops [180-183].  
The Ad fiber is composed of a thin N-terminal tail, a shaft, and a knob domain.  The shaft 
is composed of variable numbers of β-strand repeats. The numbers of repeats largely 
determine the length of the shaft, which varies between Ads from different families 
[184].  The knob contains loops that are lettered A–J. The fiber knob loops bind to 
cellular receptors. The A–B fiber knob loops of most Ad bind to the coxsackie virus and 
adenovirus receptor (CAR) [185], which is expressed mainly on epithelial cells in mature 
organisms [186].  The majority of group B adenoviruses bind to CD46 [187], a 
complement regulatory protein that is expressed on most cells in humans and NHPs, but 
only in testes and sperm in mice [188].  Cell entry is mediated upon binding to a 
secondary receptor, which in some Ad viruses such as Ad5, is provided by an Arg-Gly-
Asp motif within the penton base that binds to αvβ3 or αvβ5 integrins [189].  The Ad 
genome encodes several additional minor capsid proteins; IIIa, VI, VIII, and IX.  The 
functions of these proteins have been reviewed in detail elsewhere [190]. 
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Figure 1.6. Organization of the adenovirus genome and structure of adenovirus.  (A) 
Arrows indicate the direction of transcription and translation of adenovirus early (E1-E4) 
and late (L1-L5) gene products in the wild type adenovirus genome.  ITR: inverted 
terminal repeat.  (Adapted from Tatis N. and Ertl H., [177]).  (B) The adenovirus capsid 
consists of three primary structural proteins: hexon, penton base and fiber.  A total of 240 
hexon proteins fill the 20 facets of the icosahedral capsid and edges of the capsid.  At 
each of the 12 vertices, lie penton proteins consisting of penton bases and fiber proteins.  
Minor protein components (IIIa, VI, VIII and IX) are also associated with the external 
surface of the capsid.  Six other structural components are situated in the virus core, five 
of which bind to the double stranded DNA genome [V, VII, Mu, IVa2 and the terminal 
protein (TP)].  The remaining component is the 23K virion protease which plays a vital 
role in virus assembly (Adapted from Russell W.C., [191]). 
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1.5.2 Host immune response to adenovirus infection 
Adenoviruses are highly immunogenic.  Upon infection of these viruses, they 
initiate the innate immune system by pathogen-associated molecular pattern molecules 
(PAMPs).  PAMPs bind to pathogen recognition receptors on host cells, including those 
of the innate immune system, thus initiating production of pro-inflammatory cytokines 
and differentiation of immature dendritic cells into professional antigen-presenting cells 
[192]. Systemic administration of high doses of Ad5 vectors to mice [193] or monkeys 
[194] is known to trigger rapid release of IL-6, IL-12, and TNF-α which fosters 
accumulation of transduced macrophages and dendritic cells in lymphatic tissues. 
Adenovirus-induced maturation of dendritic cells was shown to be Nuclear Factor-
KappaB (NF-κB)-dependent [195].  One study described activation of dendritic cells 
through direct interaction with the β-stranded region of the fiber knob [196]. Another 
study demonstrated activation of dendritic cells through an autocrine TNF-α-mediated 
mechanism where TNF-α secretion triggered by interaction of RGD sequence within the 
penton base facilitated differentiation of immature dendritic cells [197].  Cytotoxic CD8+ 
T cells and memory CD4+ T cells rapidly develop soon after adenovirus infection [198-
201].  CD8+ responses were originally thought to be HLA class I-restricted.  Multiple 
epitopes recognized by CD8+ T cells have been mapped to the highly conserved distal 
termini of the hexon.  Recently, an extensive study [198] conducted with adenovirus-
reactive human cytotoxic T lymphocyte (CTL) and an overlapping hexon peptide library 
identified 33 stimulating peptides that possesses both HLA class I and II restriction.  Of 
these peptides, five were overlapping CD4 and CD8 T-cell epitopes.  Moreover, all of 
these immunogenic peptides lie within the conserved region of the hexon.  Interestingly, 
the hexon is considered a potent adjuvant for activation of cellular immune responses 
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[202].  Only minimal responses to the other capsid proteins, fiber and penton base have 
been described in many animal models of infection.  Similar observations have been 
made with respect to cellular proliferative responses [203], although there has been one 
report suggesting a role for fiber or IIIa in the propagation of this response [204]. 
 
1.5.3 Impact of pre-existing immunity on adenovirus-based vaccine efficacy 
To date, E1/E3 deleted replication-deficient human serotype 5 Ad vectors (rAd5) 
are heralded as the most promising vaccine platform for many life threatening infectious 
diseases [205].  Deletion of early genes (E1/E3) allows the genome to accommodate 
transgene cassettes of up to 8 kb in size.  It is also important to note that adenovirus can 
efficiently infect differentiated and non-dividing cells without chromosomal integration 
[206].  Since the first human clinical trial in 1993, more than 340 clinical trials have been 
conducted using rAd5-based vectors for a wide variety of applications ranging from 
acquired immune deficiency disease (AIDS) to cancer [177, 207].  This suggests that 
rAd5 vectors continue to be of high clinical interest.   In preclinical animal models, these 
vectors were shown to induce potent antigen-specific immune responses [208, 209].  T 
cells were mainly of the CD8+ T-cell subset, although low CD4+ T-cell responses of the 
T-helper (Th) cell type 1 were also induced.  These responses were clearly reduced by 
pre-existing immunity (PEI) to the vector [210, 211].  This problem is further highlighted 
by the prevalence of PEI to Ad5 in the general population, which currently limits the 
clinical use of any Ads in immunization platforms.  For example, 30-60% of adults in the 
United States and up to 80-100% of humans residing sub-Saharan Africa have anti-Ad 
NABs as a result of natural infection [212]. 
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Activation of B cell-mediated immune responses against Ad vectors result in the 
generation of neutralizing antibodies (NABs) to all major viral capsid proteins (hexon, 
penton base, fiber) and some minor proteins with respect to virus dose (Figure 1.7).  Once 
NABs bind to the capsid proteins of rAd5-based vectors they form Ad5-NABs 
complexes, that activate dendritic cells through a Fc-receptor dependent mechanism, 
thereby generating Ad5-specific CD8+ T cells.  The activated CD8+ T cells rapidly 
eliminate Ad-vaccine infected cells by expressing pro-inflammatory cytokines and 
chemokines including IL-6, TNF-α, IFN-γ, macrophage inflammatory protein (MIP)-2 
and MIP-1α [193, 213, 214].  Therefore, repeated immunizations with AdHu5 vectors in 
a prime-boost format have not been overly effective.  Antigen-specific T cell responses 
were remarkably sustained and failed to contract after the initial effector phase.  This was 
linked to the vectors' ability to persist in a transcriptionally active form in T cells after a 
single dose of virus were given to intramuscular route in mice [215].  A recently 
conducted human clinical trial with an rAd5-based human immunodeficiency virus 1 
(HIV-1) vaccine provided evidence of increased HIV acquisition in individuals that had 
PEI to the Ad vector prior to vaccination.  This result clearly demonstrates the impact of 
PEI in lowering immunogenicity of rAd5-based vectors despite that the exact 
immunological mechanisms responsible for failure of the clinical are not completely 
understood at this time.      
1.5.4 Strategies to circumvent PEI for successful adenovirus-based vaccination   
1.5.4.1 Capsid modification and novel adenovirus vector development  
Consistent with the Western blot image displayed in Figure 1.7, a recent study 
conducted with chimeric rAd5 vectors displaying hexon, penton base and fiber proteins  
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Figure 1.7. Characterization of adenovirus NABs by Western blotting and ELISA 
isotyping.  Details of this experiment can be found in reference 125.  (A) Western blot of 
adenovirus capsid proteins resolved on a 9% SDS-PAGE gel. Each lane was incubated 
with a different dilution of stock serum containing anti-Ad polyclonal antibodies.  Serum 
concentrations at or above 5 ND50 bound the primary adenovirus capsid proteins (hexon, 
penton, fiber). Fiber binding was lost at the 0.5-ND50 concentration.  Hexon binding was 
detected in the 0.05- and 0.005-ND50 preparations.  Binding of adenovirus capsid proteins 
could not be detected at the 0.0005-ND50 concentration.  (B) Isotyping assays revealed 
that anti-Ad NABs obtained after a single injection of virus mostly consist of IgG 
antibodies with Ig2b being the primary isotype in the 500-, 5-, and 0.05-ND50 
preparations.  Marked amounts of IgM antibodies were detected in the 500-ND50 
preparation only.  Samples from the 0.005- and 0.0005-ND50 preparations were below the 
detection limit of the assay (Adapted from Choi J.H. et al., [125]) . 
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from other Ad serotypes demonstrated that hexon-specific NABs play a major role in 
reducing immunogenicity of rAd5 vector [183].  Roberts and colleagues generated a 
hexon-chimeric rAd5 vector (rAd5HVR48) by substituting hypervariable regions (HVRs) 
of rAd5 hexon into HVRs from Ad serotype 48, which has a particularly low sero-
prevalence in humans.  This vector was not neutralized by Ad5 NAB in vitro [216, 217].  
They also found that rAd5HVR48 was capable of inducing potent transgene-specific 
CD8+ T cell-mediated and antibody responses in mice with established PEI to Ad5.  
Numerous researchers have shown that Ad vectors isolated from various species 
(chimpanzee, canine, porcine and bovine) are capable of inducing potent immune 
responses in animals with PEI to Ad5 [102].  Human isolates of Ads that have minimal 
exposure rates in general population (serotypes 11 and 35) also demonstrated potential to 
bypass PEI to Ad5 [218, 219].   
 
1.5.4.2 Formulation development 
The glucocorticoid dexamethasone (DEX, a FDA-approved immunosuppressive 
agent) was successfully used in early studies to circumvent immune activation and 
toxicity induced by Ad vectors [220, 221].  DEX inhibits vector-induced innate immune 
activation by blocking the NF-κB, activator protein (AP)-1, and mitogen activated protein 
kinase (MAPK) pathways [222].  Formulation of Ad5 vector with dexamethasone-
spermine/dioleoylphosphatidylethanolamine (DS/DOPE) allowed transgene expression 
after re-administration of a homologous Ad5 vector without generating measurable serum 
anti-Ad5 NABs in mice [222].  Another strategy to reduce the immune response against 
the Ad vector includes chemical modification with biocompatible polymers.  The primary 
goal of this strategy has been to mask adenovirus capsid proteins through covalent 
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attachment of polyethylene glycol or poly-N-(2-hydroxypropyl)-methacrylamide to free 
lysine residues after purification of the vectors with respect to genetic modification as 
described previously [223].  This approach allows for easy modification of virus capsid 
proteins and has shown excellent potential to protect Ad vector from proteolytic 
degradation, increase serum half-life and reduce anti-vector immunity.  The first attempt 
to PEGylate Ad5 vector was performed by O`Riordan and co-workers in 1999 [224].  
They revealed that: 1) capsid proteins including hexon, penton base and fiber proteins are 
the targets of PEG modification, 2) this process does not compromise the integrity of the 
virus capid, and 3) PEGylated Ad5 vector can escape neutralization in vitro.  Croyle et al. 
further confirmed that a PEGylated Ad5 vector can significantly reduce Ad5-specific 
cytotoxic T lymphocyte (CTL) activity and circulating NAB while suppressing Th1 type 
responses against the virus [225].  Th2 type responses, however, remain unchanged 
(Th1<Th2) when compared to those elicited by unmodified Ad5.  In addition, the authors 
have shown that a PEGylated Ad5 vector prolonged transgene expression relative to an 
unmodified vector in mouse lungs after intratracheal administration.  Of note, they further 
confirmed that PEGylation allowed efficient transgene expression in lung or liver without 
elevating anti-Ad5 NAB in mice with established PEI [225, 226].  Interestingly, repeated 
administration of Ad5 vector PEGylated with different functional linkers (treyslated 
(TM) PEG/succinimidyl-succinate (SS) PEG) allowed significant transgene expression 
while the same functional linker (TM-PEG/TM-PEG) failed to induce transgene 
expression after a second dose, implying that antigen switching approaches can escape 
NAB and therefore allow repeated Ad5 vector administration for limited applications 
[225].    
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1.5.4.3 Mechanistic approaches: Dissecting the immune response against Ad.  
The immune response to Ad vectors can be divided into three different stages 
[227, 228].  The first innate stage of immune activation involves recognition of Ad 
through TLRs and antigen presentation.  After innate immune activation, three co-
stimulatory signals are required to induce Ad5 specific T and B cell mediated immune 
responses: 1) epitope recognition through the T cell receptor (TCR), 2) co-stimulatory 
molecule binding (CD40/CD40-ligand (CD40L)), and 3) pro-inflammatory cytokine 
stimulation.  Based on this, scientists thought that interference with CD40/CD40L 
interactions might reduce CD4+ helper T cell activation and reduce Ad5-specific NAB 
levels [229, 230].  In addition, another mechanistic approach utilized strategies to prevent 
cell surface molecule interactions between CTL antigen 4 (CTLA-4) and B7 (CD80 
and/or 86) to inhibit T cell activation [231, 232]. 
 
CD40/CD40 ligand: In an early attempt to reduce anti Ad5-NAB levels in the lung after 
repeated vector administration, Yang et al., found that administration of IFN-γ or IL-12 
block Th2-type CD4+ cell activation and anti-Ad5 IgA production in bronchoalveolar 
lavage fluid [230].  However, the utility of this approach is limited since IL-12 and IFN-γ 
induce concurrent activation of Th1 type CD4+ T cells and up-regulate major 
histocompatibility complex (MHC) class I expression on APCs which eliminate Ad-
infected cells by cytotoxic T cell responses.  In order to fully activate T cells through 
APC stimulation both MHC/T cell receptor (TCR) interaction and co-stimulatory signals 
are required [233].  CD40L is transiently expressed at high levels on activated CD4+ T 
cells and bind to CD40 expressed on B cells and APCs [233].  Thus to reduce this effect, 
Yang et al. blocked CD40/CD40L interaction using anti-CD40L antibody and 
successfully diminished Ad-specific immune responses [229, 230].  Scaria et al. have 
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also shown that transient blockade of CD40/CD40L interactions between activated CD4+ 
T cells and B cells and/or APCs with a mouse monoclonal anti-CD40L antibody inhibited 
the generation of anti Ad5-NAB and allowed persistent transgene expression in the lung 
[234].   
 
CTLA4/B7: Another target molecule for immune suppression is CTL antigen 4 
(CTLA4).  CTLA4 is a co-stimulatory molecule expressed on CD4+ T helper cells that 
sends an inhibitory signal to APCs [228].  The soluble form of CTLA4 conjugated to the 
Fc portion of IgG (CTLA4Ig) has been widely used for immune suppression in 
transplantation [235].  CTLA4 binds to B7 (CD80 and/or 86) with 100 to 1000 fold 
higher avidity than CD28.  This binding down-regulates CD28/B7 interactions and 
inhibits T cell activation [231, 232].  Recent studies have shown that co-administration of 
Ad5 encoding CTLA4Ig (rAd5CTLA4Ig) with another Ad5 vector exhibited prolonged 
transgene expression in multiple tissues without induction of tolerance to Ad5 or its 
transgene [235].  In the context of vaccine development, this approach reduced anti Ad5- 
NAB with respect to to animals vaccinated with rAd5 vector alone. 
  
Type I IFNs: As mentioned previously, a single dose of Ad initiates rapid increases in 
multiple pro-inflammatory cytokines.  This triggers a complex set of interactions between 
innate and adaptive immune responses and subsequent activation of B cell-mediated 
immune responses.  Type I IFNs are produced by plasmacytoid dendritic cells (pDCs) 
during virus infection that send their signal through a heterodimeric receptor composed of 
two subunits, IFN-α receptor 1 and 2 (IFNAR1, IFNAR2) [236].  This signaling pathway 
confers anti-viral immunity through suppression of virus replication and induction of cell 
death in virus-infected cells [237].  Recent studies using IFNR-/- mice have shown that 
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generation of anti-Ad5 NAB occurs through type I IFN signaling [238].  Type I IFN 
blockade using monoclonal antibodies before vector administration, also diminished anti-
Ad5 NAB levels without compromising transgene expression.  While excessive induction 
of type I IFNs during administration of Ad vectors reduces the level of transgene 
expression, it also limits production of transgene-specific antibody responses [239].  
These results suggest that the type I IFN signaling pathways may be an interesting target 
to promote vector re-administration. 
1.5.4.4 Routes of vaccination 
Administration of antigens to mucosal surfaces can lead to a variety of immune 
responses, or can result in immune tolerance.  In general, the balance between active 
immunity and tolerance is dependent on the nature of the antigen and its interaction with 
the mucosal inductive site [240].  Antigens delivered by mucosal routes are mostly taken 
up by M cells found in the mucosal epithelium and delivered to underlying lymphoid 
tissue comprised of cells responsible for initiation of immune responses including APCs, 
T cells, and B cells [241].  This is often referred to as the mucosal associated lymphoid 
tissue (MALT; Figure 1.8) where antigen processing and presentation take place [240].  
Peyer's patches, in the gut, and nasopharynx-associated lymphoid tissue (NALT) in the 
nose are the main components of MALT and are important inductive sites for the 
generation of mucosal immunity through the ingestion and inhalation of antigen in the 
intestinal and respiratory tracts, respectively [242].  The common mucosal immune 
system (CMIS) connects these inductive sites with effector sites, therefore, mucosally 
delivered antigens are capable of stimulating antigen-specific Th2 cell dependent IgA 
responses and Th1 cell and cytotoxic T lymphocyte dependent immune responses in 
mucosal effector tissues [242-247].  
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Figure 1.8. The common mucosal immune system (CMIS) Mucosal antigens taken up 
by M cells are delivered to dendritic cells and presented to T cells in the lymphoid 
tissues.  CD4+ T cells that are stimulated by dendritic cells then preferentially induce 
IgA-committed B-cell development in the germinal center of the lymphoid follicle.  After 
IgA class switching and affinity maturation, antigen-specific CD4+ T cells and IgA+ B 
cells migrate to effector sites (such as the nasal passage and intestinal lamina propria) and 
produce dimeric (or polymeric) forms of IgA. These dimeric forms of IgA then become 
secretory IgA by binding to polymeric Ig receptors that are displayed on the monolayer of 
epithelial cells lining the mucosa. Secretory IgA is then released into the nasal passage 
and intestinal tract that can then effectively bind antigen during infection.  TCR, T cell 
receptor.  (Adapted from Hiroshi Kiyono H. and Fukuyama S. [242]) 
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Activated T and B cells then migrate from the MALT to regional lymph nodes 
and then into circulation, providing an opportunity for establishment of systemic 
immunity.  Due to these unique properties of the mucosal immune system, administration 
of a vaccine by mucosal routes is able to induce significantly different types of immune 
responses with respect to systemic administration. Mucosal (needle-free) delivery of 
vaccine preparations are appealing in terms of lowering acute phase toxicity often 
associated with injections and promoting strong immune responses in those with PEI.  
We have shown that a single I.N. vaccination of Ad5-based EBOV vaccine successfully 
protects mice against lethal EBOV infection in the presence of PEI [101].  Although this 
approach allows for self-immunization and significantly eliminates biological waste 
associated with injectable vaccines, the potential for re-direction of the recombinant virus 
to the central nervous system (CNS) through the olfactory bulbs has raised some 
concerns for the safety of this route of administration of Ad-based vaccines [248, 249].  
Oral administration of recombinant Ad-based vaccines also allows for easy self-
immunization, eliminates pain associated with vaccination and is considered to be safe.  
Due to these benefits, an oral tablet vaccine consisting of live Ad4 and Ad7 are currently 
used for military populations with age 17-50 years old to prevent severe febrile acute 
respiratory disease (ARD) [250].  Oral administration of a chimpanzee derived Ad 
serotype 68 (AdC68) based vaccine expressing rabies virus glycoprotein (rab.GP) has 
been recently shown to induce significant levels of systemic and mucosal antibodies 
specific to the transgene in mice with PEI to the vector.  Furthermore, homologous or 
heterologus prime/boost immunization with AdC68rab.GP or AdHu5rab.GP, 
respectively, showed enhanced antibody responses [251].  This vaccine platform is 
currently under-developed due to the intestinal barrier composed of a physical layer of 
tightly joined epithelial cells that limit translocation of foreign macromolecules including 
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viruses and bacteria, restrict effective transduction of enterocytes to induce strong 
immune responses.  Previously we tested the protective efficacy of an unformulated Ad5-
based EBOV vaccine after oral administration in naïve mice and those with PEI to Ad5.  
Groups of ten mice were vaccinated with 1×109 ivp of unmodified Ad-CAGoptZGP by 
the P.O. route.  Twenty-eight days post-immunization, mice were challenged with a 
highly lethal dose (1,000 pfu≃30,000 x LD50) of mouse adapted-EBOV (MA-EBOV) via 
intraperitoneal injection.  As shown in Figure 1.9 A and B, the challenge was uniformly 
lethal in control mice given sterile saline by I.M. injection.  A single oral dose of 
unformulated vaccine (1×109 ivp) did not afford protection against lethal challenge in 
mice regardless of the existence of PEI to rAd5.  This suggests that it is necessary to 
develop formulations that protect the virus from the harsh environment of the GI tract, 
enhance virus uptake and induce significant level of antigen-specific immune responses 
for successful oral immunization with a rAd5-based vaccine.  This data prompted us to 
realize that in order to develop an effective Ad5-based EBOV vaccine for use in endemic 
and endemic areas.  1) Non-traditional methods of mucosal immunization and 
development formulations that strengthen certain arms of the immune response 
compromised by prior exposure to Ad5 must be identified to enhance the potency of the 
vaccine, and 2) The manner by which PEI to Ad5 is induced in a rodent model will also 
significantly impact the type of immune response elicited by an Ad5-based EBOV 
vaccine which may vary according to the immunization route.   
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Figure 1.9. Oral immunization with an unformulated rAd5-based Ebola vaccine 
fails to protect animals in the presence of PEI.  Naïve B10.BR mice (n=10/group) and 
those with PEI to Ad5 (n=10/group) were vaccinated via the oral route (1x109 ivp of Ad-
CAGoptZGP).  Mice were challenged with 1,000 pfu (≃30,000 x LD50) of mouse-
adapted Zaire Ebola 28 days after immunization.  Data represents percent survival (a, c) 
and percent change of body weight (b, d) over time and is reported as average body 
weight from each treatment group.    
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1.6 Objectives 
The objective of this research project is to develop an effective and safe Ad5-
based mucosal vaccine against EBOV.  EBOV has been identified as the cause of several 
highly lethal outbreaks of hemorrhagic fever for which there is no effective treatment or 
cure.  Development of an effective prophylactic vaccine against EBOV would be highly 
significant in preventing outbreaks which are both naturally occurring or the result of 
bioterrorist activity.  In this regard, development of novel vaccine candidates and 
modifications of previously developed vaccines were made to improve expression and 
immunogenicity.  However, PEI to Ad5 is a significant issue, very little is known about 
the types of immune responses induced by these vaccines to encoded transgene products 
in individuals with PEI to the virus.  It is also unclear at this time how closely current 
models of PEI induction (I.M. injection) resemble what naturally exists in the general 
population.  Given this, the following hypothesis was generated:  a) Immunization by the 
sublingual mucosa may be sufficient to confer protective immune responses in the 
presence of PEI, b) Mucosal immunization with a formulated rAd5-Ebola vaccine should 
restore Zaire-GP specific immune responses compromised by PEI and improve protection 
upon challenge with Ebola Zaire.   
 
More specifically, the aims of this project were   
  
i. Identify the sublingual mucosa as a novel, non-invasive method for 
protective vaccination against Zaire Ebola virus infection.  This was 
achieved by evaluating the Zaire-GP specific systemic and mucosal T and 
B cell mediated immune responses after sublingual administration of the 
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rAd5-Ebola vaccine in naïve mice and those with PEI.   Protective 
efficacy of this strategy was determined by lethal challenge with rodent-
adapted Zaire Ebola virus.  (Chapter II) 
 
ii. Modeling PEI to adenovirus in rodents to determine immunological 
requirements for successful development of an Ad5-based Ebola 
vaccine.  This was achieved by evaluating the impact of PEI induced by 
the systemic (I.M.) or mucosal (I.N.) route on multifunctional CD8+ T cell 
and antibody responses following immunization with an rAd5-based Ebola 
vaccine via the I.M., I.N. or S.L. route.  Additional challenge studies were 
performed to determine if these specific immune parameters correlate with 
the ability of the adenovirus-based Ebola vaccine to protect rodents 
(mice/guinea pigs) with PEI to Ad5. (Chapter III)  
 
iii. Develop formulations for used with an Ad5-based Ebola vaccine with 
potential to bypass PEI.  This was achieved by evaluating in vitro/in vivo 
performance of formulations that could protect an Ad5-based vaccine 
from neutralization and restore compromised adaptive-immune responses 
in mice with mucosally induced PEI.  To determine protective efficacy of 
selected formulations, vaccinated rodents (mice/guinea pigs) were 
challenged with rodent-adapted Zaire Ebola virus. (Chapter IV)  
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CHAPTER TWO 
A Single Sublingual Dose of an Adenovirus-Based Vaccine Protects 
Against Lethal Ebola Challenge Ebola Virus Infection 
 
2.1 Introduction  
Ebola hemorrhagic fever is a severe, often-fatal disease in humans and non-
human primates caused by Ebola, a single stranded RNA virus of the Filoviridae family.  
Four of the five known species of Ebola are infectious to humans, with Zaire and Sudan 
having case fatality rates of ~90 and 55% respectively [252]. Although Bundigbugyo, 
first identified in 2007 in Uganda, has the lowest reported fatality rate to date (25%), only 
a single, non-lethal infection in an individual working on an infected chimpanzee can be 
attributed to Cote d’Ivoire [43, 253].  Ebola-Reston has primarily caused disease in non-
human primates and pigs, with notable IgG antibodies detected in the absence of clinical 
infection reported in individuals working in close proximity to sick animals in the 
Philippines [254].   Clinical manifestations of infection develop within 2 - 21 days after 
exposure. Initial, non-specific flu-like symptoms (malaise, chills, fever) rapidly progress 
to severe nausea, diarrhea, shortness of breath, hypotension, bleeding and coma [255]. 
Because there are currently no licensed vaccines or medicinal agents available for 
preventing or managing Ebola, supportive measures to maintain blood volume and 
electrolyte balance are the only therapeutic options for infected patients [256].  
The scarcity of medicinal remedies, the unpredictability of outbreaks and its 
possible use as a bioweapon highlight the necessity for an effective immunization 
strategy for prevention of Ebola infection and limiting its spread once it is recognized.  
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Currently, there are 5 promising vaccine platforms that employ recombinant vector 
systems for the delivery of genes containing sequences of Ebola proteins. Although 
plasmid-based vaccines have had limited success alone, they have been effective when 
given with recombinant adenoviruses expressing Ebola glyco- and nucleoproteins, in 
prime-boost regimens [257].  Virus-like particles, containing key Ebola surface proteins, 
require several doses to confer protective immunity [258]. While adenovirus and human 
parainfluenza virus type 3 (HIPV3) vectors expressing Ebola glycoprotein can confer 
protection after a single dose, these vectors are common pathogens and may be 
ineffective in those with prior exposure by natural means [259].  A single dose of 
vesicular stomatitis virus (VSV) expressing Ebola glycoproteins has conferred protection 
against lethal Ebola challenge in primates [118].  Recent efforts to expand the utility of 
the VSV and adenovirus platforms involve the development of multivalent vaccines 
capable of protecting against several species of Ebola in a single dose in both pre- and 
post-exposure scenarios [166, 167].  However, the current VSV platform, much like the 
HIPV3-based vaccine, utilizes replication competent virus, which may pose a significant 
risk to certain patient populations [260].  Until recently, these vaccines have been given 
by the injectable route. In this report, we assess the utility of the sublingual mucosa as a 
site for immunization against Ebola with a recombinant adenovirus-based vaccine.  
The buccal and the sublingual mucosa are attractive sites for the delivery of 
medicinal compounds. In humans, the buccal and sublingual mucosa consist of an 
immobile expanse of smooth muscle that supports an epithelium of 40-50 layers of 
actively dividing squamous, non-keratinized cells [261]. Although this layer is a 
significant barrier for absorption of large molecules, it can provide a large surface area 
for transduction and antigen expression.  Cell turnover is relatively slow (4-14 days), 
allowing for continued release of antigen.  Below the epithelial layer is a dense vascular 
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network, allowing direct entry into the systemic circulation and avoiding pre-systemic 
metabolism of antigen in the gastrointestinal tract, a limitation of oral vaccines.  
Professional antigen presenting cells (APCs) and T lymphocytes also reside within the 
mucosa, with direct access to mucosal-associated lymphoid tissues [262].  The studies 
outlined in this report were designed to employ a novel immunization method, largely 
unexplored in the context of adenovirus-mediated vaccine delivery, to address two very 
critical issues associated with clinical use of this virus in vaccination protocols: a) limited 
utility and b) susceptibility to unwanted side effects in those with prior exposure to 
adenovirus.  Adenovirus serotype 5 is ubiquitous in nature and infects humans frequently, 
making pre-existing immunity to the virus a global phenomenon [126, 263].  The first 
series of studies in this report assess the adenovirus transduction efficiency in the 
sublingual mucosa and its ability to recruit antigen presenting cells during immunization. 
Systemic and mucosal T and B cell responses to Ebola Zaire glycoprotein after 
sublingual immunization were then characterized by in vitro and in vivo assays in naive 
mice and those with pre-existing immunity to adenovirus.  These results and survival 
rates after challenge with mouse-adapted Ebola Zaire were compared to those generated 
after immunization by intramuscular injection and by the oral and nasal routes. 
 
2.2 Materials and Methods 
2.2.1 Adenovirus production   
The E1/E3-deleted adenovirus serotype 5 vector expressing the codon optimized 
full length Ebola Zaire glycoprotein sequence (Genbank/NCBI; Mayinga strain 76, Gene 
accession number: AF086833) under the control of the chicken-β-actin promoter used in 
these studies (Ad-CAGoptZGP) was created as previously described [104] and amplified 
 52 
in HEK 293 cells (ATCC CRL-1573) according to established methods.  Virus was 
purified from cell lysates by banding twice on cesium chloride gradients and desalted by 
dialysis overnight in 100 mM potassium phosphate buffer (pH 7.4) using specialized 
dialysis cassettes (Silde-A-Lyzer, 3 ml volume, 10K MWCO, Pierce Biotechnology, 
Rockford, IL). The initial concentration of each preparation was determined by 
measuring the optical density at 260 nm according to the method of Maizel et al. [264].  
Infectious titer was determined by serial dilution of each preparation, infection of HEK 
293 cells for 48 hours and immunodetection of the hexon protein using the Adeno-X 
Rapid Titer Kit (Clontech, Mountain View, CA) according to the manufacturer’s 
instructions.  Preparations with infectious to physical particle ratios below 1:200 were 
used in this study. 
 
2.2.2 Animal Studies  
All procedures were approved by the Institutional Animal Care and Use 
Committees at The University of Texas at Austin and the University of Texas Medical 
Branch in Galveston and are in accordance with the guidelines established by the 
National Institutes of Health for the humane treatment of animals. 
 
2.2.2.1 Immunization 
Six-week-old male B10.Br mice (MHC H-2k) were obtained from the Jackson 
Laboratory (Bar Harbor, ME) and housed in a temperature-controlled, light-cycled 
facility at the Animal Research Center of The University of Texas at Austin with free 
access to standard rodent chow (Harlan Teklad, Indianapolis, IN) and tap water.   Mice 
were anesthetized by a single intra-peritoneal injection of a 3.9:1 (v:v) mixture of 
ketamine (100 mg/ml, Wyeth, Fort Dodge, Animal Health, Overland Park, KS) and 
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xylazine (100 mg/ml, Sigma Aldrich, St. Louis, MO).  Once deep plane anesthesia was 
achieved, mice were immunized with 1×108 infectious particles of Ad-CAGoptZGP 
regardless of immunization route.  Mice immunized by intramuscular injection were 
given by 50 microliters of the preparation into each gastrocnemius muscle located on the 
mouse hindlimb.  Mice immunized orally were given the same dose and volume (100 
microliters) of virus with oral feeding needles (18G, 2.25 mm dia., Popper & Sons, Inc, 
New Hyde Park, NY). Nasal immunization was performed by slowly dripping 10 
microliters of the preparation into each nostril using a standard micropipette (Gilson, 
Middleton, WI).   For sublingual immunization, sterile forceps were placed under the 
tongue of the mouse and 10 µl of the preparation slowly dispensed with a standard 
micropipette.  Animals immunized by the nasal and sublingual routes were maintained in 
an upright position for 30 minutes after vaccination in order to minimize accidental 
swallowing of the vaccine. 
 
2.2.2.2 Establishment of Pre-Existing Immunity to Adenovirus 
Pre-existing immunity to adenovirus serotype 5 was established in 3-week-old 
B10.BR mice by directly injecting 2.5×1011 particles of first generation adenovirus 
expressing β-galactosidase under the control of a CMV promoter (AdlacZ) in the muscle 
of each hindlimb 30 days prior to vaccination with Ad-CAGoptZGP.  This protocol has 
been documented to activate T and B cells against virus capsid proteins and elicit 
humoral immunity [101]. Twenty-four days later, blood was collected via the saphenous 
vein and serum screened for anti-adenovirus neutralizing antibodies (NABs) as described 
below.  At the time of vaccination, mice had an average anti-adenovirus circulating NAB 
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titer of 1:165 + 22, which falls within the lower range of average values reported in 
humans after natural infection [126].  
 
2.2.2.3 Challenge with Mouse-Adapted Ebola Zaire Virus (MA-ZEBOV)  
All challenge experiments were performed under biosafety level 4 (BSL-4) 
conditions in an AAALAC accredited animal facility at the Robert E. Shope BSL-4 
Laboratory at the University of Texas Medical Branch in Galveston, Texas.  Twenty-one 
days post-immunization, vaccinated mice were transferred to UTMB where they were 
challenged on day 28 by intraperitoneal injection with 1,000 pfu (30,000 × LD50) of MA-
ZEBOV [87].  After challenge, animals were monitored for clinical signs of disease and 
weighed daily for 14 days.  At the end of the study, survivors were bled and serum 
samples γ-irradiated (5 Mrad) prior to removal from the BSL-4 lab for analysis. 
 
2.2.3 Localization and Characterization of Transduced Cells in the Sublingual 
Epithelium  
To assess adenovirus-induced gene expression and uptake patterns after 
sublingual immunization, 1.0×108 infectious particles of AdlacZ were given to B10.Br 
mice as described. Sublingual tissues were harvested 0, 2 and 24 hours post-
immunization, rinsed with saline, rapidly immersed in disposable peel-away molds 
containing Tissue-Tek® O.C.T compound (Sakura Finetek, Torrance, CA) and stored at -
80 °C prior to analysis.  To assess transgene expression, frozen trans verse sections (5 
μm) were fixed for 10 minutes in 0.5% glutaraldehyde in phosphate buffered saline (PBS, 
pH 7.4), rinsed twice for 10 minutes in PBS containing 1 mM magnesium chloride and 
 55 
incubated in PBS containing the colorimetric substrate for β-galactosidase, 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-Gal, Gold Biotechnology, St. Louis, MO), 5 
mM K3Fe(CN)6, 5 mM K4Fe(CN) 6, and 1 mM MgCl2 for 24 hours.  Antigen presenting 
cells located near the site of immunization were identified by fixing frozen sections for 
20 minutes with ice cold acetone, washing in PBS (pH 7.4) and subsequent incubation in 
3 % H2O2 (ACS Certified, Fisher Scientific, Pittsburgh, PA) for 5 minutes to inactivate 
endogenous peroxidase activity.  After washing, sections were then incubated with either 
rat anti-mouse MHC class II monoclonal antibody, rat anti-mouse CD11b monoclonal 
antibody or Armenian hamster anti-mouse CD11c antibody (all at 1:100 dilution, Abcam, 
Cambridge, MA) in PBS containing 1% bovine serum albumin (BSA, Sigma) for 2 hours 
at room temperature in a humidified chamber followed by incubation with either a 
horseradish-peroxidase-conjugated rabbit anti-Armenian hamster IgG polyclonal 
antibody (1:250, Abcam) or a rabbit anti-rat IgG polyclonal antibody (1:500, Abcam) in 
PBS and 1% BSA for 1 hour at room temperature.  Sections were further developed with 
3-amino-9-ethylcarbazole (ACE) and H2O2 substrate buffer (Sigma) and counter stained 
with Mayer`s hematoxylin (Sigma-Aldrich).  Sections were examined under light 
microscopy with a Lecia DM LB microscope (Leica Microsystems Inc., Bannockburn, 
IL) and photographed using a Leica DFC 320 camera.  
 
2.2.4 The T Cell Response 
The T cell response to Ebola Zaire glycoprotein was assessed by evaluation the 
frequency of CD8+ T cells expressing interferon-gamma (IFN-γ) by flow cytometery and 
ELISPOT.  The effector memory T cell response was evaluated by measuring cell 
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proliferation after stimulation with an Ebola-glycoprotein-specific peptide in vitro and by 
an in vivo cytotoxic T cell (CTL) assay.  
 
2.2.4.1 Intracellular cytokine staining 
Ten days after vaccination, mice were sacrificed and single cell suspensions of 
splenocytes isolated by grinding tissues through sterile cell strainers (70 µm mesh, BD 
Falcon, Franklin Lakes, NJ) into sterile 50 ml conical tubes containing Leibovitz's L-15 
medium (Mediatech, Inc., Herndon, VA).  Cells were pelleted by centrifugation and red 
blood cells removed though lysis by resuspending the pellet in an equal volume of ACK 
lysis buffer (Quality Biological, Inc., Gaithersburg, MD) for 2 minutes.  Cells were 
washed three times with sterile PBS to completely remove the lysis buffer and the 
concentration adjusted to 2×106 cells/well in complete Dulbecco’s Modified Eagle′s 
Medium (DMEM, Mediatech), 50 µM β-mercaptoethanol (Sigma), penicillin (10,000 
I.U./ml)/streptomycin (10,000 µg/ml) (Gibco, Invitrogen, Grand Island, NY), L-
glutamine (1mM, Hyclone, Salt Lake City, UT), 50 U/ml mouse interleukin-2 (IL-2, R & 
D Systems, Minneapolis, MN), 1 mM sodium pyruvate (Lonza, Walkersville, MD), 1 
mM non-essential amino acids (Lonza), and 1 µg/ml Brefeldin A (Sigma).  Cells were 
cultured for 5 hours at 37°C in 5% CO2 with the TELRTFSI peptide (5 μg/ml, New 
England Peptide, Gardner, MA) that carries the Ebola Zaire glycoprotein 
immunodominant MHC class I epitope for mice with the H-2k haplotype (B10.Br) [265] 
as described previously [101].  Negative control cells were stimulated with an irrelevant 
peptide, which carries a binding sequence for influenza hemagglutinin (YPYDVPDYA, 5 
μg/ml, GenScript, Piscataway, NJ).  Samples were incubated with PerCP-Cy5.5-labeled 
anti-CD3ε and fluorescein isothiocyanate (FITC)-labeled CD8α antibodies (1:150 in 
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PBS, BD Pharmingen, San Diego, CA) for 30 minutes at 4 °C.  Cells were then fixed and 
permeabilized with Cyto-fix/Cytoperm (BD Pharmingen) for 20 minutes at 4 °C.  For 
intracellular cytokine staining, cells were washed with Cytoperm wash buffer and stained 
with phycoerytherin (PE)-labeled anti-mouse IFN-γ antibody (1:150 in Cytoperm, BD 
Pharmingen) for 30 minutes at 4 °C.  Cells were washed twice and positive cells counted 
using three-color flow cytometry (FACS Calibur, BD Biosciences, Palo Alto, CA) in The 
University of Texas at Austin Flow Cytometry Core Facility.  Over 500,000 events were 
captured per sample.  Data were analyzed by FCS Express (Version 3, De Novo 
Software, Los Angeles, CA).  A response was considered to be positive when the 
frequency of IFN-γ positive CD8+ T cells in samples stimulated with the relevant peptide 
was more than 5 times that obtained from cells stimulated with the irrelevant peptide. 
 
2.2.4.2 ELISPOT 
ELISPOT assays were performed using the ELISpot Mouse Set (BD Pharmingen) 
according to the manufacturer’s instructions.  Briefly, a 96-well ELISPOT plate was pre-
coated with 5 μg/ml anti-mouse IFN-γ capture antibody overnight at 4 °C.  Coated wells 
were blocked with complete DMEM for 2 hours at room temperature.  Cells were 
isolated from the spleen, bronchoalveolar lavage fluid, MLNs and SMLNs as described, 
washed twice with complete DMEM and added to each well (5×105 cells/well) with the 
TELRTFSI peptide (0.5 μg/well).  Plates were placed at 37°C for 20 hours with 5% CO2.  
Negative control cells were incubated with an irrelevant peptide (YPYDVPDYA, 0.5 
μg/well).  Wells were washed twice with water to lyse cells and then washed with buffer 
(0.05% Tween-20 in PBS, pH 7.4) and subsequently incubated with biotinylated anti-
mouse IFNγ antibody at a concentration of 2 µg/ml for 2 hours at room temperature.  
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Following three consecutive washes with buffer, wells were incubated with 5 µg/ml 1 of 
horseradish peroxidase (HRP)-conjugated streptavidin antibody for 1 hour at room 
temperature.  Wells were then washed once with buffer, once with PBS alone and 
developed with AEC substrate (Sigma).  Spots were counted using an automated ELISpot 
reader (CTL-ImmunoSpot® S5 Micro Analyzer, Cellular Technology Ltd., Shaker 
Heights, OH). 
 
2.2.4.3 CFSE assay 
Splenocytes were isolated 42 days post-vaccination as described and stained using 
the Vybrant CFDA SE Cell Tracer kit (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol.  Briefly, mononuclear cells were extensively washed with pre-
warmed wash media (PBS + 0.1 % BSA) and stained with 5 μM of CFDA SE for 10 
minutes at 37°C and 5% CO2.  Cells were then washed twice with complete RPMI-1640 
media (Mediatech) containing 10% FBS, penicillin (10,000 I.U./ml)/streptomycin 
(10,000 µg/ml), 1mM non-essential amino acids, 1mM sodium pyruvate and 50 µM β-
mercaptoethanol, brought to a concentration of 5×106 cells/well and cultured for 5 days at 
37°C with 5% CO2 in the presence of the TELRTFSI peptide (5 μg/ml).  Cell surface 
markers were identified with a cocktail of antibodies (perCPCy5.5 labeled–anti-CD8, PE 
labeled–anti-CD44, and allophycocyanin (APC) labeled–anti-CD62L, 1:150, BD 
Pharmingen).  For evaluation of adenovirus serotype 5-specific memory CD4 T cell 
proliferation, CFSE staining was performed as described except that 5×106 CFSE labeled 
mononuclear cells were incubated with 5×1010 particles of a recombinant adenovirus 
serotype 5 that does not contain a transgene cassette (AdNull) [266] to exclude transgene 
specific proliferation for 5 days at 37° C with 5% CO2. These cells were then stained with 
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PE-anti-CD3ε and PerCP-Cy5.5-CD8α antibodies (1:150 in PBS, BD Pharmingen) for 
30 minutes at 4 °C.  All samples were analyzed by flow cytometry. Over 1,000,000 
events were captured per sample for these assays.     
 
2.2.4.4 In Vivo Cytotoxic T Lymphocyte (CTL) Assay. 
In vivo CTL assays were performed according to established methods [267-269].  
Splenocytes from naïve B10.BR mice were isolated as described and split into two 
populations.  One population was stained with 5 μM CFSE (CFSEHI) and the other with 
0.5 μM (CFSELOW) for 10 minutes at 37° C.  After washing with RPMI-1640, CFSEHI 
cells were pulsed with 5 µM of TELRTFSI peptide for 45 minutes at 37°C and 5% CO2.  
The CFSELOW population was maintained under the same conditions without peptide.  
CFSEHI cells were extensively washed with sterile PBS to remove unbound peptide and 
counted. CFSELOW cells were treated in the same manner.  Cells from each population 
were mixed at a 1:1 ratio and further diluted in sterile PBS to a concentration of 1×108 
cells/ml.  A total of 2×107 cells from this mixture in 200 µl of sterile PBS were injected 
via the tail vein into naive control mice and those that had been previously vaccinated 
with Ad-CAGoptZGP.  Twenty-four hours after adoptive transfer of CFSE-labeled target 
cells, mice were sacrificed and single cell suspensions from the spleen and SMLNs were 
isolated.  Differential CFSE intensities from each isolated population were assessed by 
flow cytometery.  Percent specific lysis of target (CFSEHI) cells was calculated as:  
• Percent lysis = [1 – (ratio control mice/ratio vaccinated mice)] × 100;  
• Ratio = percent CFSELOW/percent CFSEHI 
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2.2.5 The B Cell Response 
Anti-Ebola Zaire glycoprotein antibodies were characterized by ELISA.  Anti-
adenovirus antibodies were quantitated using an in vitro neutralization assay.  For these 
assays, mice were terminally bled 42 days after immunization and serum separated from 
whole blood by centrifugation.  Bronchioalveolar lavage fluid was collected in situ with a 
20G catheter inserted into the proximal trachea, flushing the lower airways 3 times with 1 
milliliter of Leibovitz's L-15 medium (Mediatech).  All samples were stored at -80 °C 
and heat-inactivated at 56°C for 30 minutes prior to analysis. 
 
2.2.5.1 Production of Recombinant Ebola Zaire Glycoprotein  
Full length Ebola Zaire glycoprotein was produced using the Zaire GP33-637ΔTM-
HA construct according to published methods [270, 271].  HEK 293T cells (70% 
confluent) were transfected with the plasmid in DMEM containing 10% FBS, 1% 
Penicillin/Streptomycin, 1mM L-glutamine and 1mM sodium pyruvate using a standard 
calcium phosphate transfection kit (Clontech, Mountain View, CA). Supernatant was 
harvested 4 days later, concentrated using a centrifugal filter device (Centricon plus-100, 
Millipore, Billerica, MA) and purified by anti-HA immunoaffinity chromatography 
(Roche, San Francisco, CA).  
 
2.2.5.2 Characterization of Ebola Zaire Glycoprotein-Specific Antibodies 
Flat bottom, untreated 96 well plates (Evergreen Scientific, Los Angeles, CA) 
were coated with purified recombinant full-length Ebola Zaire glycoprotein (0.5 µg/well) 
in PBS (pH 7.4) overnight at 4°C, washed 4 times with PBS containing 0.05% Tween 20, 
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and blocked in PBS (pH 7.4) containing 1% ELISA grade BSA (Sigma) for 1 hour at 
room temperature. Heat-inactivated serum and BAL were serially diluted in 2-fold 
increments in sterile PBS.  One hundred microliters of each dilution was added to the 
antigen-coated plates for 2 hours at room temperature.  Plates were washed 4 times with 
PBS containing 0.05% Tween 20 and incubated with HRP-conjugated goat anti-mouse 
IgG, IgG1, IgG2a, IgG2b, IgA and IgM antibodies (1:2,000, Southern Biotechnology 
Associates, Birmingham, AL) in separate wells for 1 hour at room temperature. Plates 
were washed and 200 µl of substrate solution (0.4 mg/ml o-phenylenediamine (Sigma) in 
50 mM phosphate-citrate buffer, pH 5.0 with 0.03 % (v/v) hydrogen peroxide) added to 
each well.  The plate was incubated at room temperature for 10 minutes and optical 
densities read at 450 nm on a microplate reader (Tecan USA, Research Triangle Park, 
NC).  Endpoint titers were expressed as the reciprocal log2 titer of the last dilution giving 
an OD at 450 nm of 0.1 units higher than background according to the method of Frey et 
al. [272].   
 
2.2.5.3 Anti-Adenovirus Serotype 5 Neutralizing Antibody  
Circulating anti-adenovirus antibody levels were assessed in samples from mice 
in which pre-existing immunity was established prior to immunization according to 
established methods [273].  Heat-inactivated serum was diluted in DMEM in twofold 
increments starting from a 1:20 dilution. Each dilution was mixed with adenovirus 
expressing β-galactosidase (1 × 106 pfu), incubated for 1 hour at 37 °C and applied to 
HeLa cells seeded in 96-well plates (1 × 104 cells/well).  After this time, 100 µl of 
DMEM supplemented with 20% FBS were added to each well.  Cells were incubated for 
24 hours and expression of β-galactosidase measured by histochemical staining.  For 
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each sample, the serum dilution that corresponded to a 50% reduction in transgene 
expression was obtained by the proportionate distance method. The absence of 
neutralization in samples containing medium only (negative control) and FBS (serum 
control) and an average titer of 1:1,280 + 210 read from an internal positive control stock 
serum were the criteria for qualification of each assay.  
 
2.2.6 Serum Cytokines and Transaminases 
Cytokines (IL-6, IL-12, TNF-α, IL-2 and IL-10) were quantitated with 
commercially available ELISA kits according to the manufacturer's protocols (Invitrogen, 
BioSource International, Camarillo CA).  Serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels were determined using Vitros AST/SGOT and 
ALT/SGPT DT slides on a Vitros DTSC autoanalyzer (Ortho Clinical Diagnostics, 
Rochester, NY). 
 
2.2.7 Statistical Analysis 
Data were analyzed for statistical significance using SigmaStat (Systat Software 
Inc., San Jose, CA) by performing a one-way analysis of variance (ANOVA) between 
control and experimental groups, followed by a Bonferoni/Dunn post-hoc test when 
appropriate. Differences in the raw values among treatment groups were considered 
statistically significant when p<0.05.  
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2.3. Results  
2.3.1 Immunohistochemical Analysis of Transgene Expression and Accumulation of 
Antigen Presenting Cells Induced by Sublingual Administration of an Adenovirus-
Based Vaccine  
In order to evaluate the sublingual mucosa as a potential target for adenovirus-
based vaccines, we first examined transgene expression in TR146 cells, an established 
model of human oral mucosa [274, 275], and mice.  The virus easily infected human oral 
epithelial cells, with nearly every cell expressing high levels of β-galactosidase 24 hours 
after infection (Figure 2.1b).  Frozen transverse sections obtained from mice given saline 
clearly illustrated the thick keratinized, pluristratified squamous epithelial layer that 
covers the murine sublingual mucosa, the lamina propria and numerous fibroblasts that 
lie underneath (Figure 2.1c).  Clusters of acinar cells located in the lamina propria stained 
positive for β-galactosidase 24 hours after administration of a single sublingual dose of 1
×108 infectious virus particles (ivp) (black arrows, Figure 2.1e).  The transgene could not 
be detected in sections from animals given saline (Figure 2.1c) and those necropsied 2 
hours after immunization (Figure 2.1d).   Because antigen presenting cells at the site of 
administration are a key determinant of the potency of a vaccine, histochemical staining 
was also performed to trace migration patterns of MHC class II cells in the sublingual 
tissue over time. MHC class II+ cells were widely disseminated in both the epithelial 
layer and the lamina propria of sections taken from untreated animals (Figure 2.1f).  Two 
hours after sublingual immunization, large clusters of MHC class II+ cells were noted at 
the delivery site (Figure 2.1g).  Further characterization of these cells revealed that they 
were predominantly CD11c(+)/CD11b(-) (Figures 2.1i-1n). 
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Figure 2.1 Adenovirus Serotype 5 Efficiently Transduces TR146 Cells and the 
Murine Oral Mucosa after Sublingual Administration and Stimulates Migration of 
CD11c(+)/CD11b(-) Antigen Presenting Cells to the Delivery Site.   a) Uninfected 
TR146 cells.   b) TR146 cells infected with adenovirus 5 expressing β-galactosidase 
(MOI 30) for 24 hours prior to histochemical staining.  c) Longitudinal section of 
sublingual mucosa from an animal given saline (Vehicle) stained for endogenous β-
galactosidase expression (none noted).  d) Buccal mucosa obtained 2 hours after 
sublingual administration of 1 × 108 ivp of AdlacZ stained for β-galactosidase expression 
(none noted).  e) β-galactosidase expression in submandibular glands 24 hours after 
treatment (black arrows).  f) Cryosection from mouse given saline stained for cells 
expressing MHC class II antigens (brown dots). g) Cryosection taken 2 hours after 
administration of adenovirus and stained for the presence of MHC class II+ cells.  h) 
MHC class II+ cells in the oral mucosa 24 hours after administration of adenovirus.  
Cells staining positive for MHC II antigens were also positive for CD11c surface 
molecules (Panels i-n).  Magnification: Panels a-f, h, i and l 200×; Panel h, j, k, m, 
and n 100× . 
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2.3.2 Systemic and Mucosal T Cell Responses Against Ebola Glycoprotein After 
Sublingual Immunization of Naïve Mice and Those with Pre-Existing Immunity to 
Adenovirus  
To evaluate the CD8+ T cell-mediated immune response against Ebola Zaire GP 
elicited after sublingual immunization, naïve B10.Br mice and those with established pre-
existing immunity to adenovirus were given 1×108 ivp of the vaccine by the 
intramuscular (IM), intranasal (IN), sublingual (SL) and oral (PO) routes.  Ten days later, 
mice were sacrificed, splenocytes harvested and the proportion of Ebola Zaire GP-
specific interferon-gamma (IFN-γ) producing CD8+ T cells evaluated by flow cytometry.  
As seen previously [101], IM administration induced the strongest response in naïve mice 
(Figure 2.2a).  This was reduced by 85.7% in mice with prior exposure to adenovirus.  
Although the frequency of IFN-γ producing CD8+ T cells was much lower in mice 
vaccinated by the IN and SL routes (2.25 and 1.37% respectively), pre-existing immunity 
suppressed the response elicited by these delivery methods to a lesser degree (36% IN 
and 33% SL).  Oral immunization failed to produce significant numbers of IFN-γ 
producing CD8+ T cells in both naïve mice and those with pre-existing immunity.  
Similar trends were noted for ELISPOT data (Figure 2.2b). 
Since primary Ebola infections occur through direct exposure of mucosal surfaces 
to blood or bodily fluids from infected patients [260], the mucosal T cell-mediated 
immune response was also evaluated by quantifying the number of IFN-γ secreting 
mononuclear cells harvested from various compartments.  In contrast to what was 
observed for the systemic response, pre-existing immunity significantly increased the 
number of activated IFN-γ secreting cells in the bronchoalveolar lavage fluid (BAL) of 
mice immunized by the IM route (p<0.001, Figure 2.2b).  B10.Br mice (10/group) were 
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given 1 × 108 ivp of a recombinant adenovirus expressing Ebola Zaire GP by various 
routes. A subset of mice from each treatment group (n=5) were given 2.5 × 1011 particles 
of adenovirus containing the β-galactosidase transgene by intramuscular injection 28 
days prior to vaccination to establish pre-existing immunity.  This group is denoted as 
PEI.  Mice treated in this manner had an average antibody titer of 1:165 + 22 prior to 
vaccination.  Prior exposure to the virus did, however, significantly reduce the number of 
IFN-γ secreting cells in the submandibular lymph nodes (SMLN, 85 + 13.9 spot-forming 
cells (SFCs)/million mononuclear cells (MNCs), naïve vs. 23.8 + 4.7 SFCs/million 
MNCs, pre-existing immunity (PEI), p<0.001) and mesenteric lymph nodes (MLN, 134.5 
+ 6.6 SFCs/million MNCs, naïve vs. 18.5 + 14.1 SFC/million MNCs, PEI p<0.05) (IM, 
Figure 2.2b).  Although prior exposure to adenovirus did not compromise the number of 
IFN-γ secreting cells in BAL and MLN of mice immunized by the IN route, a significant 
rise in the number of these cells in the SMLNs was noted (28.5 + 6.8 SFCs/million 
MNCs naïve vs. 64.8 + 10.2 SFC/million MNCs, PEI p<0.01).  The mucosal T cell 
response elicited by SL immunization was the most profoundly enhanced in the SMLNs 
and MLNs of mice with PEI to adenovirus (p<0.001 and p<0.05 respectively).  The T cell 
response in BAL was not compromised by PEI in this treatment group (Figure 2.2b). 
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Figure 2.2 Pre-Existing Immunity to Adenovirus Strengthens the CD8+ T cell 
Response Against Ebola Zaire Glycoprotein in Mice Immunized by the Sublingual 
Route.  Panel A. Systemic CD8+ T Cell Response in Naïve Mice and those with Pre-
Existing Immunity to Adenovirus.  Numbers written in each box represent the proportion 
of each cell population that was activated by Ebola Zaire GP-specific peptide sequences.  
Panel B. Mucosal CD8+ T Cell Response.  Lymphocytes were harvested from various 
compartments of individual mice and analyzed by ELISPOT 10 days after immunization.  
Results are reported as the mean ± the standard error of the mean. *, p<0.05, **, p<0.01, 
***, p<0.001, one-way ANOVA, Bonferroni/Dunn post-hoc analysis.  
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2.3.3 Effect of sublingual immunization on localized and systemic antibody 
production 
Sublingual immunization with 1 × 108 ivp of our vaccine significantly increased 
anti-Ebola Zaire GP IgG1, IgG2 and IgM responses in naive mice with respect to the 
same dose given by the IM route (Figure 2.3a).  IgM was the only isotype reduced by 
pre-existing immunity to the adenoviral vector (Figure 2.3b).  Aside from this, there was 
no significant difference between anti-Ebola Zaire GP IgG1 and IgG2 levels obtained 
from naïve mice immunized by the SL route and those with prior exposure to adenovirus 
(Figures 2.3a and 2.3b).  Similar trends were noted after intranasal administration.  In 
contrast, pre-existing immunity did significantly reduce total IgG and IgG1 levels in mice 
vaccinated by the intramuscular route by a factor of 1.5 and completely obliterated 
production of 1gG2a and IgM (Figures 2.3a and 2.3b).  Pre-existing immunity to 
adenovirus significantly compromised total anti-Ebola Zaire GP IgG, IgG1, IgM levels of 
animals vaccinated orally.  IgG2a and Ig2b could not be detected in any samples from 
this treatment group (Figure 2.3b).  Immunization by the SL and IN routes elicited 
notable anti-Ebola Zaire GP IgG and IgM in BAL with respect to the IM route that were 
not compromised by pre-existing immunity to adenovirus (p<0.05, Figure 2.3d).  Anti-
Ebola Zaire GP IgG and IgM were not detected in BAL from animals immunized orally. 
Anti-Ebola Zaire GP IgA antibodies were not detected in serum or BAL samples taken 
from all treatment groups. 
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Figure 2.3 Sublingual Immunization Induces Higher Levels of Ebola Zaire-Specific 
IgG and IgM Antibodies in Serum and BAL than Intramuscular Immunization that 
are not Compromised by Pre-existing Immunity.  Serum (Panels A and B) and 
bronchoalveolar lavage fluid (BAL, Panels C and D) were collected from naïve mice and 
those with prior exposure to adenovirus 42 days after immunization by various routes. 
End point titers are expressed as the reciprocal log2 titer of the last dilution giving an OD 
at 450 nm of 0.1 units higher than background.  Results are expressed as average values + 
the standard error of the means and are representative of two separate experiments each 
containing 4 mice per immunization route.  *, p<0.05, **, p<0.01, ***, p<0.001, one-way 
ANOVA, Bonferroni/Dunn post-hoc analysis. 
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2.3.4 Effect of Sublingual Immunization on the Generation of Local and Systemic 
Ebola-Zaire Glycoprotein-Specific Effector Memory and Effector Cytotoxic T Cell 
Responses  
CD8 T cell memory is a crucial component of protective immunity against 
microbial infection.  Memory T cells, a heterogeneous population that can be separated 
into central and effector subsets, respond with enhanced kinetics and magnitude to ensure 
protection against re-infection [276].  Central memory cells, located in lymphoid organs, 
express CD44 and CD62L (CD44hiCD62Lhi), are highly proliferative and slowly respond 
to antigen [277].   Effector memory T cells with increased levels of CD44 but markedly 
reduced levels of CD62L (CD44hiCD62Llo), have less proliferative potential, re-circulate 
preferentially through non-lymphoid tissues, and are immediately cytolytic upon re-
exposure to antigen [278]. The presence and cytolytic activity of effector memory T cells 
after sublingual immunization were assessed by two separate assays.  Ebola Zaire GP-
specific T cells harvested from the spleen 42 days after immunization were first tested for 
their ability to rapidly proliferate when pulsed with an Ebola Zaire GP-specific peptide in 
an in vitro CFSE assay (Figures 2.4A and 2.4B).  Five days after restimulation, 3.7 + 
0.6% effector memory CD8+ T cells obtained from mice given the vaccine by IM 
injection had undergone proliferation in response to the antigenic epitope (Figure 2.4B).  
This was quite similar to that found in samples obtained from mice given the vaccine by 
the IN route (3.02 + 0.4%) and approximately twice that found in samples from mice 
immunized by the SL route (1.6 + 0.1%) and four times that found in samples from mice 
immunized orally (0.72 + 0.08%).   
In order to determine if a single SL dose of our vaccine could induce functional 
anti-Ebola Zaire GP effector CTL responses, in vivo CTL assays were performed. 
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Syngeneic splenocytes harvested from naïve mice and pulsed with ZEBOV GP-specific 
peptide served as targets that were transferred to vaccinated mice 42 days after 
immunization.  Before transfer, pulsed cells were labeled with CFSE dye, to facilitate 
monitoring of cell fate in vivo by flow cytometry in the spleen and submandibular lymph 
nodes.  As an internal control, the same number of non-pulsed splenocytes labeled with a 
lower concentration of CFSE was co-injected with the pulsed cells.  The shift in the ratios 
of the two CFSE positive populations provoked by elimination of the pulsed cells, as seen 
in Figure 2.4C, allows for quantitative measurement of cell lysis in response to the Ebola 
glycoprotein antigen.  Significant elimination of the pulsed CFSEHI population was noted 
in both the spleen (83.6 + 0.2%) and submandibular lymph nodes (79.2 + 0.8%) of mice 
vaccinated by intramuscular injection (Figure 2.4D).  The observed killing activity 
induced by IN and SL immunization was somewhat lower in both the spleen (34.4 + 
1.1%, IN, 26.9 + 0.8% SL) and SMLNs (26.5 + 2.2%, IN, 17.2 + 2.0% SL).   
 
2.3.5 Toxicological Profile of the Adenovirus-Based Vaccine after Sublingual 
Administration   
Administration of recombinant adenovirus induces a potent innate immune 
response largely directed against the vector and later against the transgene product.  
These effects are highlighted by significant increases in serum cytokines (IL-6, IL-12, 
TNF-α) as early as 6 hours and return to baseline within 24 hours after administration 
[279].  Hepatotoxicity can also occur, as indicated by sharp increases in serum 
transaminases (AST/ALT) 4-7 days after treatment [280].    
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Figure 2.4 Sublingual Immunization Can Induce Long-Lasting Antigen-Specific T 
Cell-Mediated Immune Responses.  Panel A. Scatter Plot Illustrating the CD8 Effector 
Memory T Cell Response to an Ebola Glycoprotein-Specific Peptide as Determined In 
Vitro.  Panel B. Quantitative Analysis of the Effector Memory T Cell Response: CFSE 
Assay.  Panel C. Histograms Illustrating the Ebola Glycoprotein-Specific Cytolytic T 
Cell Response In Vivo.  The number above each peak in the histogram plot denotes the 
percentage of gated CFSEHI (right peak) and CFSELOW (left peak) cells for each 
subpopulation.  Panel D. Quantitative Analysis of the Effector Cytotoxic T Cell 
Response: In Vivo CTL Assay. Data represent the average values obtained from two 
separate experiments each containing 4 mice per treatment group.   
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In order to evaluate the innate immune response to the adenoviral vector, serum samples 
were collected 6 hours after immunization and analyzed for IL-6, IL-12 and tumor 
necrosis factor alpha (TNF-α).  Serum IL-6 was significantly elevated after immunization 
by the IM (876.5 + 114.5 pg/ml, p<0.001) and IN (498.3 + 169.4 pg/ml, p<0.01) routes 
with respect to mice given saline (23 + 16 pg/ml, data not shown).  Although IL-6 was 
found in samples obtained from mice vaccinated by the SL (55.6 + 25.4 pg/ml) and PO 
(14.9 + 8.0 pg/ml) routes, they were not statistically different from baseline values 
(Figure 2.5A).   Although IL-12 (112.2 + 35.8 pg/ml) and TNF-α (28.1 + 21.7 pg/ml) 
levels of mice immunized by the IM route were approximately 1.5 times that of baseline 
values (Figures 2.5B and 2.5C), circulating amounts of each cytokine were not 
statistically different from baseline in samples obtained from mice immunized by the IN, 
PO and SL routes. Serum transaminse levels followed a similar pattern with alanine 
(ALT) and aspartate (AST) aminotransferase levels in samples from mice vaccinated by 
the IM route spiking 4 days after treatment to 3 times baseline, while samples from 
animals immunized by other routes were within baseline values (ALT: 31.5 + 0.95 U/L, 
AST: 49 + 5.8 U/L, Figure 2.5d).  AST and ALT levels of those vaccinated by IM 
injection returned to baseline by day 7 (data not shown). 
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Figure 2.5 Sublingual Immunization Significantly Reduces Production of IL-6 in 
Response to the Adenovirus Vector and Minimizes Toxicity Associated with 
Adenovirus-Based Vaccines.  Serum IL-6 (A), IL-12 (B) and TNF-α (C) were assessed 
from samples taken from B10.Br mice 6 hours after administration of a single dose of 1 × 
108 ivp of a first generation adenovirus expressing Ebola Zaire glycoprotein by various 
routes.  (D ) Serum amino alanine (ALT) and aspartate (AST) aminotransferase levels 
were evaluated 4 days after immunization. Data reflect average values + the standard 
error of the mean for four mice from each treatment group. *, p<0.05, **, p<0.01, ***, 
p<0.001, one-way ANOVA, Bonferroni/Dunn post-hoc analysis.   
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2.3.6 Effect of Sublingual Immunization on Survival after Challenge with Mouse-
Adapted Ebola Zaire 
As a final test to evaluate the utility of our sublingual immunization strategy, 
naïve mice and those with prior exposure to adenovirus were vaccinated with 1×108 ivp 
by the IM and either 1×108 ivp or SL routes and challenged with a lethal dose of mouse-
adapted Ebola Zaire (1,000 pfu ~ 30,000 × LD50).  In order to identify a dose that would 
only offer partial protection when given sublingually, a separate group of naïve mice 
were given 1×107 ivp of the vaccine (SL (low), Figures 2.6A and 2.6B) and challenged in 
the same manner.  The challenge was uniformly lethal in control mice given saline.  In 
contrast, all of the mice vaccinated by the IM route survived without notable loss of body 
weight.  Eighty percent of the mice given the same dose of the vaccine by the SL route 
survived challenge while 70% survived after treatment with the lower dose (1×107 ivp) by 
the same route.  In line with previous studies [101], prior exposure to adenovirus 
significantly compromised the efficacy of the vaccine when given by the IM route with 
only 20% survival observed in this treatment group (PEI/IM, Figure 2.6A).  The immune 
response elicited after SL immunization was less effected by pre-existing immunity with 
33.3% survival noted.  
Analysis of samples taken post-mortem revealed sharp elevations in serum ALT 
(4,536.7 + 617.7 U/L) and AST (6,737.5 + 1,469.9 U/L), indicative of severe liver 
damage from infection, in animals that did not survive challenge (Figure 2.6C).  Samples 
from these animals also contained elevated levels of cytokines (IL-2, 1,433.3 + 251.8 
pg/ml, IL-6, 318.3 + 139.8 pg/ml, IL-10, 862.1 + 34.2 pg/ml, Figure 2.6D), another 
hallmark of fulminant Ebola infection, while samples from survivors contained only trace 
amounts of each cytokine.  
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Figure 2.6 Sublingual Vaccination Performs in a Manner Similar to that of 
Traditional Intramuscular Vaccination with Respect to Survival after Lethal 
Challenge.  (A) Kaplan-Meier survival curve. *indicates a significant difference with 
respect to the PEI/IM treatment group  *, p<0.05, **, p<0.01, ***, p<0.001.   (B) Body 
Weight Profile After Challenge.  (C) Serum amino alanine (ALT) and aspartate (AST) 
aminotransferase levels post-challenge.  (D) Serum Cytokines Post-Challenge.  For 
panels C and D, data reflect average values + the standard error of the mean for five mice 
per group. *indicates a significant difference between values from survivors (fatalities).  
* p<0.05, ** p<0.01, ***p<0.001, one-way ANOVA, Bonferroni/Dunn post-hoc 
analysis. 
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2.3.7 Effect of Sublingual Immunization on the Immune Response to the Adenoviral 
Vector 
In an effort to understand the type of immune responses elicited against the 
adenoviral vector after SL vaccination of mice with prior exposure to adenovirus, we 
evaluated the proliferative response of adenovirus-specific memory CD8+ and CD4+ T 
cells isolated from mice with established pre-existing immunity and immunized by the 
IM, IN, and SL routes (Figure 2.7).  A fairly even distribution of CD8+ (1.5%) and CD4+ 
(1.9%) T cells were noted after stimulation of cells isolated from naïve mice immunized 
by the IM route (Figure 2.7a).  A similar response was observed in mice with prior 
exposure to adenovirus immunized by the SL route (CD8+ (1.2%) and CD4+ (1.6%)).  In 
contrast, a preferential expansion of CD4+ T cells (4.4%) with respect to CD8+ T cells 
(0.22%) in response to the virus was noted in mice with pre-existing immunity 
immunized by the IM route.  A similar trend was found in samples from mice with prior 
exposure to adenovirus immunized by the nasal route.  Pre-existing immunity also 
exponentially increased the amount of circulating anti-adenovirus antibodies after IM 
immunization as levels rose from an average of 1:165 + 22 prior to vaccination to 1:5,038 
+ 44 after treatment (Figure 2.7b).  Anti-adenovirus antibodies found in mice with pre-
existing immunity and vaccinated by the SL route were not significantly different from 
levels found prior to vaccination (1:120 + 75). 
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Figure 2.7 Sublingual Immunization Does Not Facilitate Preferential Expansion of 
Anti-Adenovirus CD4+ Memory T Cells and Curtails Production of Anti-
Adenovirus Neutralizing Antibodies in Mice with Prior Exposure to Adenovirus 
Serotype 5.  A) Adenovirus-Specific Memory T Cell Proliferation.  Splencoytes were 
harvested, labeled with CFSE and co-cultured with a recombinant adenovirus serotype 5 
vector without a transgene cassette (AdNull) for 5 days.  The number in each dot plot 
denotes the percentage of gated CFSE-negative cells for each subpopulation.  Numbers 
and gates in red indicate the CD4+ population.  Numbers and gates in blue indicate the 
CD8+ population.  B) Anti-Adenovirus Antibodies After Immunization of Mice with Pre-
Existing Immunity.  Data reflect average values + the standard error of the mean for 
samples collected from 8 mice/group over 2 separate experiments. *indicates a significant 
difference between different immunization routes. ***p<0.001, one-way ANOVA, 
Bonferroni/Dunn post-hoc analysis.  Naïve –mice given saline (negative control). 
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2.4 Discussion 
One of the primary goals of our laboratory is to develop a potent, long-acting 
vaccine for Ebola that can be given orally.  Although an oral wild type adenovirus 
vaccine has been effectively used for over 25 years in the military [281], successful 
immunization with replication defective adenoviruses by the oral route has been a 
significant challenge. Immunization with recombinant adenovirus serotype 5 encoding 
antigens from rabies, influenza, and other viruses has afforded some protection against 
infection in animals [282-284]. However, oral immunization requires a much higher dose 
[285] to elicit much lower immune responses than achieved with systemic delivery [286].  
In previous studies, 1 × 1010 virus particles (1 × 109  ivp) of our adenovirus-based Ebola 
vaccine induced markedly lower T and B cell responses than those achieved by 
intramuscular and nasal delivery, but was fully protective against Ebola challenge (200 × 
LD50) [101, 103].  A pilot study performed prior to initiating those outlined in this 
manuscript found that sublingual administration of a dose that was 10-fold lower (1 × 108 
ivp) could elicit systemic and mucosal responses that were superior to those induced by 
oral immunization and conferred 80% protection against challenge with a standard dose 
of 30,000 × LD50 of mouse adapted Ebola [87].  Although we did not challenge mice 
immunized orally in this set of experiments, we believe that they would not have 
survived given the overall poor immune response achieved by this delivery route (Figures 
2.1 – 2.3). 
Sublingual administration has been successfully used for allergen-specific 
desensitization for several decades and its safety and ease of use are well established 
[287].  In 1998, the World Health Organization (WHO) officially recognized this 
approach as a valid treatment for allergic rhinitis, asthma and hymenoptera venom allergy 
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[288].  More recently, sublingual delivery has been evaluated as a viable means for 
effective immunization against bacterial (H. pylori, C. trachomatis), parasitic (P. 
falciparum) and viral (measles, influenza, papilloma, human immunodeficiency) 
pathogens [289-295].  In the context of vaccine development, the majority of these 
protocols required several doses of the inactivated microbe or recombinant antigenic 
proteins formulated with one or several adjuvants for successful protection against 
challenge with the wild-type pathogen.  Çuburu et al. found that administration of several 
doses of human papiloma (HPV) virus-like particles without adjuvant successfully 
mounted an immune response sufficient to clear a recombinant HPV vector from the 
systemic circulation of vaccinated mice [291].  In addition, a single dose of live influenza 
given by the sublingual route without adjuvant afforded heterosubtypic and homologous 
protection against challenge with different strains of influenza [296].  The majority of 
these studies, regardless of antigen, adjuvant or recombinant vaccine carrier, identify the 
submandibular lymph nodes as the primary inductive sites for the immune response and 
that antigens are captured locally by Langerhans cells and MHC II+ dendritic cells 
through phagocytosis, macropinocytosis or receptor-mediated endocytosis. These cells 
then travel to the lymph nodes, where, based upon the nature of the antigen, the type of 
antigen presenting cell and the local microenvironment (cytokine, chemokine signals), 
they incite pro-inflammatory conditions for strong, broad cellular and humoral protective 
immune responses [297, 298].  It has recently been found that activation of immune cells 
in the submandibular lymph nodes takes place through antigen/adjuvant-mediated 
expression of CCR7 on MHC II+ dendritic cells and subsequent migration in response to 
CCL19 and CCL21 chemokines produced within the lymph node [299].  In many cases, 
this favored T helper type 1 (Th1) responses [292].  
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Prior to this work, few reports have described the transduction efficiency of 
recombinant adenoviral vectors in the sublingual and buccal mucosa [300, 301].  
Recombinant adenovirus 5 easily transduced an established model of the human 
submucosal epithelium in vitro as well as that of the mouse in vivo (Figure 2.1).  We also 
found that sublingual delivery of the virus rapidly attracted a significant number of MHC 
II+ antigen presenting cells to the site for a limited period of time.  Several different types 
of dendritic cells are located throughout the murine oral mucosa such as myeloid 
dendritic cells present at the mucosal/submucosal junction, Langerhans cells located 
within the mucosal epithelium and plasmacytoid dendritic cells found in the submucosal 
region [297, 302].  In an effort to identify innate mechanisms that influence T cell 
responses following immunization with recombinant adenoviruses, Lindsay et al. found 
that the virus does not efficiently transduce plasmacytoid dendritic cells but does infect 
CD11c(+)CD8(-)B220(-) migratory dendritic cells and a small population of 
CD11c(+)CD8(+)B220(-) cells efficiently in vivo [303]. Seventy two hours after the virus 
was given, a notable population of CD11b(+)/F4/80(+)/DEC205(+) cells expressing the 
transgene was detected.  This phenotype is consistent with that of migrating Langerhans 
cells [121].  This and the fact that the majority of our MHC II (+) population were also 
positive for CD11c, suggest that CD11c(+)CD8(+)B220(-) cells were responsible for the 
Ebola Zaire GP-specific CD8+ T cell response against Ebola Zaire GP after sublingual 
administration.  This response may have been further supported by stimulation of helper 
T cells by CD11c(+)CD8(-)B220(-) migratory dendritic cells and/or Langherhans cells 
activated either through direct infection or by endocytosis and processing of the Ebola 
Zaire GP produced by transduced epithelial cells within the submucosa. Although a 
limited number of resident plasmacytoid dendritic cells were likely infected with the 
recombinant adenovirus, they could be responsible for the observed trend toward Th2 
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responses, as indicated by the IgG1/IgG2a ratios found in samples obtained from mice 
immunized by the sublingual route (Figure 2.3).  Additional studies to characterize the 
types of antigen presenting cells that collect in the submucosa, their transduction and 
migration patterns are warranted in order to provide an accurate assessment of the 
manner by which sublingual immunization with recombinant adenovirus-based vaccines 
confers protective immunity are warranted. 
Prior exposure to adenovirus serotype 5 remains a significant issue and continues 
to limit the clinical utility of this vector for immunization and gene transfer applications. 
Although anti-adenovirus 5 antibody levels are generally low before age 2, when many 
immunization regimens are initiated or completed, they increase with age [304] and vary 
according to geographical location with the lowest levels found in the United States (30-
60% of the population positive), moderate levels in Europe and Asia (40-80% positive) 
and the highest levels found to date in sub-Saharan Africa (80-100% positive) where 
many vaccines are needed [126].  In the studies outlined here, pre-existing immunity to 
the adenovirus was induced by a single intramuscular injection of 2.5×1011 particles of an 
unrelated virus 30 days prior to immunization.  Although there is some debate about how 
closely this mimics real life infections since adenovirus serotype 5 is commonly acquired 
through the respiratory mucosa, this method did elicit systemic levels of anti-adenovirus 
antibodies that fell within the range of that observed in the general population [126].  Pre-
existing immunity induced in this manner significantly compromised the systemic 
antigen-specific T cell response in all treatment groups (Figure 2.2b).  Despite this, the 
antigen-specific T cell response in the submandibular and mesenteric lymph nodes was 
significantly enhanced and the B cell response unaffected by prior exposure to adenovirus 
in mice immunized by the sublingual route (Figures 2.2b and 2.3). Although the nature of 
this response is not understood at this time, it is apparent that pre-existing immunity 
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enhanced infection of local antigen presenting cells and/or recruited more cells to the site 
of immunization that were infected with the virus, resulting in an increase in the number 
of antigen-specific CD8+ T cells in the regional lymph nodes.  In contrast, pre-existing 
immunity limited the amount of virus that could reach systemic compartments and, in 
turn, a lower overall systemic response was noted with respect to that observed in naïve 
mice.  The B cell response may not have been compromised since local uptake and 
processing of the Ebola glycoprotein in dendritic and other migratory antigen presenting 
cells was not compromised by pre-existing immunity as it was established in our model.  
Additional studies evaluating the response after pre-existing immunity is established by 
nasal instillation of adenovirus prior to immunization and characterization of transduction 
and activation patterns of regional and systemic antigen presenting cells are currently 
underway in our laboratories. 
Although sublingual immunization elicited antigen-specific T and B cell 
responses at a level similar to that achieved by nasal immunization in naïve mice, 
protection against challenge was significant but not complete (Figure 6).    We believe 
that the primary reason for this lies in the fact that, unlike humans, the sublingual mucosa 
of the mouse is covered with a thick, keratinized surface layer.  Addition of surfactants 
like polysorbate 80 and sugars like cyclodextrins at appropriate concentrations to our 
preparations may have improved survival in this model by their ability to increase virus 
uptake and transduction efficiency [305].  Additional studies in larger animal models of 
Ebola infection (Guinea pigs, primates) which have non-keratinized mucosal linings 
similar to humans will provide additional support for the utility of sublingual 
immunization using adenovirus-based vaccines against Ebola and possibly other 
pathogens [306, 307].  Although pre-existing immunity compromised the ability of the 
sublingual vaccine to afford protection against challenge, this result does illustrate that 
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the systemic T cell response must be at a certain level for protection.  The increase in 
antigen-specific T cells in the submandibular and mesenteric lymph nodes suggests that 
the immune responses elicited by sublingual immunization in those with prior exposure 
to adenovirus may be protective against aerosol challenge with Ebola.   Plans for 
evaluation of sublingual immunization with our vaccine in larger animal models are 
currently underway and additional studies in mice using permeability enhancers and 
alternate methods of challenge are ongoing. 
Although reduction of the potency of an adenovirus-based vaccine in those with 
pre-existing immunity to adenovirus 5 is a legitimate concern, recent results from a phase 
IIb clinical trial suggesting that those with measurable anti-adenovirus antibodies given 
an adenovirus-based vaccine were more susceptible to HIV infection illustrate that pre-
existing immunity to the carrier can significantly influence the type of immune response 
elicited by the vaccine and that it may not be appropriate in the context of some 
infectious disease models.  In this particular case, the initial hypothesis was that 
adenovirus-antibody complexes enhanced maturation of dendritic cells [308] which, in 
turn, induced a preferential expansion of memory CD4+ rich in CCR5, the co-receptor 
required for HIV infection [309], in the mucosal tissues, subsequently increasing the 
number of targets available for HIV infection and replication [310].  Although it has now 
been shown that this was not the primary cause of the increase in HIV infection in 
immunized individuals with pre-existing immunity [311], we demonstrate that sublingual 
immunization with an adenovirus-based vaccine minimizes expansion of CD4+ T cells in 
mice with prior exposure to adenovirus and could be useful in mitigating untoward 
effects in special patient populations (Figure 2.7).   
To our knowledge, this is the first report in which a sublingual immunization 
strategy for effective protection against Ebola is described.  Unlike current immunization 
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strategies, sublingual delivery promotes compliance since it does not require skilled 
medical personnel and is easier to administer than nasal preparations.  This is important 
for those anxious about medical visits, common in developing countries, and allows for 
effective administration by family or the patient.  Nasal vaccination can induce unwanted 
effects in the nervous system with reports of Bell’s palsy in patients given an inactivated 
influenza vaccine containing a toxin-based adjuvant [312] and adenoviral vectors in the 
olfactory bulb in mice causing concern for long-term effects associated with these 
vaccines [313].  To date, no side effects have been reported as a result of sublingual 
delivery of antigen [287].  Our results also indicate that while the antigen-specific 
immune response was compromised by prior exposure to the adenovirus, sublingual 
administration of the vaccine significantly reduced anti-viral immune responses that have 
been previously associated with untoward effects in special patient populations.  
Inclusion of reagents that promote transduction and subsequent antigen expression and 
modification of capsid proteins to target specific antigen presenting cell populations will 
further improve the utility of this highly favorable delivery route. 
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CHAPTER THREE 
Modeling Pre-Existing Immunity to Adenovirus in Rodents: 
Immunological Requirements for Successful Development of a rAd5-
based Ebola Vaccine  
3.1 Introduction  
Human adenovirus serotype 5 (Ad5) is currently a very attractive vaccine 
platform that can induce strong innate and adaptive immune responses against encoded 
antigens with only mild side effects [164-166].  Therefore, recombinant Ad5 (rAd5)-
viruses been actively developed as vaccines for many pathogenic bacteria and viruses 
(anthrax, hepatitis C, malaria, rabies, botulism).  Many of these have been protective in 
animal models of disease [314-317].  While these results are quite encouraging, pre-
existing immunity (PEI) to Ad5 in the general population is considered to be a major 
hurdle that has prevented progression of these vectors to the clinic.  Recent data suggests 
that approximately 37% of people in the U.S., 79.87% in South Africa and 84.67% in 
Gambia have serological evidence of prior exposure to Ad5 with respect to measurable 
serum Ad5-neutralizing antibody titers in healthy adult individuals [318].  This may 
manifest as the induction of high levels of pro-inflammatory cytokines at the time the 
vector is given, a humoral antibody response that neutralizes the adenovirus, or a cellular 
immune response that targets and destroys cells expressing adenoviral antigens [193, 213, 
214].  
Several methods have been developed to resolve issues associated with PEI 
including 1) increasing the vaccine dose to override neutralization, 2) development of 
vaccine platforms using rare human serotypes (Ad11, Ad12, Ad35) or those that infect 
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other species (chimpanzee, porcine, bovine), 3) genetic modification of capsid proteins to 
block neutralizing antibody binding residues (i.e. hexon-chimeric adenoviruses), and 4) 
modification of virus surface proteins with biocompatible polymers [218, 219, 319-322].  
Each approach has shielded Ad-based vaccines from recognition by the immune system 
and prevented neutralization by anti-Ad5-neutralizing antibodies. However, each requires 
further study due to poor immunogenicity [128].  To date, the primary route for 
administration of many rAd5-based vaccines is intramuscular injection, which can 
quickly induce strong systemic immune responses to both the encoded antigen and the 
Ad vector with respect to mucosal administration.  However, the potency of a rAd5-based 
vaccine following IM injection is significantly reduced by prior exposure to the vaccine 
vector and often leads to serious side effects [100, 101, 128, 311].  We have shown 
mucosal immunization can bypass PEI [101].  Administration of a rAd5-based Ebola 
vaccine by the intranasal and sublingual routes can induce significant systemic and local 
immune responses in naïve mice and those with prior exposure to Ad5 sufficient for 
protection against lethal challenge with Zaire Ebola.    
To date, intramuscular injection of adenovirus continues to be used to establish 
PEI to the virus in various animal models [100, 101, 128].  However, since natural 
infection by Ad5 occurs through respiratory mucosa in humans, it is unclear how this 
model of PEI resembles what naturally exists in the general population [177, 206].  
Despite the fact that there is a general consensus within the scientific community that PEI 
to Ad is a significant issue that must be addressed when developing a clinical therapeutic 
using this virus, very little is known about this particular immunological state with 
respect to how it influences the immune response to the encoded transgene and the virus 
itself.  
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One of the primary goals of our laboratory is to develop a potent, long-acting 
adenovirus-based vaccine for EBOV that is highly effective in those with prior-exposure 
to Ad.  In order to meet this goal, we conducted the study summarized here to evaluate 
how PEI to Ad, when induced by the mucosal route, affects the immune response to an 
encoded transgene.  This was evaluated after immunization by several different routes.  
The second objective of this study was to identify a method for induction of PEI to Ad, 
which could serve as a very stringent test for novel formulation candidates, designed to 
improve vaccine potency in those with prior exposure to the virus.  Assays to evaluate the 
quantitative and qualitative antigen-specific T cell responses were performed on naïve 
animals and those with PEI established by different routes.  Antibody responses to Ebola 
glycoprotein and to the adenovirus vector were also assessed.   Survival after lethal 
challenge served as a final indicator of the stringency of each model of PEI.  This data 
also assisted us in identifying specific types of immune responses that must be 
reconstituted through formulation or other modifications the vaccine in order to promote 
survival from EBOV in those with prior-exposure to Ad.   
 
3.2 Materials and methods 
3.2.1 Adenovirus production 
The codon optimized full-length Zaire Ebola glycoprotein sequence (Genbank/NCBI; 
Mayinga strain 76, Gene accession number: AF086833) was cloned in an E1/E3-deleted 
adenovirus serotype 5 vector under the control of chicken-β-actin promoter (Ad-
CAGoptZGP) and further amplified in HEK 293 cells (ATCC, CRL-1573) as previously 
described [100, 104].  Virus was purified from cell lysates by two rounds of cesium 
chloride gradient ultracentrifugation.  Virus bands were desalted by dialysis overnight in 
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100mM potassium phosphate buffer (pH 7.4) using dialysis cassettes (Silde-A-Lyzer, 3 
ml volume, 10K MWCO, Pierce Biotechnology, Rockford, IL).  The initial virus 
concentration was calculated by the following formula: virus particles/ml= (absorbance at 
260 nm)×(dilution factor)× (1.1×1012).  Infectious titer was determined using the Adeno-
X Rapid Titer Kit (Clontech, Mountain View, CA) according to the manufacturer’s 
instructions.  Preparations with infectious to physical particle ratios below 1:200 were 
used in this study. 
 
3.2.2 Animal studies  
All procedures were approved by the Institutional Animal Care and Use 
Committees at The University of Texas at Austin and the University of Texas Medical 
Branch in Galveston and are in accordance with the guidelines established by the 
National Institutes of Health for the humane treatment of animals. 
 
3.2.2.1 Immunization 
Six-week-old male B10.Br mice (MHC H-2k) and male Hartley guinea pigs (body 
weight: 400 g) were obtained from the Jackson Laboratory (Bar Harbor, ME) and Charles 
River Laboratories (Wilmington, MA), respectively.  Animals were housed in a 
temperature-controlled, 12 hour light-cycled facility at the Animal Research Center of 
The University of Texas at Austin and were given free access to standard rodent chow 
(Harlan Teklad, Indianapolis, IN) and tap water.  Animals were anesthetized by a single 
intra-peritoneal injection of a 3.9:1 (mice) or 7.5:1 (guinea pigs) mixture of ketamine 
(100 mg/ml, Wyeth, Fort Dodge, Animal Health, Overland Park, KS) and xylazine (100 
mg/ml, Sigma Aldrich, St. Louis, MO).  Once deep plane anesthesia was achieved, 
animals were immunized with 1×108 (mice) or 1×107 ~ 109 (guinea pigs) infectious 
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particles of Ad-CAGoptZGP by various routes.  Intramuscular injection involved direct 
injection of the preparation into each gastrocnemius muscle located on the hind limb 
(mice: 50 μl/muscle, guinea pigs: 100 μl/muscle).  Nasal immunization was performed by 
slowly dripping the preparation into each nostril (mice: 10 μl/nostril, guinea pigs: 50 
μl/nostril) using a standard micropipette (Gilson, Middleton, WI).  For sublingual 
immunization, sterile forceps were placed under the tongue of the animal and 10 µl of the 
preparation slowly dispensed with a standard micropipette as described previously [100].  
Animals given the vaccine by the nasal and sublingual routes were maintained in an 
upright position for 30 minutes after immunization in order to minimize accidental 
swallowing of the preparation. 
 
3.2.2.2 Establishment of pre-existing immunity to adenovirus 
First generation adenovirus expressing β-galactosidase under the control of the 
cytomegalovirus promoter (AdlacZ) was used to establish PEI to adenovirus serotype 5 in 
mice and guinea pigs [100, 101].  Twenty-eight days prior to vaccination, systemic PEI 
was induced by directly injecting 5×1010 (mice) or 1×1012 (guinea pigs) infectious 
particles of AdlacZ to the muscle of each hind limb in a volume of 50 μl (mice) or 100 μl 
(guinea pigs).  Twenty-four days later, blood was collected via the saphenous (mice) or 
cephalic (guinea pigs) vein and serum screened for anti-adenovirus neutralizing 
antibodies (NABs) as described below.  A schematic illustrating the time course for 
establishment of PEI, immunization, sample collection and analysis is illustrated in 
Figure 3.1.  At the time of vaccination, animals had an average anti-adenovirus 
circulating NAB titer of 1:171 + 48, which falls within the lower range of average values 
reported in humans after natural infection [126, 212].  
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3.2.2.3 Challenge with rodent-adapted Ebola Zaire 
All challenge experiments were performed under biosafety level 4 (BSL-4) 
conditions in an AAALAC accredited animal facility at the Robert E. Shope BSL-4 
Laboratory at the University of Texas Medical Branch in Galveston, Texas.  Twenty-one 
days post-immunization, vaccinated mice were transferred to UTMB where they were 
challenged on day 28 by intraperitoneal injection with 1,000 pfu of mouse [87] or guinea 
pig adapted-ZEBOV [337].  After challenge, animals were monitored for clinical signs of 
disease and weighed daily for 14 days.  At the end of the study, survivors were bled and 
serum samples γ-irradiated (5 Mrad) prior to removal from the BSL-4 lab for analysis. 
3.2.3 The T cell response 
The T cell response to Ebola Zaire glycoprotein was assessed by evaluation 
mononuclear cells expressing interferon-gamma (IFN-γ) by ELISPOT.  CD8+ T cells 
expressing IFN-γ, IL-2, TNF-α were assessed by multiparameter flow cytometery.    
3.2.3.1 ELISPOT 
ELISPOT assays were performed using the ELISpot Mouse Set (BD Pharmingen) 
according to the manufacturer’s instructions.  Briefly, a 96-well ELISPOT plate was pre-
coated with 5 μg/ml anti-mouse IFN-γ capture antibody overnight at 4 °C.  Coated wells 
were blocked with complete Dulbecco’s Modified Eagle′s Medium (DMEM, Mediatech) 
for 2 hours at room temperature.  Cells were isolated from the spleen, bronchoalveolar 
lavage fluid, MLNs and SMLNs as described previously [100], washed twice with 
complete DMEM and added to each well (5×105 cells/well) with the TELRTFSI peptide 
(0.5 μg/well, New England Peptide, Gardner, MA) that carries the  
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Figure 3.1 General in vivo study design.  B10.Br mice (36/group) and Hartley guinea 
pigs (15/group) were given 1×108 ivp (mice), 1×107 ~ 109 ivp (guinea pigs) of a Ad-
CAGoptZGP by various routes. A subset of mice from each treatment group were given 
either 5×1010 (mice: n=12) or 1×1012 (guinea pigs: n=5) particles of adenovirus containing 
the β-galactosidase transgene by intramuscular injection or intranasal administration 28 
days prior to vaccination to establish PEI.  This group is denoted as IM PEI or IN PEI, 
respectively.     
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Ebola Zaire glycoprotein immunodominant MHC class I epitope for mice with the H-2k 
haplotype (B10.Br) [265].  Plates were placed at 37°C for 20 hours with 5% CO2.  
Negative control cells were stimulated with an irrelevant peptide, which carries a binding 
sequence for influenza hemagglutinin (YPYDVPDYA, 5 μg/ml, GenScript, Piscataway, 
NJ).  Wells were washed twice with deionized water to lyse cells, washed with buffer 
(0.05% Tween-20 in PBS, pH 7.4) and subsequently incubated with biotinylated anti-
mouse IFNγ antibody at a concentration of 2 µg/ml for 2 hours at room temperature.  
Following three consecutive washes with buffer, wells were incubated with 5 µg/ml 1 of 
horseradish peroxidase (HRP)-conjugated streptavidin antibody for 1 hour at room 
temperature.  Wells were then washed once with buffer, once with PBS alone and plates 
developed with AEC substrate (Sigma).  Spots were counted using an automated ELISpot 
reader (CTL-ImmunoSpot® S5 Micro Analyzer, Cellular Technology Ltd., Shaker 
Heights, OH). 
3.2.3.2 Multiparameter flow cytometry 
Single cell suspensions of splenocytes were isolated from immunized mice as 
previously described [100].  Red blood cells were removed by resuspending the pellet in 
an equal volume of ACK lysis buffer (Quality Biological, Inc., Gaithersburg, MD) for 2 
minutes.  Cells were washed three times with complete DMEM, 50 µM β-
mercaptoethanol (Sigma), penicillin (10,000 I.U./ml)/streptomycin (10,000 µg/ml) 
(Gibco, Invitrogen, Grand Island, NY), L-glutamine (1mM, Hyclone, Salt Lake City, 
UT), 1 mM sodium pyruvate (Lonza, Walkersville, MD), 1 mM non-essential amino 
acids (Lonza).  2×106 splenocytes were cultured with TELRTFSI peptide (0.5 μg/well) as 
described previously [338-340].  Negative control cells were stimulated with an irrelevant 
peptide (YPYDVPDYA, 0.5 μg/well).  Following stimulation, cells were surface stained 
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with fluorescein isothiocyanate (FITC)-labeled anti-mouse CD8α antibodies (1:150 in 
PBS, BD Pharmingen, San Diego, CA) for 30 minutes at 4 °C and treated with Cyto-
fix/Cytoperm (BD Pharmingen) for 20 minutes at 4 °C.  For intracellular cytokine 
staining, cells were labeled with PE-labeled anti-mouse IFN-γ, PerCP-Cy5.5-labeled 
TNF-α and APC-labeled IL-2 antibodies (1:150 in Permwash, BD Pharmingen) for 30 
minutes at 4 °C.  Cells were washed twice and positive cells counted using four-color 
flow cytometry (FACS Fortessa, BD Biosciences, Palo Alto, CA) in The University of 
Texas at Austin Flow Cytometry Core Facility.  Over 500,000 events were captured per 
sample.  Data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).    
3.2.4 The B cell response 
Anti-Ebola Zaire glycoprotein antibodies were characterized by ELISA.  Anti-
adenovirus antibodies were quantitated using an in vitro neutralization assay.  For these 
assays, animals were bled 28 (guinea pigs) or 42 (mice) days after immunization and 
serum separated from whole blood by centrifugation.  All samples were heat-inactivated 
at 56°C for 30 minutes and stored at -80 °C prior to analysis. 
 
3.2.4.1 Production of recombinant Ebola Zaire glycoprotein  
Full length Ebola Zaire glycoprotein was produced using the Zaire GP33-637ΔTM-
HA construct according to published methods [270].  HEK 293T cells (70% confluent) 
were transfected with the plasmid in DMEM containing 10% FBS, 1% 
Penicillin/Streptomycin, 1mM L-glutamine and 1mM sodium pyruvate using a standard 
calcium phosphate transfection kit (Clontech, Mountain View, CA). Supernatant was 
harvested 4 days later, concentrated using a centrifugal filter device (Centricon plus-100, 
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Millipore, Billerica, MA) and purified by anti-HA immunoaffinity chromatography 
(Roche, San Francisco, CA).  
 
3.2.4.2 Characterization of Ebola Zaire glycoprotein-specific antibodies 
Flat bottom, Immulon 2HB plates (Fisher Scientific, Pittsburgh, PA) were coated 
with purified Zaire GP33-637ΔTM-HA (3 µg/well) in PBS (pH 7.4) overnight at 4°C.  
Plates were washed 4 times with PBS containing 0.05% Tween 20 and blocked in PBS 
(pH 7.4) containing 1% BSA (Sigma) for 1 hour at room temperature. Heat-inactivated 
samples were diluted 1:20 in sterile PBS.  One hundred microliters of each dilution was 
added to the antigen-coated plates for 2 hours at room temperature.  Plates were washed 4 
times with PBS containing 0.05% Tween 20 and incubated with HRP-conjugated goat 
anti-mouse IgG, IgG1, IgG2a, IgG2b, IgM (1:2,000, Southern Biotechnology Associates, 
Birmingham, AL) or HRP-conjugated goat anti-guinea pig IgG, IgG1, IgG2, IgM 
antibodies (1:2,000, Bethyl Laboratories, Inc., Montgomery, TX) in separate wells for 1 
hour at room temperature.  Plates were washed and 200 µl of substrate solution (0.4 
mg/ml o-phenylenediamine (Sigma) in 50 mM phosphate-citrate buffer, pH 5.0 with 0.03 
% (v/v) hydrogen peroxide) added to each well.  The plate was incubated at room 
temperature for 10 minutes and optical densities read at 450 nm on a microplate reader 
(Tecan USA, Research Triangle Park, NC).    
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3.2.4.3 Anti-adenovirus serotype 5 neutralizing antibody  
Circulating anti-adenovirus antibody levels were assessed in samples from mice 
in which PEI was established prior to immunization according to established methods 
[341].  Heat-inactivated serum was diluted in DMEM in twofold increments starting from 
a 1:20 dilution. Each dilution was mixed with a standard method of adenovirus 
expressing β-galactosidase (1 × 106 pfu), incubated for 1 hour at 37 °C, and applied to 
HeLa cells seeded in 96-well plates (1 × 104 cells/well).  After this time, 100 µl of 
DMEM supplemented with 20% FBS were added to each well.  Cells were incubated for 
24 hours and expression of β-galactosidase measured by histochemical staining.  For 
each sample, the serum dilution that corresponded to a 50% reduction in transgene 
expression was obtained by the proportionate distance method [357].  The absence of 
neutralization in samples containing medium only (negative control) and FBS (serum 
control) and an average titer of 1:1,280 + 210 read from an internally generated positive 
control stock serum were criteria for qualification of each assay.  
 
3.2.5 Serum cytokines and transaminases 
Cytokines (IL-6, IL-10 and IFN-γ) were quantitated from serum collected from 
mice with commercially available ELISA kits according to the manufacturer's protocols 
(Invitrogen, BioSource International, Camarillo CA).  Serum alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) levels were determined using Vitros 
AST/SGOT and ALT/SGPT DT slides on a Vitros DTSC autoanalyzer (Ortho Clinical 
Diagnostics, Rochester, NY). 
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3.2.6 Statistical analysis 
Data were analyzed for statistical significance using SigmaStat (Systat Software 
Inc., San Jose, CA) by performing a one-way analysis of variance (ANOVA) between 
control and experimental groups, followed by a Bonferoni/Dunn post-hoc test when 
appropriate. Differences in the raw values among treatment groups were considered 
statistically significant when p < 0.05.  
 
3.3. Results  
3.3.1 The effect of pre-existing immunity to adenovirus on the magnitude of antigen 
specific CD8 T cell response 
In order to determine how establishment of PEI by either the systemic or mucosal 
routes influenced the antigen-specific T cell response, cells were collected 10 days after 
immunization.  Ad-CAGoptZGP induced the strongest responses in the systemic and 
mucosal compartments of naïve animals than in those with PEI, regardless of 
immunization route (Figure 3.2).  Prior exposure to the virus by IM injection followed by 
vaccination by the same route (IM PEI/IM), significantly reduced the number of activated 
cells in the spleen with respect to that observed when PEI was established by the nasal 
route (IN PEI/IM) (783 + 48.9 spot-forming cells (SFCs)/million mononuclear cells 
(MNCs): IM PEI/IM vs. 1,377.3 + 49.49 SFCs/million MNCs: IN PEI/IM, p<0.001; 
Figure 3.2A).  Similar trends were noted when PEI was established by nasal 
administration and immunization occurred in similar manner (IN PEI/IN) (414.67 + 
15.64 SFCs/million MNCs: IN PEI/IN vs. 672 + 62.77 SFCs/million MNCs: IM PEI/IN, 
p<0.05; Figure 3.2A).  For SL immunization, mucosal PEI suppressed the number of 
antigen-specific IFN-γ secreting CD8+ T cells to a larger degree than systemic PEI (304 + 
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20.40 SFCs/million MNCs: IN PEI/SL vs. 473 + 35.86 SFCs/million MNCs: IM PEI/SL, 
p<0.01; Figure 3.2A).  Mucosal PEI also reduced the average number of IFN-γ+ cells in 
BAL of mice immunized by the IN route with respect to PEI established by IM injection 
(1,210 + 26.77 SFCs/million MNCs: IM PEI/IN vs. 683.8 + 76.64 SFCs/million MNCs: 
IN PEI/IN, p<0.001; Figure 3.2B).  In contrast, prior exposure to the virus significantly 
enhanced the number of activated cells in SMLNs with respect to naïve animals when the 
vaccine was given by either IN or SL routes. A significant rise in the SMLNs of mice 
immunized by IN route in the presence of systemic PEI immunized was also noted (85 + 
27.83 SFCs/million MNCs: Naive/IN vs. 122.5 + 19.6 SFCs/million MNCs: IM PEI/IN, 
p<0.05; Figure 3.2D).  The T cell response elicited by SL immunization was enhanced in 
the SMLNs of mice with systemic or mucosal PEI (65.5 + 23.46 SFCs/million MNCs: 
naïve/SL vs. 171.5 + 10.97 SFC/million MNCs: IM PEI/SL; 294 + 15.64 SFC/million 
MNCs: IN PEI/SL p<0.001; Figure 3.2D).  
3.3.2 Route of PEI induction significantly alters Zaire Ebola glycoprotein-specific 
multifunctional CD8+ T cell responses 
Although rAd5-based vectors elicited significantly high levels of IFN-γ responses 
in naïve mice, they are substantially less immunogenic when the vaccine is given by the 
same route used for PEI induction (IM PEI/IM, IN PEI/IN; Figure 3.2A).  Conversely, 
PEI suppressed this response to a lesser degree when the vaccine was given by an 
alternative route (IN PEI/IM, IM PEI/IN; Figure 3.2A).  We have previously shown that a 
single dose of vaccine given by the intranasal route induced a similar level of IFN-γ+ 
CD8+ T cell responses in mice with PEI established by the IM route with respect to naïve 
animals immunized by IM injection [101].  However, vaccine-induced protection was 
completely abrogated following IM injection in mice with IM PEI [100, 101]. 
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Figure 3.2 Route of pre-existing immunity induction to adenovirus significantly 
affects the magnitude of CD8+ T cell response against Ebola Zaire glycoprotein in 
the systemic and mucosal compartments of mice immunized by various routes.  The 
frequency of IFN-γ positive mononuclear cells was analyzed from the spleen (panel A), 
the lung via bronchioalveolar lavage (BAL; panel B), the mesenteric lymph nodes (MLN; 
panel C) and submandibular lymph nodes (SMLN; panel D) 10 days post-immunization 
by ELISPOT.  Samples were obtained from naïve animals and those with PEI to Ad5 
established by IM or IN route.  *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA, 
Bonferroni/Dunn post-hoc analysis. 
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Collectively, these data suggest that the magnitude of antigen-specific IFN-γ responses is 
not predictive of vaccine-elicited protection from EBOV challenge in mice with PEI to 
the vaccine carrier. To further characterize the impact of PEI induction by the systemic or 
mucosal route on vaccine induced CD8+ T cell responses, we undertook a more 
comprehensive functional analysis of cytokine producing CD8+ T cells using multi-
parameter flow cytometry.  With this strategy, we were able to delineate seven distinct 
cytokine-producing cell populations and characterize them at the single-cell level based 
on varying combinations of IFN-γ, IL-2 and TNF-α secretion patterns.  The relative 
frequency of these distinct populations defines the quality of the vaccine-induced CD8+ 
response.  Complete analysis of IFN-γ producing cells identified four distinct 
populations: IFN-γ+, IFN-γ+IL-2+, IFN-γ+TNF-α+ and IFN-γ+IL-2+TNF-α+.  This analysis 
further revealed a correlation between the frequency of multifunctional CD8+ T cells 
(IFN-γ+IL-2+TNF-α+) and the manner by which PEI induced in mice immunized by IM, 
IN or SL routes.  Ten days after vaccination, systemic PEI (IM PEI/IM) not only 
suppressed the total frequency of Zaire GP-specific IFN-γ secreting CD8+ T cells in mice 
immunized by the IM route (5.30%: Naïve/IM vs. 1.82%: IM PEI/IM; Figure 3.3A), but 
also elicited a lower level multifunctional CD8+ T cells (triple producers: IFN-γ+IL-
2+TNF-α+) with respect to naive mice immunized by the same route (35.4 + 0.37 %: 
Naive/IM vs. 24.29 + 2.01 %: IM PEI/IM, p<0.001; Figure 3.3C).  Although PEI induced 
by the IN route also reduced the total frequency of IFN-γ secreting CD8+ T cells with 
respect to naïve animals (5.30%: Naïve/IM vs. 3.18%: IN PEI/IM; Figure 3.3A), the 
quality was not significantly reduced (35.4 + 0.37 %, Naive/IM vs. 37.88 + 0.83 %, IN 
PEI/IM, p<0.001; Figure 3.3C).   
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Figure 3.3 Polyfunctionality of the Zaire GP-specific CD8+ T cell response following 
intramuscular injection is significantly reduced by systemic PEI.  Naïve B10.Br mice 
and those with PEI established by the IM or IN route (10/group) were immunized with 
Ad-CAGoptZGP  (1 × 108 ivp) by intramuscular injection.  Panel A. Numbers written in 
the upper right corner of each scatter plot represent the portion of each cell population 
that was activated by Ebola Zaire GP-specific peptide sequences.  Panel B. Each 
positively responding cell is assigned to total 7 possible combinations of IFN-γ, IL-2 and 
TNF-α and presented as a bar graph.  Panel c. Depiction of Zaire GP-specific 
multifunctional CD8+ T cells in pie chart format.  Triple producers are depicted in the red 
arc.  The blue arc highlights IFN-γ producing cells.  Numbers in the pie chart denote the 
percentage of triple producers in a given population.  Results are reported as the mean ± 
the standard error of the mean. ***p<0.001, one-way ANOVA, Bonferroni/Dunn post-
hoc analysis. 
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The next series of experiments focused on the impact of systemic and mucosal 
PEI on the quality of CD8+ T cell cytokine responses following IN administration of Ad-
CAGoptZGP.  It was previously shown that a) intramuscular PEI induction suppressed 
the magnitude of response to IFN-γ response to a lesser degree in mice vaccinated by the 
IN route, and b) and this mode of vaccination have shown complete protective efficacy in 
mice with PEI established by IM injection [101].  After IN administration of the vaccine, 
mucosal PEI suppressed the total frequency of IFN-γ+ CD8+ T cells a larger degree 
(2.58%: Naïve/IN vs. 0.89%: IM PEI/IN vs. 0.77%: IN PEI/IN, Figure 3.4A) than 
systemic PEI.  A similar trend was also noted in the multifunctional CD8+ T cell response 
(41.11 + 3.59 %: Naive/IN vs. 30.74 + 1.30 %, IM PEI/IN, p<0.05; 41.11 + 3.59 %: 
Naive/IN vs. 23.52 + 4.22 %, IM PEI/IN, p<0.01; Figure 3.4C).    
We next evaluated these parameters following SL immunization, which we have 
recently identified as a novel delivery method for Ad-based vaccines [100].  Similar to 
the results shown in Figure 3.4, the total frequency of IFN-γ producing CD8+ T cells was 
reduced to a larger degree in mice with mucosal PEI than systemic PEI (0.21%: IN 
PEI/SL and 0.66%: IM PEI/SL, respectively; Figure 3.5A).  Despite this notable 
reduction in the number of IFN-γ producing CD8+ T cells, a significant rise in the quality 
response was noted (24.20 + 0.91 %: Naive/SL vs. 37.04 + 1.91 %: IM PEI/SL, p<0.01; 
Figure 3.5C).  The quality response was also not compromised by mucosal PEI in this 
treatment group (24.20 + 0.91 %: Naive/SL vs. 20.93 + 4.92 %: IN PEI/SL, p>0.05; 
Figure 3.5C).  
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Figure 3.4 Polyfunctionality of the Zaire GP-specific CD8+ T cell response following 
intranasal immunization is significantly reduced by PEI induced by the nasal route. 
Naïve B10.Br mice and those with PEI established by the IM or IN route (10/group) were 
given Ad-CAGoptZGP (1 × 108 ivp) in the nasal cavity.  Panel A. Numbers written in the 
upper right corner of each scatter plot represent the portion of each cell population that 
was activated by Ebola Zaire GP-specific peptide sequences.  Panel B. Each positively 
responding cell is assigned to total 7 possible combinations of IFN-γ, IL-2 and TNF-α 
and presented as a bar graph.  Panel c. Depiction of Zaire GP-specific multifunctional 
CD8+ T cells in pie chart format.  Triple producers are depicted in the red arc.  The blue 
arc highlights IFN-γ producing cells.  Numbers in the pie chart denote the percentage of 
triple producers in a given population.  Results are reported as the mean ± the standard 
error of the mean.  *p<0.05, **p<0.01 one-way ANOVA, Bonferroni/Dunn post-hoc 
analysis. 
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Figure 3.5 Polyfunctionality of the Zaire GP-specific CD8+ T cell response following 
sublingual administration is significantly reduced by PEI established by the 
sublingual route.  Naïve B10.Br mice and those with PEI established by the IM or IN 
route (10/group) were given 1 × 108 ivp of a Ad-CAGoptZGP in the SL route.  Panel A. 
Numbers written in the upper right corner of each scatter plot represent the portion of 
each cell population that was activated by Ebola Zaire GP-specific peptide sequences.  
Panel B. Each positively responding cell is assigned to total 7 possible combinations of 
IFN-γ, IL-2 and TNF-α and presented as a bar graph.  Panel c. Depiction of Zaire GP-
specific multifunctional CD8+ T cells in pie chart format.  Triple producers are depicted 
in the red arc.  The blue arc highlights IFN-γ producing cells.  Numbers in the pie chart 
denote the percentage of triple producers in a given population.  Results are reported as 
the mean ± the standard error of the mean. **p<0.01, one-way ANOVA, 
Bonferroni/Dunn post-hoc analysis. 
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3.3.3 Effect of the route of PEI induction on serum antibody responses to Zaire 
Ebola glycoprotein and Ad5. 
To characterize the impact of systemic or mucosal PEI on B cell-mediated antibody 
responses 42 days after immunization, Zaire Ebola glycoprotein-specific immunoglobulin 
isotypes and adenovirus serotype 5-specific neutralizing antibody (NAB) levels were 
determined.  Induction of PEI by the IM route reduced serum Zaire GP-specific total IgG 
levels by 63.6%.  Of the serotypes tested, IgG1 was the most profoundly affected (90.8% 
reduction).  IgG2a and IgG2b followed a similar trend (78.8 and 78.35% reduced, 
respectively, Figure 3.6A).  Furthermore, a significant decrease in the production of IgG1 
was observed following IN administration of the vaccine in mice with mucosal PEI with 
respect to naïve animals (IgG1: 88.99% reduction, p<0.05, Figure 3.6B). Aside from this, 
following SL immunization there was no significant difference in the Zaire GP-specific 
IgG responses of naïve mice and those with mucosal PEI.  However, systemic PEI did 
significantly reduce Zaire GP-specific total IgG (66.3%), IgG1 (77.5%), IgG2a (80.6%) 
and IgM (80.5%) levels with respect to those seen in naïve mice (Figure 3.6C).  In an 
effort to understand B cell-mediated immune response against the adenoviral vector after 
vaccination of mice with systemic or mucosal PEI, we evaluated the circulating anti-Ad5 
NAb titer in serum samples collected 42 days after immunization.  Systemic PEI 
increased the amount of circulating anti-Ad5 NAB titer after IM immunization as levels 
rose by a factor of 5 from an average of 1:171 + 48 prior to vaccination to 1:925+ 213 
after treatment (p<0.05, Figure 3.5D).  However, the levels of anti-Ad5 NAb found in 
mice with systemic PEI following IN or SL administration of the vaccine were not 
significantly elevated from levels found prior to vaccination (1:184 + 40 (pre-
immunization) and 1:314 + 185 (post-immunization), respectively, p>0.05).  A similar 
trend was found in samples from mice immunized by IM or IN route in the presence of 
mucosal PEI. 
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Figure 3.6 The manner by which PEI is induced significantly influences Zaire GP-
specific serum antibody levels and anti-adenovirus neutralizing antibody 
production. Serum samples were collected from naive mice and those with PEI induced 
by the IM or IN route 42 days after immunization.  (A~C) Samples from individual mice 
were evaluated for the presence of ZGP-specific IgG subclasses and IgM by ELISA.  (D) 
Anti-adenovirus neutralizing antibodies produced after immunization in mice with PEI 
established by various routes. Results are expressed as average values ± the standard 
error of the means and are representative of two separate experiments each containing 12 
mice per immunization route.  *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA, 
Bonferroni/Dunn post-hoc analysis. 
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3.3.4 Effect of PEI on survival after challenge with mouse-adapted Ebola Zaire 
The most direct way of evaluating the impact of PEI induced by the IM or IN 
route on vaccine potency is to assess protection from a lethal dose of pathogen.  We did 
this by monitoring survival rate, weight loss and toxicity upon challenge of mouse-
adapted Zaire Ebola virus (1,000 pfu ~ 30,000 × LD50).  The challenge was uniformly 
lethal in control mice given saline (Figure 3.7A).  In contrast, all naive mice vaccinated 
by the IM route survived without notable loss of body weight.  In line with previous 
studies [100, 101], systemic PEI significantly compromised the efficacy of the vaccine 
when given by the IM route with only 20% survival observed in this treatment group (IM 
PEI/IM, p < 0.01, Figure 3.7A).  Interestingly, 87.5% of the mice given the same dose of 
the vaccine by the IM route in the presence of mucosal PEI survived challenge (IN 
PEI/IM, Figure 3.7A).  Samples taken from mice post-challenge revealed sharp 
elevations in serum ALT (PBS: 4,777.5 ± 342.96 U/L, IM PEI/IM: 4,110 ± 611.8 U/L, p 
< 0.001) and AST (PBS: 7,356.7 ± 417.31 U/L, IM PEI/IM: 5,860 ± 787.8 U/L, p < 
0.001), indicative of severe liver damage from Zaire Ebola infection (Figure 3.7C).  
Samples from these animals also contained elevated levels of cytokines (PBS: IL-6: 
818.58 ± 156.08 pg/ml, IL-10: 4,618.9 ± 1,482.9 pg/ml, IFN-γ: 2,188.5 ± 272.18 pg/ml, p 
< 0.05; IM PEI/IM: IL-6: 597.72 ± 577.32 pg/ml, IL-10: 1383.8 ± 143.96 pg/ml, IFN-γ: 
635.5 ± 294.65 pg/ml; Figure 3.7D), while samples from the Naïve/IM group contained 
only trace amounts of each compound (IL-6: not detected, IL-10: 17.49 ± 3.02 pg/ml, 
IFN-γ: not detected).   
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Figure 3.7 Protective efficacy of a rAd5-based Ebola vaccine following 
intramuscular injection in mice with systemic or mucosal PEI to Ad5.  Naive mice 
and those with prior exposure to adenovirus serotype 5 by IM or IN administration 
(indicated by IM PEI or IN PEI, respectively, n = 10) were challenged with a lethal dose 
of MA-ZEBOV (30,000 × LD50) by I.P. injection 28 days after IM immunization.  (A) 
Kaplan–Meier survival curve.  (B) Body weight profile after challenge.  (C) Serum 
alanine (ALT) and aspartate (AST) aminotransferase levels.  (D) Serum cytokines post-
challenge.  For panels C & D, all samples were taken 14 days post challenge from 
survivors.  Samples from non-survivors were taken at time of death.  * indicates a 
significant difference with respect to the Naive/IM treatment group. **p<0.01, 
***p<0.001, one-way ANOVA, Bonferroni/Dunn post-hoc analysis. 
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To fully define how PEI affects the immune response generated by IN 
immunization, naïve mice and those with systemic or mucosal PEI were also challenged 
with a lethal dose of mouse-adapted Ebola Zaire.  As expected, naïve mice and those with 
systemic PEI vaccinated by the IN route (Naïve/IN, IM PEI/IN) all survived challenge 
without notable loss of body weight (Figure 3.8A, B).  However, mucosal PEI 
significantly compromised the efficacy of the vaccine when given by the IN route with 
only 62.5% survival observed in this treatment group (IN PEI/IN, p < 0.05, Figure 3.8A).  
Samples taken from mice post-challenge revealed sharp elevations in serum ALT by a 
factor of 5.3 (Naive/IN: 144 ± 30.19 U/L, IN PEI/IN 768.75 ± 337.48 U/L) and AST by a 
factor of 3.3 (Naïve/IN: 330 ± 102.94 U/L, IN PEI/IN: 1086 ± 584.97 U/L, p < 0.001), 
indicative of severe liver damage from Zaire Ebola infection (Figure 3.8C).  Samples 
taken from animals in with PEI induced by IN route also contained significantly higher 
levels of cytokines (IL-6: 302.45 ± 39.10 pg/ml, IL-10: 1713.3 ± 795 pg/ml, IFN-γ: 
2606.8 ± 222.15 pg/ml), while samples from naïve animals contained trace amounts of 
each compound (IL-6: 198.23 ± 184.66 pg/ml, IL-10: 260.43 ± 30.18 pg/ml, IFN-γ: not 
detected; Figure 3.8D).   
Naïve mice and those with systemic or mucosal PEI vaccinated by the SL route 
were also challenged with a lethal dose of mouse-adapted Ebola Zaire 28 days after 
vaccination.  Consistent with previous findings [100], 80% of naïve mice and 100% of 
those with systemic PEI vaccinated by the SL route survived without notable loss of body 
weight (Figure 3.9A, B).  Interestingly, mucosal PEI did not significantly compromise the 
efficacy of the vaccine when given by the SL route with only 87.5% survival observed in 
this treatment group (IN PEI/SL, Figure 3.9A).  Samples taken from mice post-challenge 
did not significantly elevate serum ALT (Naive/SL: 39 ± 14.39 U/L, IM PEI/SL: 31.75 ± 
2.89 U/L; p>0.05) and AST (Naive/SL: 108.5 ± 32.15 U/L, IM PEI/SL:  
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Figure 3.8 Protective efficacy of a rAd5-based Ebola vaccine following intranasal 
vaccination in mice with systemic or mucosal PEI to Ad5.  Naive mice and those with 
prior exposure to adenovirus serotype 5 by IM or IN administration (indicated by IM PEI 
or IN PEI, respectively, n = 10) were challenged with a lethal dose of MA-ZEBOV 
(30,000 × LD50) by I.P. injection 28 days after IN immunization.  (A) Kaplan–Meier 
survival curve.  (B) Body weight profile after challenge.  (C) Serum alanine (ALT) and 
aspartate (AST) aminotransferase levels.  (D) Serum cytokines post-challenge.  For 
panels C & D, all samples were taken 14 days post challenge from survivors.  Samples 
from non-survivors were taken at time of death.  * indicates a significant difference with 
respect to the Naive/IN treatment group. *p<0.05, one-way ANOVA, Bonferroni/Dunn 
post-hoc analysis. 
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Figure 3.9 Protective efficacy of a rAd5-based Ebola vaccine following sublingual 
vaccination in mice with systemic or mucosal PEI to Ad5.   Naive mice and those with 
prior exposure to adenovirus serotype 5 by IM or IN administration (indicated by IM PEI 
or IN PEI, respectively, n = 10) were challenged with a lethal dose of MA-ZEBOV 
(30,000 × LD50) by I.P. injection 28 days after SL immunization.  (A) Kaplan–Meier 
survival curve.  (B) Body weight profile after challenge.  (C) Serum alanine (ALT) and 
aspartate (AST) aminotransferase levels.  (D) Serum cytokines post-challenge.  For 
panels C & D, all samples were taken 14 days post challenge from survivors.  Samples 
from non-survivors were taken at time of death.  * indicates a significant difference with 
respect to the Naive/SL treatment group. *p<0.05, one-way ANOVA, Bonferroni/Dunn 
post-hoc analysis. 
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114 ± 38.42 U/L; p>0.05), indicative of SL immunization in animals with IM PEI 
prevented hepatotoxicity associated with Zaire Ebola infection (Figure 3.9C).  Although, 
samples from this group did show elevations in the levels of cytokines with respect to 
Naïve/SL group, they were not statistically significant.  Samples from the IN PEI/SL 
group contained significantly high amounts of ALT and IFN- γ in serum with respect to 
naïve/SL group (118.75 ± 24.09 U/L (p<0.05), 1384.4 ± 222.15 pg/ml (p<0.001), 
respectively, Figure 3.9C, D).  
 
3.3.5 Effect of method of PEI induction on systemic antibody responses to Zaire 
glycoprotein in guinea pigs. 
In order to further characterize the impact of PEI on rAd5-based vaccine efficacy 
in another model of Ebola infection, we induced PEI to Ad (n=5/group) in 13 groups of 
male Hartley guinea pigs (n=5/group) 28 days prior to immunization by various routes as 
outlined in Figure 3.1.  Due to the lack of commercially available reagents to perform T 
cell assays in guinea pigs, we were not able to characterize the Zaire GP-specific T cell 
responses following vaccination as was done in mice (Figures 3.2~3.5).  However, serum 
Zaire GP-specific Ig isotypes levels were characterized in this animal model.  Induction 
of PEI by the IM route reduced serum Zaire GP-specific total IgG levels by 67.4% in 
animals immunized by the same route.  Of the serotypes tested, IgG1 was the most 
profoundly affected (95.2% reduction).  IgG2 followed a similar trend (38.1% reduced, 
Figure 3.10A).  To fully characterize the antibody-mediated response in guinea pigs 
following IN administration of the vaccine, we immunized naïve guinea pigs and those 
with systemic or mucosal PEI with doses ranging from 1 ×107 to 109 ivp.  At a high 
vaccine dose (1 ×109 ivp) mucosal PEI significantly reduced the production of IgG1 with 
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respect to naïve animals (82.2% reduction, p<0.05, Figure 3.10B).  However, the 
antibody production was blocked by lower doses of the vaccine in guinea pigs with IM or 
IN PEI (IM PEI/IN (107): Total IgG: 71.3%, IgG1: 91.8%, IgG2: 64.2% and IgM: 57.3% 
reduction; IN PEI/IN (107): Total IgG: 92.1%, IgG1: 97.3%, IgG2: 84.7 and IgM: 99.2% 
reduction p<0.01, Figure 3.10B).   Aside from this, there was no significant difference in 
the amount of each IgG isotype produced after SL immunization in the absence and 
presence of PEI (p>0.05, Figure 3.10C).     
 
3.3.6 Effect of PEI on Survival after lethal challenge in guinea pigs. 
Guinea pigs (n=5/group) were challenged with 1,000 × LD50 of guinea pig-
adapted ZEBOV (GP-ZEBOV) by i.p. injection [337].  Disease progression was followed 
and signs and symptoms of infection measured as described for mice.  Untreated guinea 
pigs (negative control: PBS) demonstrated significant weight loss starting from day 5 
post-challenge that progressed until death on days 6 to 9 (Figures 3.11, 3.12, 3.13).  
Naïve guinea pigs given the vaccine (dose: 1 × 109 ivp) were completely protected from 
infection.  Consistent with the mice challenge results, systemic PEI significantly 
decreased protective efficacy in a dose dependent manner (IM PEI/IM (109), 80% 
survival; IM PEI/IM (108), 40% survival, p < 0.01, Figure 3.11A). Post-challenge serum 
samples taken from groups of guinea pigs with systemic or mucosal PEI revealed that 
serum AST levels were significantly elevated in those with PEI established by either rout 
(PBS: 1367.7 ± 205.94 U/L, IM PEI/IM (109): 248.2 ± 153.34 U/L, IM PEI/IM (108): 
645.25 ± 182.6 U/L, IN PEI/IM (108): 601.6 ± 298.24 U/L p < 0.05) with respect to 
naïve/IM group (104 ± 37.1 U/L, Figure 3.11C) by a factor of 2.4 (IM PEI/IM: 109), 6.2 
(IM PEI/IM: 108), 5.8 (IN PEI/IM: 108).   
 114 
                  
  
Figure 3.10 PEI significantly reduces serum Zaire GP-specific antibody responses in 
guinea pigs immunized by the IM or IN routes.  Serum samples were collected from 
naive guinea pigs and those with IM or IN PEI 28 days after immunization with 1 × 107 ~ 
109 infectious particles of a recombinant adenovirus expressing ZGP by various routes. 
(A~C) Samples from individual guinea pigs were evaluated for the presence of ZGP-
specific IgG subclasses and IgM by ELISA.  Results are expressed as average values ± 
the standard error of the means and are representative of two separate experiments each 
containing 5 guinea pigs per group.  
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Figure 3.11 Protective efficacy of a rAd5-based Ebola vaccine following 
intramuscular injection in guinea pigs with systemic PEI.  Naive guinea pigs and 
those with prior exposure to Ad5 by the IM or IN routes (indicated by IM or IN PEI, 
respectively, n = 5) were challenged with a lethal dose of guinea pig-adapted Zaire Ebola 
virus (1,000 × LD50).  (A) Kaplan–Meier survival curve. (B) Body weight profile after 
challenge.  (C) Serum alanine (ALT) and aspartate (AST) aminotransferase levels post-
challenge.  For panel C, samples from non-survivors were taken at time of death. 
Samples from survivors were taken 14 days post-challenge.  * indicates a significant 
difference with respect to the Naive/IM treatment group. *, p < 0.05, **, p < 0.01, one-
way ANOVA, Bonferroni/Dunn post-hoc analysis. 
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We also evaluated how PEI affects survival following IN immunization in this 
animal model (Figure 3.12).  The protective efficacy following IN administration of the 
vaccine in animals with mucosal PEI was also decreased in a dose dependent manner 
(Figure 3.12A).  At a high vaccine dose complete protection was achieved (IN PEI/IN 
(109)).  However, with a 100 fold lower vaccine dose, the challenge was uniformly lethal 
in animals with PEI regardless of the immunization route (IM PEI/IN (107), IN PEI/IN 
(107): no survivors, Figure 3.12A).  Post-challenge serum samples taken from groups of 
guinea pigs with systemic or mucosal PEI revealed that serum ALT (IM PEI/IN (107): 
229 ± 6.78 U/L, IN PEI/IN (107): 323 ± 157.72 U/L, p < 0.001) and AST (IM PEI/IN 
(107): 1,525 ± 123.64 U/L, IN PEI/IN (107): 2,192 ± 726.29 U/L, p < 0.001) levels were 
significantly elevated with respect to naïve/IN (107) group (ALT: 37 ± 4.85 U/L, AST: 
74.4 ± 13.78 U/L, Figure 3.12C).  
We lastly determined protective efficacy of SL immunization in guinea pigs in the 
presence of systemic or mucosal PEI.  Consistent with the mouse challenge results, 80% 
of naïve mice and those with systemic PEI vaccinated by the SL route (Naïve/SL, IM 
PEI/SL) survived without notable loss of body weight (Figure 3.13A, B).  In addition, 
mucosal PEI did significantly compromise the efficacy of the vaccine when given by the 
SL route with only 40% survival observed in this treatment group (IN PEI/SL, p < 0.05, 
Figure 3.13A).  Samples taken from guinea pigs post-challenge did not contain 
significantly elevated serum ALT (Naive/SL: 46 ± 2.16 U/L, IM PEI/SL: 40 ± 5.63 U/L, 
IN PEI/SL: 34.33 ± 7.80 U/L) and AST (Naive/SL: 65 ± 10.6 U/L, IM PEI/SL: 201.5 ± 
120.5 U/L, IN PEI/SL: 218 ± 173.2 U/L) levels after challenge (Figure 3.13C).    
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Figure 3.12 Protective efficacy of a rAd5-based Ebola vaccine following intranasal 
administration is significantly decreased in guinea pigs with PEI established by the 
IN route.  Naive guinea pigs and those with prior exposure to Ad5 by the IM or IN 
routes (indicated by IM or IN PEI, respectively, n = 5) were challenged with a lethal dose 
of guinea pig-adapted Zaire Ebola virus (1,000 × LD50).  (A) Kaplan–Meier survival 
curve. (B) Body weight profile after challenge.  (C) Serum alanine (ALT) and aspartate 
(AST) aminotransferase levels post-challenge. * indicates a significant difference with 
respect to the Naive/IN treatment group. *, p < 0.05, ***, p < 0.001, one-way ANOVA, 
Bonferroni/Dunn post-hoc analysis.   
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Figure 3.13 Protective efficacy of a rAd5-based Ebola vaccine following sublingual 
administration is significantly decreased in guinea pigs with IN PEI.  Naive guinea 
pigs and those with prior exposure to Ad5 by the IM or IN routes (indicated by IM or IN 
PEI, respectively, n = 5) were challenged with a lethal dose of guinea pig-adapted Zaire 
Ebola virus (1,000 × LD50).  (A) Kaplan–Meier survival curve. (B) Body weight profile 
after challenge.  (C) Serum alanine (ALT) and aspartate (AST) aminotransferase levels 
post-challenge. * indicates a significant difference with respect to the Naive/SL treatment 
group. *, p < 0.05, one-way ANOVA, Bonferroni/Dunn post-hoc analysis. 
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3.4. Discussion 
Natural transmission of Ebola virus involves direct contact with body fluids of 
infected individuals and may also involve the respiratory mucosa [31, 40, 342]. 
Therefore, a fully protective vaccine against Ebola virus will require generation of strong 
systemic and local antigen specific T cell immunity with the aid of humoral responses to 
prevent or substantially limit infection.  Many studies in rodents indicate that different 
routes of vaccination have profoundly different effects on the type and strength of the 
immune response [101, 125, 339, 343].  For example, intramuscular (IM) injection of 
rAd5-based vaccines induces strong systemic compartment restricted immune responses 
while mucosal immunization (nasal, sublingual) induces both systemic and mucosal 
immune responses.  However, the strong antiviral immune responses and protective 
efficacy conferred by systemic administration of our rAd5-based Ebola vaccine was 
significantly impaired by PEI to the adenovirus carrier while mucosal administration of 
the vaccine afforded excellent protective potential.  Due to this, mucosal vaccination has 
long been thought to be a promising strategy to bypass neutralization associated with PEI.  
It is important to note that the high level of protection following mucosal vaccination was 
achieved even with very moderate IFN-γ responses with respect to that induced by IM 
immunization [100].  We have also demonstrated that Zaire glycoprotein-specific 
antibody responses were not reduced after mucosal vaccination in mice with systemic 
PEI [100].  
The mechanism by which PEI dampens adaptive immunity includes prevention of 
Ad vector transduction of target cells through neutralization or killing of Ad infected 
cells.  Previous reports have demonstrated that PEI induced by IM injection significantly 
block uptake of Ad5 in CD11c+ DCs and decrease the frequency of CD8+ T cell responses 
following IM immunization with rAd5-based vaccine [303].  Until recently, analysis and 
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comparison of the number of IFN-γ producing T cells generated by a vaccine candidate 
has been most widely used to assess efficacy for microbial infections that require cellular 
immunity for recovery and protection [100-103, 323].  However, there are many 
examples illustrating that the frequency of IFN-γ response is not a comprehensive 
immune correlate of protection [324-330].  A more extensive analysis of the T cell 
repertoire in which specific combinations of functional cytokine responses are assessed 
simultaneously at the single cell level has recently been developed [331].  Data acquired 
by multiparameter flow cytometry and analyzed by boolean gating revealed that CD8+ T 
cells that secrete IFN-γ and TNF-α have enhanced CTL activity compared with CD8+ T 
cells that secrete IFN-γ alone.  Secretion of IL-2 in conjunction with these cytokines 
fosters expansion of effector T cells to enhance memory T cell function [332-336].  As 
technology for multiparameter analysis of T cell isolates has progressed, it is clear that 
the quality of the T cell response after immunization is a strong predictor of protective 
efficacy of many vaccine candidates.  In this study, we demonstrated that induction of 
PEI by the same route used for immunization significantly compromises the antigen-
specific multifunctional CD8+ T cell and antibody responses while a different route of 
immunization did not suppress the antigen-specific immune response.  These data suggest 
that the route of immunization differentially activates CD11c+ DC or non-DCs required to 
induce CD8 T cell and antibody responses by rAd5 in the setting of PEI induced by IM or 
IN route.  For example, following I.N. immunization in animals with IM PEI, airway 
epithelial cells transduced by our vaccine could express the Zaire GP encoded by the 
vector, and the antigen could be taken up by tissue resident CD11c+ DC or other 
migratory APCs due to the local inflammation caused by immunization.  It is also 
important to note that CD4+CD25+ regulatory T cell populations suppress CD8 T cell 
responses [302,303].  Thus, additional studies are required to evaluate level of 
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CD4+CD25+ regulatory T cells produced after immunization in naïve animals and those 
with PEI to clearly demonstrate the effect of PEI on the immunogenicity of the rAd5-
based vaccine. 
A recent report showed that CD8+ T cell response is required for protection in 
vaccinated non-human primates with rAd5-based Ebola vaccine [98].  However, Qui et 
al., further demonstrated that antibodies is another immune parameter that correlates with 
survival after lethal ZEBOV challenge [59, 60].  We have shown that serum Zaire GP-
specific antibody response was significantly reduced following IM injection of our 
vaccine in mice with systemic PEI, while the antibody response was not changed after IN 
administration [100].  In this study, we have further demonstrated that the strength of the 
antibody response is highly dependent on the PEI induction route.  The reduced antibody 
responses were restored in mice immunized a route different than that used for PEI 
induction to a level similar to that seen in naïve animals.  Taken together, the decrease in 
magnitude and quality of antigen-specific CD8+ T cells and antibody responses result in 
poor survival in IM PEI/IM, IN PEI/IN groups upon challenge with ZEBOV in mice and 
guinea pigs.  
It has also been suggested that PEI to the vaccine carrier can be bypassed by 
increasing the dose of rAd5-based vaccine administered [315].  In this study, we have 
further confirmed that this is a feasible strategy to circumvent PEI and that the dose at 
which PEI is induced must always be heavily considered when evaluating new vaccine 
platforms designed to circumvent PEI.  The protective efficacy following IN 
administration in animals with systemic PEI gradually decreased in a dose dependent 
manner.  It is also important to note that at a low IN vaccine dose in guinea pigs, both IM 
and IN PEI significantly reduced protective efficacy.  These data raise the conclusion that 
in order to induce protective T and B cell-mediated immune responses that are not 
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impeded by PEI following IN administration requires a certain window of vaccine dose.  
We have shown a somewhat different pattern for protective efficacy in mice and guinea 
pigs following SL administration.  In mice, despite the fact that mucosal PEI significantly 
reduced antigen-specific CD8+ T cell magnitude and quality responses with respect to 
systemic PEI, protective efficacy was not significantly reduced.  However, the difference 
in survival in the guinea pigs model further support the hypothesis that SL immunization 
elicited a threshold level of T cell-mediated immunity necessary for protection against 
Ebola and antibodies produced by the vaccine when given via the SL route may not 
enough to fully compensate for the low T cell responses.   
Delivery of recombinant adenoviral vaccines to either the nasal or oral mucosa is 
an attractive vaccination strategy for many reasons.  Vaccines administered in this 
manner will offer improved safety with respect to disease transmission and needle-stick 
injuries among health care workers, significant issues of concern in developing countries 
where the demand for many vaccines is high [349].  Mucosal administration of vaccines 
also reduces the pain associated with vaccination, eliminates the need for specialized 
training programs for large vaccination campaigns and makes self-administration of the 
vaccine possible.  This mode of vaccination may also significantly reduce systemic 
toxicity associated with recombinant adenovirus.  However, it is important to realize that 
mucosal route is not always the primary choice for rAd5-based vaccine.  The major 
limitation surrounding PEI study in animal models is that the wild type human 
adenovirus does not replicate in most animal models tested including in rodents and non-
human primates [344].  Although, Masek-Hammerman and colleagues used a host range 
mutant adenovirus known to replicate in rhesus monkey to study how PEI to Ad5 
influences mucosal trafficking of Ad5-specific CD4 T cells after immunization with 
rAd5-based HIV vaccine, this approach is expensive and sometimes difficult to access 
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[345, 346].  To our knowledge, this is the first repot in which the modeling of PEI to 
adenovirus is described.  Our result also indicate that establishment of PEI by the same 
route used for immunization is the most stringent model for evaluating the potency of 
rAd5-based vaccines.  Therefore, inclusion of reagents that have potential to restore the 
impaired antiviral immunity will necessary for effective immunization in those with PEI.  
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CHAPTER FOUR 
Development of Intranasal Formulations for a Human Adenovirus 
Serotype 5-Based Vaccine with Potential to Bypass Pre-Existing 
Immunity 
4.1 Introduction  
Since its discovery, recombinant adenovirus serotype 5 (rAd5) has been 
developed as highly potent vaccine carrier which can induce both cellular and humoral 
immune responses against an encoded transgene in a wide variety of animal models [101, 
103, 107, 108, 194, 315, 317, 319].  For this reason, rAd5 is one of the most well-
understood vectors currently under development for use as a vaccine for various life-
threatening diseases including human immunodeficiency virus type-1 (HIV-1) and Ebola 
virus infections [98, 101, 103, 104, 107, 108, 128, 218, 311].  Despite these promising 
features, the high frequency of pre-existing immunity (PEI) in the developing world may 
significantly limit the immunogenicity and clinical utility of rAd5-based vaccines [100, 
101, 128, 218].  To resolve this issue, many groups have deigned rAd vectors from 
different Ad subfamilies with infectious tropisms very distinct from Ad5.  Chimeric rAd 
vectors substitution of the hyper-variable regions (HVRs) in the hexon proteins of Ad5 
with sequences from these novel vectors also prevented neutralization by anti-Ad5 
antibodies [128, 217-219, 350].  However, these modified vectors cannot induce antigen-
specific immune responses at the level seen by rAd5 in naïve animals [128].  To resolve 
this issue, Liu et al., have demonstrated that heterologous rAd prime-boost regimens 
utilizing two serologically distinct rAd vectors can elicit remarkably potent immune 
responses.  The most favorable protocols involved priming with either a rAd26 or rAd5 
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vector followed by a boost with a chimeric rAd5 vector [351].  Due to the documented 
toxicity associated with repeated systemic administration of rAd vectors and the length of 
time required for prime-boost regimens to elicit protective immune responses, this 
approach is not realistic [337, 342]. 
Nasal administration has been suggested as a rather simplistic method to bypass 
systemic PEI to Ad5.  This delivery method fosters very high-localized immune 
responses to the delivered transgene and, more specifically, has afforded full protection in 
animals with PEI to Ad5 from lethal challenge with Ebola [101].  Our previous work has 
shown that when PEI is induced in the respiratory tract in a manner similar to natural 
exposure, two important immunological parameters are dampened: 1) the multifunctional 
CD8 T cell response, and 2) antigen-specific antibody responses.  Both of these are 
required for protection from Ebola.  Since Ad5 is a respiratory virus, we hypothesized 
that nasal administration of rAd vaccines may not be a suitable strategy to circumvent 
PEI in humans. In order for a formulation to be effective in those that have naturally 
come in contact with Ad, it must be capable of restoring antigen-specific adaptive 
immune responses.  However, excipients to enhance immunogenicity of the vector must 
be carefully chosen.   
Absorption enhancers are commonly investigated for nasal vaccines due to their 
ability to increase residence time within the nasal cavity and interrupt tight junctions, 
allowing penetration beyond the epithelial barrier [343, 345, 346]. PEGylated Ad5-
vectors successfully delivered genes to the respiratory epithelium in animals with PEI to 
Ad5 [225].  Microencapsulation of adenovirus in a biodegradable poly(D,L-lactic-co-
glycolic acid) (PLGA) matrix has also enhanced transduction efficiency of the virus in 
various target tissues while reducing vector-induced toxicity [162, 349, 352, 353].  
Mixtures of pharmaceutically acceptable excipients such as sugars, surfactants and lipid 
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have also improved transgene expression in the airway epithelium by promoting cellular 
uptake of the Ad5 vector through the trans cellular pathway [225, 343, 345, 353].  
The primary goal of this study was to develop novel formulations for a nasal 
vaccine with three specific properties: 1) the ability to protect the vector from 
neutralization by anti-Ad5 NAB, 2) the ability to enhance cellular uptake of adenovirus 
particles in the nasal cavity or airway epithelium, and 3) the ability to induce potent 
immune responses to vector-encoded antigen with minimal response to the vector.  We 
first assessed the ability of several preparations to improve adenovirus transduction 
efficiency across two significant anatomical barriers: the intestinal and airway 
epithelium.  We also evaluated the ability of successful candidates to induce antigen-
specific CD8+ T cell responses following IN administration of our rAd5-based Ebola 
vaccine in mice with PEI established by the nasal route.  The quality of the antigen-
specific CD8+ T cell response, CD8+ T cell memory and antibody isotypes generated by 
each formulation were then characterized.  Survival rates after challenge with rodent-
adapted Ebola Zaire, the most stringent test of a formulation candidate provided valuable 
information to identify immunological requirements for survival from Ebola. 
 
4.2 Materials and Methods 
4.2.1 Adenovirus Production 
First generation E1/E3 deleted recombinant adenovirus serotype 5 vectors 
expressing E. coli β-galactosidase (AdlacZ) or the green fluorescent protein (AdGFP) 
were amplified in HEK 293 cells.  Each virus was purified from cell lysates by banding 
twice on cesium chloride gradients followed by desalting over an Econo-Pac 10 DG 
disposable chromatography column (BioRad, Hercules, CA) equilibrated with potassium 
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phosphate buffer (pH 7.4).  Preparations with a ratio of infectious to total particles of 
1:100 were used for these studies.  For immunological analysis and challenge stidueis, a 
first generation E1/E3 deleted adenovirus serotypes 5 vector expressing a codon 
optimized pCAGα-optZGP expression cassette was constructed and amplified in 
HEK293 cells and purified as described in Chapters 2 and 3.  The infectious titer of this 
virus was determined with the Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA) 
according to the manufacturer’s instructions.  Preparations of this virus, Ad-
CAGoptZGP, with infectious to physical particle ratios below 1:200 were used in this 
study. 
 
4.2.2 Formulation 
All formulations were prepared at 5X concentrations, sterile filtered through 0.22 
μm filters (Corning, Lowell, MA) and diluted with freshly purified virus in sterile PBS 
(pH 7.4) immediately prior to use.  
 
4.2.2.1 PEGylation of recombinant adenovirus 
PEGylation of AdlacZ and Ad-CAGoptZGP were performed according to 
established protocols [225, 226].  The protein content of the virus preparation was 
determined using BioRad DC protein assay reagents (BioRad, Hercules, CA) and bovine 
serum albuin as a standard in a microplate format.  Ten micrograms of tresyl chloride 
activated monomethoxypoly(ethylene)glycol (Sigma Aldrich, St. Louis, MO) were added 
for each microgram of protein present in the purified virus preparation.  The coupling 
reaction was stopped with the addition of L-lysine after 2 hours.  Reaction byproducts 
were removed by buffer exchange over a second Econo-Pac 10DG disposable 
chromatography column (BioRad, Hercules, CA) equilibrated with sterile PBS (pH7.4).  
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PEGylated preparations were then diluted to final working concentrations with sterile 
PBS (pH7.4). 
 
 
4.2.2.2 Preparation of PLGA microspheres 
AdlacZ and Ad-CAGoptZGP vectors were embedded in PLGA microspheres 
using a standard W/O/W double emulsion and solvent evaporation method [161, 352].  
One milliliter of virus at a concentration of 5×1012 vp was added to ethyl acetate (Sigma 
Aldrich) containing 100 mg poly(lactic-co-glycolic acid) (50:50, Sigma Aldrich).  The 
primary W/O emulsion solution was briefly homogenized for 30 seconds and then added 
to 10 ml of an aqueous solution containing 5%(w/v) polyvinyl alcohol (PVA, Sigma 
Aldrich).  This secondary W/O/W emulsion was homogenized for 60 seconds and further 
agitated with a magnetic stirring rod for 2 h at 4°C to evaporate the co-solvent.  The 
PLGA microspheres were collected by centrifugation at 2000 rpm for 3 min, and washed 
five times with sterile PBS.  The amount of AdlacZ or Ad-CAGoptZGP within the PLGA 
microspheres was determined by digesting PLGA polymer with 1 N NaOH for 24 h to 
extract the virus particles into the aqueous solution.  The number of virus particles was 
determined by UV Spectroscopy and an infectious titer assay.  The average encapsulation 
efficiency of the preparation was 21.6 ± 4.4 % (n=3).  Aliquots of each preparation were 
placed in sterile containers and stored at various temperatures to evaluate stability and 
release rates over time.  The number of infectious virus particles released from 
microspheres was determined by serial dilution of collected supernatants and evaluation 
of β-galactosidase expression in HEK293 cells. 
 
 
 129 
4.2.2.3 Particle size analysis 
The average particle size of each PLGA microsphere preparation was determined 
with a DynaPro LSR laser light scattering device and detection system (Wyatt 
Technology Corporation, CA) as described previously [367].  Twenty-two microliters of 
sample were added to a quartz cuvette and sealed with a plastic stopper.  Particle size 
readings were collected every 10 s for 1 min. Regularization histograms and assignment 
of hydrodynamic radii values to various subpopulations within the sample were 
calculated using DynaLS software (Wyatt/Protein Solutions).  Each analysis was 
qualified by assessment of particle size of a standard solution of polystyrene beads with a 
hydrodynamic radius that is approximately that of a single adenovirus particle 
(35 ± 1.5 nm, Duke Scientific, Palo Alto, CA) and of the formulation (blank control). The 
absence of any detectable particles in the blank formulation and readings within ±2 nm of 
the labeled value of the bead standard were the criteria for qualification of each analysis. 
 
4.2.2.4 In vitro screening of formulations and cytotoxicity assays 
A volume of 200 μl of formulations containing AdlacZ or AdGFP (MOI 100) 
were added to differentiated Caco-2 (HTB-37) or Calu-3 cells grown on 12 well plates in 
the absence or presence of anti-Ad5 neutralizing antibodies at a concentration of 0.05 - 
50 ND50 and incubated for 2 hours at 37°C in 5% CO2.  Formulations were then removed 
from cell monolayers.  Cleared supernatant was kept on ice for cytotoxicity testing.  
Cytotoxicity was assessed by measuring lactate dehydrogenase (LDH) release into the 
formulation with a cytotoxicity detection kit (Roche Applied Science, Indianapolis, IN) 
according to manufacturer`s instructions.  Complete lysis was achieved by the addition of 
1% sodium dodecyl sulfate to some monolayers.  These samples were used as a positive 
control.  Cells were then washed with sterile PBS and further incubated for 48 hours at 
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37°C in 5% CO2.  Transduction efficiency was measured by detecting expression of β-
galactosidase by histochemical visualization through X-gal staining.  GPF was detected 
by using flow cytometry (FACS Fortessa, BD Bioscience).  
 
4.2.3 Animal Studies  
All procedures were approved by the Institutional Animal Care and Use 
Committees at The University of Texas at Austin and the University of Texas Medical 
Branch in Galveston and are in accordance with the guidelines established by the 
National Institutes of Health for the humane treatment of animals. 
 
4.2.3.1 Immunization 
Six-week-old male C56/BL7 (MHC H-2d), B10.Br mice (MHC H-2k) and male 
Hartley guinea pigs (body weight: 400 g) were obtained from the Jackson Laboratory 
(Bar Harbor, ME) and Charles River Laboratories (Wilmington, MA), respectively. All 
were housed in a temperature-controlled, 12 hr light-cycled facility at the Animal 
Research Center of The University of Texas at Austin with free access to standard rodent 
chow (Harlan Teklad, Indianapolis, IN) and tap water.  Mice immunized orally were 
fasted 12 hrs prior to vaccination and given 1×109 infecious particles of unmodified or 
formulated vaccine in a volume of 100 μl with oral feeding needles (18G, 2.25 mm dia., 
Popper & Sons, Inc, New Hyde Park, NY).  For nasal immunization, animals were 
anesthetized by a single intra-peritoneal injection of a 3.9:1 (mice) or 7.5:1 (guinea pigs) 
mixture of ketamine (100 mg/ml, Wyeth, Fort Dodge, Animal Health, Overland Park, 
KS) and xylazine (100 mg/ml, Sigma Aldrich, St. Louis, MO).  Once deep plane 
anesthesia was achieved, animals were immunized with 1×108 (mice) or 1×107-109 
(guinea pigs) infectious particles of formulated Ad-CAGoptZGP by slowly dripping the 
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preparation alternatively into each nostril (mice: 10 μl, guinea pigs: 50 μl) using a 
standard micropipette (Gilson, Middleton, WI). Animals were maintained in an upright 
position for 30 minutes after vaccination in order to minimize accidental swallowing or 
chocking of the vaccine. 
 
4.2.3.2 Establishment of Pre-Existing Immunity to Adenovirus 
First generation adenovirus expressing β-galactosidase under the control of a 
cytomegalovirus promoter (AdlacZ) was used to establish PEI to adenovirus serotype 5.  
Twenty-eight days prior to vaccination, mucosal PEI was induced by placing 5×1010 
(mice) or 1×1012 (guinea pigs) particles of AdlacZ in the nasal cavity as described above.  
Twenty-four days later, blood was collected via the saphenous (mice) or cephalic (guinea 
pigs) vein and serum screened for anti-adenovirus neutralizing antibodies (NABs) as 
described below.  At the time of vaccination, animals had an average anti-adenovirus 
circulating NAB titer of 1:165 + 22, which falls within the lower range of average values 
reported in humans after natural infection [347, 348].  
 
4.2.3.3 Histological evaluation of transgene expression  
E. coli β-galactosidase expression in the lung was assessed 4 days after intranasal 
administration of formulated AdlacZ.  Lungs were harvested 0, 2 and 24 hours post-
immunization, rinsed with saline, rapidly immersed in disposable peel-away molds 
containing Tissue-Tek® O.C.T compound (Sakura Finetek, Torrance, CA) and stored at -
80 °C prior to analysis.  To assess transgene expression, frozen sections (5 μm) were 
fixed for 10 minutes in 0.5% glutaraldehyde in phosphate buffered saline (PBS, pH 7.4), 
rinsed twice for 10 minutes in PBS containing 1 mM magnesium chloride and incubated 
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in PBS containing the colorimetric substrate for β-galactosidase, 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-Gal, Gold Biotechnology, St. Louis, MO), 5 mM 
K3Fe(CN)6, 5 mM K4Fe(CN) 6, and 1 mM MgCl2 for 24 hours at 37°C in 5% CO2 .  
Sections were then counterstained with Eosin for 10 min at room temperature (Sigma 
Aldrich).  Sections were examined under light microscopy with a Lecia DM LB 
microscope (Leica Microsystems Inc., Bannockburn, IL) and photographed using a Leica 
DFC 320 camera.    
 
4.2.3.4 Challenge with Rodent-Adapted Ebola Zaire 
All challenge experiments were performed under biosafety level 4 (BSL-4) 
conditions in an AAALAC accredited animal facility at the Robert E. Shope BSL-4 
Laboratory at the University of Texas Medical Branch in Galveston, Texas.  Twenty-one 
days post-immunization, vaccinated mice and guinea pigs were transferred to UTMB 
where they were challenged on day 28 by intraperitoneal injection with 1,000 pfu of 
mouse (30,000 × LD50) or guinea pig adapted-ZEBOV [354].  After challenge, animals 
were monitored for clinical signs of disease and weighed daily for 14 days.  At the end of 
the study, survivors were bled and serum samples γ-irradiated (5 Mrad) prior to removal 
from the BSL-4 lab for analysis. 
 
4.2.4 ELISPOT assay 
ELISPOT assays were performed using the ELISpot Mouse Set (BD Pharmingen) 
according to the manufacturer’s instructions.  Briefly, a 96-well ELISPOT plate was pre-
coated with 5 μg/ml anti-mouse IFN-γ capture antibody overnight at 4 °C.  Coated wells 
were blocked with complete Dulbecco’s Modified Eagle′s Medium (DMEM, Mediatech) 
for 2 hours at room temperature.  Cells were isolated from the spleen, bronchoalveolar 
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lavage fluid, MLNs and SMLNs as described [100], washed twice with complete DMEM 
and added to each well (5×105 cells/well) with the TELRTFSI peptide (0.5 μg/well, New 
England Peptide, Gardner, MA) that carries the Ebola Zaire glycoprotein 
immunodominant MHC class I epitope for mice with the H-2k haplotype (B10.Br) [338-
340].  Plates were placed at 37°C for 20 hours with 5% CO2. Negative control cells were 
stimulated with an irrelevant peptide, which carries a binding sequence for influenza 
hemagglutinin (YPYDVPDYA, 0.5 μg/well, GenScript, Piscataway, NJ).  Wells were 
washed twice with water to lyse cells, then washed with buffer (0.05% Tween-20 in PBS, 
pH 7.4) and subsequently incubated with biotinylated anti-mouse IFNγ antibody at a 
concentration of 2 µg/ml for 2 hours at room temperature.  Following three consecutive 
washes with buffer, wells were incubated with 5 µg/ml of horseradish peroxidase (HRP)-
conjugated streptavidin antibody for 1 hour at room temperature.  Wells were then 
washed once with buffer, once with PBS alone and developed with AEC substrate 
(Sigma).  Spots were counted using an automated ELISpot reader (CTL-ImmunoSpot® 
S5 Micro Analyzer, Cellular Technology Ltd., Shaker Heights, OH). 
 
4.2.5 Multiparameter flow cytometry 
Single cell suspensions of splenocytes were isolated from immunized mice and 
red blood cells removed by resuspending the pellet in an equal volume of ACK lysis 
buffer (Quality Biological, Inc., Gaithersburg, MD) for 2 minutes.  Cells were washed 
three times with complete DMEM, β-mercaptoethanol (50 µM, Sigma), penicillin 
(10,000 I.U./ml)/streptomycin (10,000 µg/ml) (Gibco, Invitrogen, Grand Island, NY), L-
glutamine (1mM, Hyclone, Salt Lake City, UT), 1 mM sodium pyruvate (Lonza, 
Walkersville, MD), 1 mM non-essential amino acids (Lonza).  2×106 splenocytes were 
cultured with TELRTFSI peptide (0.5 μg/well) and 1 µg/ml Brefeldin A (Sigma) for 5 
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hours at 37°C in 5% CO2.  Negative control cells were incubated with an irrelevant 
peptide (YPYDVPDYA, 0.5 μg/well).  Following stimulation, cells were surface stained 
with fluorescein isothiocyanate (FITC)-labeled anti-mouse CD8α antibodies (1:150 in 
PBS, BD Pharmingen, San Diego, CA) for 30 minutes at 4 °C and treated with Cyto-
fix/Cytoperm (BD Pharmingen) for 20 minutes at 4 °C.  For intracellular cytokine 
staining, cells were labeled with PE-labeled anti-mouse IFN-γ, PerCpCy5.5-labeled TNF-
α and APC-labeled IL-2 antibodies (1:150 in Permwash, BD Pharmingen) for 30 minutes 
at 4 °C.  Cells were washed twice and positive cells counted using four-color flow 
cytometry (FACS Fortessa, BD Biosciences, Palo Alto, CA) in The University of Texas 
at Austin Flow Cytometry Core Facility.  Over 500,000 events were captured per sample.  
Data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).   
  
4.2.6 CFSE assay 
Splenocytes were isolated 42 days post-vaccination as described [100] and stained 
using the Vybrant CFDA SE Cell Tracer kit (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol.  Briefly, mononuclear cells were extensively washed with pre-
warmed (37°C) buffer (PBS + 0.1 % BSA) and stained with 5 μM of CFDA SE for 10 
minutes at 37°C under 5% CO2.  Cells were then washed twice with complete RPMI-
1640 media (Mediatech) containing 10% FBS, penicillin (10,000 I.U./ml)/streptomycin 
(10,000 µg/ml), 1mM non-essential amino acids, 1mM sodium pyruvate and 50 µM β-
mercaptoethanol. Cells were seeded at a concentration of 5×105 cells/well in 96 well 
plates and cultured for 5 days at 37°C with 5% CO2 in the presence of the TELRTFSI or 
DAPIYTNV [200] peptide (0.5 µg/well).  Cell surface markers were identified by 
incubating cells with a cocktail of antibodies (perCPCy5.5 labeled-anti-mouse-CD8, PE 
labeled-anti-mouse-CD44, and allophycocyanin (APC) labeled-anti-mouse-CD62L, 
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1:150, BD Pharmingen).  All samples were analyzed by flow cytometry. Over 1,000,000 
events were captured per sample for these assays. 
 
4.2.7 The B Cell Response 
Anti-Ebola Zaire glycoprotein antibodies were characterized by ELISA.  Anti-
adenovirus antibodies were quantitated using an in vitro neutralization assay.  For these 
assays, animals were bled 28 (guinea pigs) or 42 (mice) days after immunization.  Serum 
was separated from whole blood by centrifugation.  All samples were heat-inactivated at 
56°C for 30 minutes and stored at -80 °C until analysis. 
4.2.7.1 Production of Recombinant Ebola Zaire Glycoprotein  
Full length Ebola Zaire glycoprotein was produced using the Zaire GP33-637ΔTM-
HA construct [355] according to published methods [356]. HEK 293T cells (70% 
confluent) were transfected with the plasmid in DMEM containing 10% FBS, 1% 
Penicillin/Streptomycin, 1mM L-glutamine and 1mM sodium pyruvate using a standard 
calcium phosphate transfection kit (Clontech, Mountain View, CA). Supernatant was 
harvested 4 days later, concentrated using a centrifugal filter device (Centricon plus-100, 
Millipore, Billerica, MA) and Ebola glycoprotein purified by anti-HA immunoaffinity 
chromatography (Roche, San Francisco, CA).  
4.2.7.2 Characterization of Ebola Zaire Glycoprotein-Specific Antibodies 
Flat bottom, Immulon 2HB plates (Fisher Scientific, Pittsburgh, PA) were coated 
with purified Zaire GP33-637ΔTM-HA (3 µg/well) in PBS (pH 7.4) overnight at 4°C.  
Plates were washed 4 times with PBS containing 0.05% Tween 20, and blocked with PBS 
 136 
containing 1% BSA (Sigma) for 1 hour at room temperature. Heat-inactivated samples 
were diluted (1:20) in PBS.  One hundred microliters of each dilution was added to 
antigen-coated plates for 2 hours at room temperature.  Plates were washed 4 times with 
PBS containing 0.05% Tween 20 and incubated with HRP-conjugated goat anti-mouse 
IgG, IgG1, IgG2a, IgG2b and IgM (1:2,000, Southern Biotechnology Associates, 
Birmingham, AL) or HRP-conjugated goat anti-guinea pig IgG, IgG1, IgG2 and IgM 
antibodies (1:2,000, Bethyl Laboratories, Inc., Montgomery, TX) in separate wells for 1 
hour at room temperature.  Plates were washed and 200 µl of substrate solution (0.4 
mg/ml o-phenylenediamine (Sigma) in 50 mM phosphate-citrate buffer, pH 5.0 with 0.03 
% (v/v) hydrogen peroxide) added to each well.  The plate was incubated at room 
temperature for 10 minutes and optical densities read at 450 nm on a microplate reader 
(Tecan USA, Research Triangle Park, NC).    
4.2.7.3 Anti-Adenovirus Serotype 5 Neutralizing Antibody  
Circulating anti-adenovirus antibody levels were assessed in samples from mice 
in which PEI was established prior to immunization as described in the literature [341].  
Heat-inactivated serum was diluted in DMEM in twofold increments starting from a 1:20 
dilution. Each dilution was mixed with adenovirus expressing β-galactosidase (1 × 106 
pfu), incubated for 1 hour at 37 °C, and applied to HeLa cells seeded in 96-well plates (1 
× 104 cells/well).  After this time, 100 µl of DMEM supplemented with 20% FBS were 
added to each well.  Cells were incubated for 24 hours and expression of β-galactosidase 
measured by histochemical staining.  Dilutions that reduced transgene expression by 50% 
were calculated using the method of Reed and Muench [357].  The absence of 
neutralization in samples containing medium only (negative control) and FBS (serum 
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control) and an average titer of 1:1,280 + 210 read from an internal positive control stock 
serum were the criteria for qualification of each assay. 
 
4.2.8 Serum Cytokines and Transaminases 
Mouse cytokines (IL-6, IL-10 and IFN-γ) were quantitated with commercially 
available ELISA kits according to the manufacturer's protocols (Invitrogen, BioSource 
International, Camarillo CA).  Serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels in mice and Guinea pigs were determined using Vitros 
AST/SGOT and ALT/SGPT DT slides on a Vitros DTSC autoanalyzer (Ortho Clinical 
Diagnostics, Rochester, NY). 
 
4.2.9 Statistical Analysis 
Data were analyzed for statistical significance using SigmaStat (Systat Software 
Inc., San Jose, CA) by performing a one-way analysis of variance (ANOVA) between 
control and experimental groups, followed by a Bonferoni/Dunn post-hoc test when 
appropriate. Differences in the raw values among treatment groups were considered 
statistically significant when p<0.05.  
 
4.3 Results 
4.3.1 Effect of formulation on the immunogenicity and protection against lethal 
challenge following oral administration of a rAd5-based Ebola vaccine 
Previously, we have shown that formulations capable of protecting rAd5-based 
vaccines from the harsh physiological conditions of the GI tract also weaken tight 
junctions and significantly improve transgene expression in the intestinal epithelia [184].  
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Under the rationalization that an increase in the expression of a vector-encoded antigen 
will strengthen the immune response against the antigen, we selected a non-ionic sugar 
based detergent (n-dodecyl-β-D-maltopyranoside, nDMPS) as a candidate excipient 
(Figure 4.1A).  In order to determine if this formulation could enhance antigen expression 
in the intestinal tract, the transduction efficiency of the formulated viruse was assessed in 
an in vitro model of the intestinal epithelium, Caco-2 cells and mice (Figure 4.1B).  
Monolayers were infected with AdGFP formulated in 100 μM nDMPS in sterile PBS 
(pH7.4) for 2 hr at 37°C (MOI: 100).  Transduction efficiency was improved from 14.75 
to 36.85% in the presence of nDMPS with respect to virus in buffer alone (w/o form.; 
Figure 4.1B).  A single oral dose of rAd5-based Ebola vaccine formulated with 100 μM 
nDMPS also significantly enhanced Zaire GP-specific IFN-γ+CD8+ T cell responses in 
B10.Br mice with respect to the unformulated vaccine (PO: 0.23%, nDMPS: 1.88%; 
Figure 4.1C).  However, nDMPS failed to elicit memory T cell populations above saline 
controls (PBS: 0.08 %, PO: 0.26%, nDMPS: 0.02%; Figure 4.1D).  Oral immunization 
with PEGylated adenovirus induced higher numbers of IFN-γ producing CD8+ T cells 
with respect to unmodified vector (Figure 4.2A).  Forty-two days after immunization, 
1.45 % of effector/effector memory CD8+ T cells (CD44HICD62LLO) in the spleens of 
mice dosed with PEGylated AdlacZ had undergone increased cell division.  This was 
significantly higher than that seen in mice given unmodified AdlacZ via oral route 
(0.26%, p<0.05, Fig. 4.2B).  These results suggest that PEGylated Ad vectors stimulate 
broad, prolonged antigen-specific CD8 T cell responses.  Based on these findings, we 
tested the protective efficacy of the PEGylated virus and that formulated with nDMPS 
after oral administration in naïve mice and those with PEI induced by the IM route.  As 
shown in Figure 4.3A and C, a single oral dose of unformulated vaccine (1×109 ivp) did 
not afford protection against lethal challenge in mice regardless of prior-exposure to 
rAd5.  In contrast, 50% of naïve mice immunized with PEGylated-Ad-CAGoptZGP 
survived upon challenge without significant loss of body weight (Figure 4.3A).   
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Figure 4.1. Formulation enhances rAd5-based vector transduction efficiency and 
effector CD8+ T cell responses.  (a) Chemical structure of n-dodecyl-β-D-
maltopyranoside: nDMPS, a non-ionic sugar-based detergent (molecular formula: 
C24H46O11, molecular weight: 510.6 Da).  (b) Representative FACS analysis of Caco-2 
cells infected with formulated AdGFP.  The vertical line in each panel demonstrates the 
difference between uninfected (peak for left) and infected cells.  (c) nDMPS increased 
antigen-specific IFN-γ+ CD8+ T cell response (PO: data from animals given unformulated 
virus).   Naïve B10.BR mice (n=3/group) were immunized with 1x109 ivp of unmodified 
or formulated rAd5-based Ebola vaccine.  For panels C & D, number in each dot plot 
denotes the percentage of Zaire GP-specific IFN-γ secreting CD8+ cells (c) and memory 
CD8+ T cell proliferation (d). 
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Figure 4.2. PEGylation improves the effector/effector memory CD8+ T cell response 
after oral administration of an rAd5-based vector.  Naïve C57/BL6 mice (n=3/group) 
were given 1x1011 vp of unmodified (PO) or PEGylated (PEG PO) AdlacZ by the oral 
route.  (a) Frequency analysis of IFN-γ producing CD8+ T cells harvested from 
splenocytes of mice (n=4/group) 10 days post immunization.  Positive cells were 
identified by intracellular cytokine staining. (b) Analysis of CD8+ T cell memory.  Cells 
positive for CD8+, CD44HI and CD62LLO were then evaluated for CFSE by 4-color flow 
cytometry.  A decrease in CFSE staining denotes cell division/expansion and response to 
antigen.  The number in each dot plot denotes the percentage of gated CFSE-negative 
cells for each subpopulation. Results are representative of two separate experiments each 
containing 4 mice per group. 
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Figure 4.3. Formulated rAd5-based Ebola vaccine candidates partially protect mice 
from lethal challenge.  Naïve B10.BR mice (n=10/group) and those with PEI to Ad5 
(n=10/group) were vaccinated with 1x109 ivp of unmodified Ad-CAGoptZGP or 
formulated vaccine via the P.O. route.  Mice were challenged with 1,000 pfu (≃30,000 x 
LD50) of mouse-adapted Zaire Ebola 28 days after immunization.  
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The nDMPS also formulation slightly improved protection (20%) with respect to the 
unmodified vaccine in naïve mice.  All preparations failed to afford protection against 
challenge in mice with PEI.  
 
4.3.2 Effect of formulation on adenovirus transduction efficiency in vitro   
Even though these oral formulation candidates did show limited success, the goal 
of this study was to develop formulations for effective immunization against Ebola when 
give across any mucosal barrier.  Thus, we screened multiple excipients for their ability 
to enhance adenoviral transduction in vitro using human lung epithelial cell lines (Calu-
3).  Selected for study fell into 3 primary categories: novel sugars and sugar derivatives 
(melezitose, raffinose), non-ionic surfactants (Pluronic F68: PF68) or absorption 
enhancers (nDMPS) to increase residence time in the nasal cavity and bioavailability by 
allowing access beyond the epithelial barrier.  A preparation of 5% w/v sucrose increased 
adenovirus transduction by a factor of 1.96 with respect to PBS control (pH 7.4, Figure 
4.4A).  Addition of other novel sugars at a raffinose or melezitose at a concentration of 
1.25% w/v, increased transduction by a factor of 1.50 and 1.34, respectively (Figure 
4.4A).  Formulations consisting of these sugars mixed in a 1:1 ratio with did not 
significantly enhance transduction (p>0.05, Figure 4.4A).  However, formulation #3 (F3), 
consisting of 1:4 ratio (10mg/ml amd 40 mg/ml) of sucrose to mannitol with 1% 
polyethylene glycol in PBS (pH 7.4) significantly increased the transduction by a factor 
of 4.84 with respect to saline control (Figure 4.4A).  The fold increase afforded by the 
formulation was higher than achieved by nDMPS (100 μM) in PBS (pH 7.4).  We next 
modified the nDMPS formulation to include the, non-ionic block co-polymer surfactant, 
PF 68 (0.005 % w/v), and mannitol (1.25% w/v) to facilitate  
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Figure 4.4 In vitro transduction efficiency of formulated adenovirus preparations 
and release profile of adenovirus in PLGA microspheres.  (A, B) Transduction 
efficiency of virus in a panel of formulations on Calu-3 cells.  Transduction of Calu-3 
cells was calculated by counting β-galactosidase expressing cells under light microscope 
after X-gal staining.  (C) Release profile of Adenovirus in PLGA microspheres.  One 
hundred milligrams of PLGA microspheres containing AdlacZ were suspended in 1ml of 
PBS at 37 °C.  At each time point, the supernatant containing released virus was collected 
by centrifugation.  The number of infectious virus particles released from microspheres 
was determined by infection in HEK293 cells.  Results are reported as the average values 
of three independent experiments. 
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transduction of Ad by increasing membrane permeability and cellular absorption.  
However, adding these excipients did not provide any additional improvement in vector 
transduction with respect to the original formulation (Figure 4.4B).  In addition, we tested 
the in vitro characteristics of adenovirus encapsulated with the bio-compatible polymer 
poly(lactic-co-glycolic acid).  Encapsulation efficiency of adenovirus in PLGA 
microspheres was 21.6 ± 4.4 % (n=3) as determined by UV Spectroscopy and an 
infectious titer assay.  Based on these values the viral concentration achieved in each 
preparation was estimated to be 1.08 × 108 virus particles of rAd5 per milligram of PLGA 
microspheres. The diameter ranged between 0.3 to 5 μm with an average 2.06 ± 1.4 μm 
as determined by dynamic light scattering.  We next determined the release profile of 
encapsulated virus from PLGA microspheres and functional integrity of the encapsulated 
virus by infecting cells with the supernatant taken at each time points.  The infectious 
virus particles were released in vitro in sterile PBS (pH 7.4) from PLGA microspheres for 
11 days, 52.5% of which occurred within the first 24 hours (Figure 4.4C).  Assuming that 
each of β-galactosidase expressing cell reflect a single infectious virus particle, 
approximately 10 % of the encapsulated virus retained the functional activity until the 
end of the study.   
  
4.3.3 In Vivo transduction efficiency of formulated adenovirus in the lung of mice 
with mucosal PEI and CD8 T cell responses against Zaire Ebola Glycoprotein 
As a result of the in vitro transduction assay and previous work done in our lab, 
we have selected three formulation candidates (F3, PLGA microspheres and PEGylated 
preparation) for in vivo performance test in naïve mice and those with PEI induced by IN 
route.  AdlacZ at a concentration of 5 × 1010 particles in each respective formulation were 
given via the intranasal route.  There was no significant difference in the β-galactosidase 
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expression in the lungs of naïve mice treated with the unformulated virus, virus placed in 
F3, PEGylated or PLGA encapsulated virus.  More importantly each formulated virus 
preparation increased transgene expression in mice with PEI to adenovirus with respect to 
unformulated virus (Figure 4.5A).  In contrast to what was observed in naïve animals, 
PEI significantly decreased the number of activated IFN-γ secreting MNCs in the spleens 
of animals given each preparation except the PEGylated vaccine (317.3 + 58.2 spot-
forming cells (SFCs)/million mononuclear cells (MNCs), naïve vs. 234.7 + 54.3 
SFCs/million MNCs, p>0.05, Figure 4.5B).  As expected, PEI significantly reduced the 
number of IFN-γ secreting cells recovered from BAL fluid in mice given unformulated 
vaccine (1,513.3 + 63.6 spot-forming cells (SFCs)/million mononuclear cells (MNCs), 
naïve vs. 526.7 + 98.2 SFCs/million MNCs, PEI, p<0.05, Figure 4.5C).  However, this 
response was not compromised by PEI in animals given PEGylated and PLGA 
encapsulated vaccines (PEGylated: 266.7 + 54.6 SFCs/ million MNCs, naïve vs. 580 + 
61.1 SFCs/million MNCs, p>0.05; PLGA MS: 1280 + 90.2 SFCs/ million MNCs, naïve 
vs. 1360 + 231.8 SFCs/million MNCs, p>0.05; Figure 4.5C).    
 
4.3.4 Different platforms of formulations alter CD8+ T cell quality responses 
A secondary objective of this study was to develop formulations that can 
reinvigorate the multifunctional CD8+ T cell response that is compromised by PEI to the 
vector.  To determine the ability of these formulations to improve the quality of the CD8 
T cell responses, functional analysis of cytokine producing CD8+ T cells at the single-cell 
level was performed for any combination of IFN-γ, IL-2 or TNF-α.  In naïve mice, the 
PLGA encapsulated vaccine produced the highest level of multifunctional CD8+ T cells 
(triple producers: IFN-γ+IL-2+TNF-α+, 30.8 + 5.04 %, Figure 4.6B).   
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Figure 4.5 Intranasal administration of formulated adenovirus significantly alters 
transgene expression and Ebola Zaire glycoprotein-specific CD8 T cell responses in 
naïve mice and those with mucosal PEI. First-generation adenovirus (AdlacZ, 5 × 1010 
virus particles) was formulated and placed in the nose of naïve C57BL/6 mice and those 
with PEI to adenovirus induced by the nasal route.  Animals were sacrificed and lung 
tissues evaluated for β-galactosidase expression by X-Gal histochemistry at day 4 (panel 
A). Ten days after immunization, lymphocytes were harvested from spleen (panel B) and 
bronchoalveolar lavage fluid (BAL, panel C) and analyzed for IFN-γ production in 
response to Ebola Zaire GP-specific peptide sequences by ELISPOT.  Results are 
reported as the mean ± the standard error of the mean and are representative of two 
separate experiments, each containing 4 mice per group. *, p<0.05, **, p<0.01, one-way 
ANOVA, Bonferroni/Dunn post-hoc analysis.
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Figure 4.6 Impact of Formulation on Zaire glycoprotein-specific multifunctional 
CD8+ T cell cytokine responses in naïve mice and those with mucosal PEI.  Ten days 
after vaccination, splenocytes were harvested, pooled according to treatment, stimulated 
with an Ebola Zaire GP-specific peptide and stained with antibodies against mouse CD8 
surface proteins and intracellular cytokines (IFN-γ, IL-2 and TNF-α).  Panel A. Boolean 
gating analysis of Zaire GP-specific CD8+ T cell populations based on polyfunctionality 
with respect to cytokine production.  Each positive cell is further evaluated with respect 
to 7 possible combinations of IFN-γ, IL-2 and TNF-α.  Data describing each specific 
population is then presented as a bar graph.  Panel B. Zaire GP-specific multifunctional 
(triple producers) CD8+ T cells are depicted as the red arc.  The blue arc highlights cells 
producing IFN-γ.  The number in the pie chart denotes the percentage of triple producers.  
Results are reported as the mean ± the standard error of the mean and are representative 
of two separate experiments, each containing 4 mice per group. 
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Mucosal PEI reduced the quality response generated by F3 (21.6 + 4.60 %, Naive vs. 
14.8 + 2.85 %, IN PEI) and PLGA encapsulated vaccine (30.8 + 5.04 %, Naive vs. 22.0 + 
7.54 %, IN PEI).  However, the response induced by PEGylated vaccine was not 
compromised (21.7 + 3.69 %, Naive vs. 26.0 + 4.74 %, IN PEI).  It is also important to 
note that the multifunctional CD8+ T cell populations generated by PEGylated or PLGA 
encapsulated vaccine in the presence of PEI induced by IN route was comparable with 
respect to those attained in Naïve/F3 group (IN PEI/PEGylated: 22.0 + 7.54 %, IN 
PEI/PLGA MS: 22.0 + 7.54 %, Naïve/F3: 21.6 + 4.60 %; Figure 4.6B).   
 
4.3.5 Effect of formulation on the generation of memory CD8+ T cell and antibody 
responses against Zaire glycoprotein and the Ad5 vector 
Generation of antigen specific memory T cells and antibody responses are crucial 
components of long-term protection against various virus/bacterial infections following 
vaccination.  In order to predict the protective efficacy of our formulated vaccine 
preparations, we evaluated the effector memory CD8 T cell response by a CFSE 
proliferation assay.  Forty-two days after immunization of naïve B10.Br mice with 
unmodified, PEGylated or PLGA encapsulated vaccine and after vaccination of those 
with mucosal PEI, splenocytes were harvested and pulsed with Zaire GP specific MHC I-
restricted peptide to test their proliferative potential.  Five days after peptide stimulation, 
samples taken from naïve mice given the unformulated vaccine contained 13.8 + 2.6% 
effector memory CD8+ T cells which had undergone proliferation in response to the 
antigenic peptide (Figure 4.7A).  This was not significantly different from that found in 
samples obtained from mice given the PLGA encapsulated vaccine (10.2 + 3.4%, p>0.05, 
Figure 4.7A).   
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Figure 4.7 PLGA encapsulated vaccine induces long-term Zaire glycoprotein-
specific memory CD8 T cell responses while suppressing production of Ad5 
neutralizing antibodies.  Panel A. Memory CD8+ T cell proliferation in response to 
Zaire GP was assessed in mice 42 days after nasal immunization.  A decrease in CFSE 
staining denotes cell division/expansion.  Panel B.  Analysis of serum anti-Ebola Zaire 
GP isotypes produced in naïve mice and those with PEI.  Panel C.  Antigen-specific 
antibody isotypes generated in BAL.  Samples were collected at the same time as those 
for Panel B.  Samples used to generate graphs in Panels D & E were collected from mice 
with 42 days after immunization.  In panels B-E, data reflect average values + the 
standard error of the mean for samples collected from eight mice per group over 2 
separate experiments.  *, p<0.05, **, p<0.01, ***, p<0.001, one-way ANOVA, 
Bonferroni/Dunn post-hoc analysis. 
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The response obtained from the PEGylated vaccine in animals with PEI was not 
statistically different from that of animals given formulated vaccine (2.42 + 1.6%, 
p>0.05, Figure 4.7A).  Although, the antigen-specific memory CD8+ T cell response was 
much lower in all animals with prior exposure to Ad, the response elicited by PLGA 
encapsulated vaccine was suppressed to a lesser degree than that observed in the other 
treatment groups (2.42 + 1.6%, Figure 4.7A).  We next characterized the anti-Zaire Ebola 
glycoprotein-specific immunoglobulin isotypes and adenovirus serotype 5-specific 
neutralizing antibody (NAB) levels in serum to characterize the impact of mucosal PEI 
on B cell-mediated immune responses (Figure 4.7B-E).  PEI significantly reduced each 
anti-Zaire GP-specific IgG isotype evaluated.  Total IgG was reduced by 70.0%.  IgG1 
was the isotype the most affected by PEI (87.4% reduced).  IgG2a and IgG2b were 
reduced by 72.3% and 26.5%, respectively (Figure 4.7B).  Interestingly, the PLGA 
encapsulated vaccine induced stronger antibody responses than the unformulated 
preparation in the presence of PEI.  Total IgG was increased by 21.7% with respect to 
unformulated preparation in this treatment group.  IgG1 and IgG2a also rose by 7.6% and 
44.9%, respectively (Figure 4.7B).  However, this formulation did not elevate Zaire GP-
specific IgG levels in BAL (Figure 4.7C).  IN administration of the unformulated vaccine 
to mice with PEI exponentially increased anti-Ad5 NAB levels from an average of 1:156 
± 28 prior to vaccination to 1:1,250 ± 300 after treatment (p<0.05, Figure 4.7D).  The 
levels of Ad5 NAB found in mice following administration of the PLGA encapsulated 
vaccine were also significantly elevated from levels found from 1:156 ± 28 prior to 
vaccination to 1:527 ± 125 after treatment (p<0.05, Figure 4.7D).  A similar trend was 
also found in BAL fluid samples (Figure 4.7E). 
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4.3.6 Effect of PLGA encapsulation on survival after lethal challenge 
To fully evaluate the utility of our encapsulated vaccine, mice with mucosal PEI 
were immunized with 1 × 108 ivp of unformulated vaccine or PLGA microspheres.  
Twenty-eight days after vaccination, mice were challenged with mouse-adapted Ebola 
Zaire.  Separate groups of naïve mice were given the same dose of unformulated vaccine 
or sterile saline and challenged in the same manner.  The challenge was uniformly lethal 
in mice given saline.  As expected, all naive mice given the unformulated vaccine 
survived without notable loss of body weight, while 60% of mice with mucosal PEI given 
the same dose of unformulated vaccine survived challenge.  The PLGA formulation 
raised the survival rate from 60% to 78% in mice with prior exposure to Ad5 (Figure 
4.8A).  Samples taken from mice given unformulated vaccine in the presence of PEI 
revealed significant elevations in ALT (916 ± 860.1 U/L) and AST (866 ± 819.4 U/L) 
from baseline (ALT: 144 ± 30.2 U/L, AST: 330 ± 102.9 U/L, Figure 4.8C).  However, 
mice given PLGA encapsulated vaccine displayed low levels of serum transaminases 
(ALT: 53 ± 12.8 U/L and AST: 55 ± 12.6 U/L, Figure 4.8C).  Samples taken from mice 
given unformulated or PLGA encapsulated vaccine during challenge did not contain 
notable amounts of serum pro-inflammatory cytokines (IL-6, IL-12, TNF-α) while 
samples from the saline control group contained significant amounts of each compound 
(Figure 4.8D). 
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Figure 4.8 Protective efficacy of PLGA encapsulated vaccine after lethal challenge 
with mouse-adapted Zaire Ebola.  Naïve mice and those with prior exposure to 
adenovirus serotype 5 (indicated by IN PEI, n=8~10) were challenged with a lethal dose 
of mouse-adapted Ebola Zaire (30,000 × LD50) by intraperitoneal injection 28 days after 
immunization with a single dose of unformulated or PLGA encapsulated Ad-
CAGoptZGP.  (A) Kaplan-Meier survival curve.  (B) Body weight profile after 
challenge.  (C) Serum amino alanine (ALT) and aspartate (AST) aminotransferase levels 
post-challenge.  (D) Serum cytokines post-challenge.  For panels c and d, data reflect 
average values + the standard error of the mean for five mice per group.  *indicates a 
significant difference with respect to the Naive/unformulated group, * p<0.05, ** p<0.01, 
***p<0.001, one-way ANOVA, Bonferroni/Dunn post-hoc analysis. 
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4.3.7 In vitro characterization of formulation #16 (F16) 
Even though the PLGA encapsulated vaccine showed promising potential in 
overcoming PEI induced by the nasal route, it could not afford 100% protection against 
lethal challenge.  Therefore, a modified in vitro screening protocol was developed for 
subsequent formulation candidates.  In this assay, formulation candidates were ranked for 
their ability to enhance adenoviral transduction in differentiated Calu-3 cells in the 
presence of various concentrations of anti-Ad5 NAB.  Freshly purified virus containing 
the green fluorescent protein expression cassette (AdGFP) at a concentration of 1.0 × 1011 
virus particles/ml was mixed with 10 mg/ml of formulation and mouse-generated anti-
Ad5 NAB stock at concentrations 0.05, 0.5, 5, and 50 times the calculated 50% 
neutralizing dose (ND50).  Forty-eight hours after infection with unformulated AdGFP, 
8.58 % of the monolayer expressed the transgene (Figure 4.9C).  Interestingly, 
formulation #16 increased virus transduction efficiency to 38.8 %.  High concentrations 
of anti-Ad5 NAB (50-ND50) significantly decreased the level of transduction of 
unformulated virus to 0.75 %.  A similar trend was noted with F16 in the presence of the 
same amount of anti-Ad5 NAB.  However, this formulation increased transduction over a 
range of anti-Ad5 NAB concentrations (F16: 5-ND50~0.05-ND50: 3.44~45.3%, vs. 
unmodified: 1.48~14.8%, Figure 4.9C).  Next, we determined if any improvement in 
transduction efficiency was the result of formulation-induced cytotoxicity.  To do this, we 
measured lactate dehydrogenase (LDH) leakage in response to the formulation 2 hrs after 
infection.  We were unable to detect any cytotoxic effects associated with formulation 
#16 even with 5 times higher concentration than that used in transduction test (50 mg/ml, 
Figure 4.9D).  
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Figure 4.9 Effect of formulation on in vitro transduction efficiency of Calu-3 cells in 
the presence of anti-Ad5 NAB.  (A) Chemical structure of core molecule of F16.  (B) 
Effect of length of side chain on transduction efficiency of AdlacZ in the presence of 
anti-Ad5 NAB.  Cells were infected with AdlacZ as described for panel A.  Positive cells 
were visualized by histochemical staining.  Unformulated and formulated virus in the 
presence of a series of anti-Ad5 NAB (0.05 - 50 ND50) concentrations were added to 
differentiated Calu-3 cells for 2hrs.  Cells were washed with sterile PBS and infection 
continued for 48 hrs.  (C) The number in each histogram denotes the percentage of GFP-
positive cells for each treatment group.  (D) Cytotoxicity of F16.  Cytotoxicity was 
evaluated by measurement of lactate dehydrogenase (LDH) released in culture medium 2 
hrs after treatment with various concentrations of F16.  
  
 155 
4.3.8 Effect of formulation #16 on the in vivo performance of our Ebola vaccine  
Mucosal PEI significantly compromised the production of Zaire GP-specific IFN-
γ-secreting mononuclear cells isolated from spleen and other mucosal compartments 
(BAL, MNLs) in mice given either unformulated or formulated vaccine (Figure 4.10A).  
As expected, mucosal PEI did significantly reduce the frequency of Zaire GP-specific 
multifunctional CD8+ T cells elicited by the unformulated vaccine (Naïve: 64.9 ± 4.88% 
vs. IN PEI: 48.6 ± 3.66%, p<0.05; Figure 4.10C).  Although PEI did reduce the 
magnitude of IFN-γ+ secreting cells in mice given the F#16 preparation, the 
multifunctional CD8+ T cell responses did not change (Naïve/unformulated: 64.9 ± 
4.88% vs. IN PEI/F16 (10 mg/ml): 60.0 ± 9.1%, p>0.05; Figure 4.10C).  The memory 
response evaluated in mice given either unformulated or formulated vaccine revealed that 
formulation #16 increased the memory response by a factor of 3.3 from 0.28 ± 0.15% 
(unformulated) to 0.93 ± 0.25% (formulation #16) (Figure 4.10D).  
 
4.3.9 Effect of formulation #16 on survival (guinea pigs) 
Several animal models have been developed to study the pathogenesis of Ebola 
virus infection.  Among these, guinea pigs and non-human primates are primary animal 
models for Ebola vaccine development because the disease progression and pathogenesis 
of virus infection most closely resembles those of the human disease [109].  Thus, we 
tested the protective efficacy of the vaccine formulated with F16 in guinea pigs.  
Importantly, to determine whether there was a dose sparing effect, we immunized the 
animals with a 10-fold lower dose than what was used in the previous mouse challenge 
studies (1×107 ivp/guinea pig).  Prior to challenge study, we evaluated serum Zaire Ebola 
glycoprotein-specific immunoglobulin isotype levels to characterize the effect of theave  
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Figure 4.10 Effect of formulation on Zaire glycoprotein-specific CD8 T cell 
responses in mice with prior to exposure to adenovirus.  Panels A-C.  Effector CD8 T 
cell responses.  Ten days after vaccination, mononuclear cells from various tissues were 
harvested, pooled according to treatment, stimulated with an Ebola Zaire GP-specific 
peptide and measured by ELISPOT (panel A) and intracellular cytokine staining (panels 
B, C). The number in the pie chart denotes the percentage of triple producers.  Panel D. 
Memory CD8 T cell responses.  Memory CD8 T cell proliferation to Zaire GP was 
assessed in mice immunized with formulated Ad-CAGoptZGP by IN route 42 days after 
treatment.  A decrease in CFSE staining denotes cell division/expansion.   Data reflect 
average values + the standard error of the mean for four mice per group.  *indicates a 
significant difference with respect to the Naive/unformulated group, * p<0.05, ** p<0.01, 
one-way ANOVA, Bonferroni/Dunn post-hoc analysis. 
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formulation on B cell-mediated antibody responses in this animal model.  PEI 
significantly compromised anti-Zaire GP-specific IgG isotypes and IgM in levels with 
respect to the levels attained in naïve animals given unformulated vaccine.  Total IgG, 
IgG1, IgG2 and IgM were reduced by 95.8%, 97.8%, 88.7% and 99.4%, respectively, 
compared to the vaccine given to naïve guinea pigs (Figure 4.11A).  Formulation #16 
increased the antigen-specific antibody responses with respect to the PLGA encapsulated 
vaccine.  Total IgG, IgG1, IgG2 and IgM were increased by 12.6%, 8.9%, 16.7% and 
21.1%, respectively (Figure 4.11A).  We next evaluated the protective efficacy of 
formulation #16 in guinea pigs with mucosal PEI.  Naïve guinea pigs and those with 
mucosal PEI were vaccinated with unformulated, formulation #16 or PLGA encapsulated 
vaccines by the IN route.  Animals were challenged with a lethal dose of guinea pig-
adapted Ebola Zaire 28 days after vaccination.  Complete protection was achieved in the 
group of naïve guinea pigs given unformulated vaccine without notable loss of body 
weight (Figure 4.11B, C).  Mucosal PEI did significantly compromise the efficacy of the 
unformulated vaccine when given by the same route as there were no survivors in this 
treatment group (IN PEI/unformulated, Figure 4.11B).  PLGA encapsulated vaccine had 
no beneficial effect on survival at a low immunization dose but, formulation #16 did 
increase the survival from 0% (IN PEI/unformulated or PLGA MS) to 20% (Figure 
4.11B).  Samples taken from guinea pigs with PEI post-challenge did contain elevated 
serum AST (IN PEI/unformulated: 2192 ± 726.3 U/L, IN PEI/PLGA MS: 879 ± 197 U/L, 
IN PEI/F16: 1119 ± 277.9 U/L) with respect to naïve animals (74.4.75 ± 13.78 U/L), 
indicative of severe liver damage from Zaire Ebola infection (Figure 4.11D).  
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Figure 4.11 Protective efficacy of formulated vaccine following IN administration in 
guinea pigs with mucosal PEI.  Naive guinea pigs and those with prior exposure to 
adenovirus serotype 5 via the nasal route (indicated by IN PEI, n = 5) were challenged 
with a lethal dose of 1,000 pfu guinea pig-adapted Ebola Zaire (1,000 × LD50) by 
intraperitoneal injection.  (A) Samples from individual guinea pigs were evaluated for the 
presence of ZGP-specific IgG subclasses and IgM by ELISA (OD at 450 nm).  (B) 
Kaplan–Meier survival curve.  (C) Body weight profile after challenge.  (D) Serum 
alanine (ALT) and aspartate (AST) aminotransferase levels post-challenge.  Data reflect 
average values ± the standard error of the mean for five mice per group. * indicates a 
significant difference with respect to the Naive/unformulated group. *, p < 0.05, **, p < 
0.01, ***, p < 0.001, one-way ANOVA, Bonferroni/Dunn post hoc analysis.   
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4.4 Discussion 
Development of effective vaccines against Ebola is a difficult task not only due to 
the lethality of the virus, but also due to the fact that testing any vaccine on humans is 
impossible.  In addition, outbreaks remain quite unpredictable which prevents 
identification of a specific high-risk population to be targeted for a clinical efficacy trial.  
Therefore, according to the “Three Animal Rule”, potential vaccine candidates must be 
tested in at least 3 different animal models of Ebola infection prior to clinical testing.  
Data from these models must provide a clear indication of measurable predictive markers 
that strongly correlate with survival before an Ebola vaccine can enter the clinic.  
Therefore, potential vaccine candidates must be tested in these animal models of EBOV 
infection to provide sufficient data to indicate measurable predictive markers that 
correlate with survival [60, 98].  To date, vaccines derived from recombinant adenovirus 
serotype 5 (rAd5) expressing Zaire Ebola virus glycoprotein have been highly efficacious 
in mice, guinea pigs and non-human primates with only a single dose [100, 101, 108, 
339].  However none of these Ad-based platforms have been completely effective in 
models of PEI [348].  We have previously shown that immunization with a rAd5-Ebola 
vaccine by the same route in which PEI is induced, significantly reduces the antigen-
specific multifunctional CD8+ T cell response and antibody production and promotes 
anti-vector immunity.  This finding prompted us to adopt the hypothesis that 
reinvigoration these responses would significantly improve vaccine potency in those with 
prior exposure to Ad5. Therefore, the primary objective of these studies was to develop 
formulations for recombinant rAd5-based vaccines that could promote strong immune 
responses against the encoded Ebola Zaire glycoprotein while minimizing the immune 
response to the viral vector.   
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Previous work in our laboratory demonstrated that formulations consisting of 
pharmaceutically acceptable excipients could enhance the physical stability, absorption of 
virus and substantially increase adenoviral transduction efficiency to the lung epithelium 
with minimal toxicity [225, 345].  In the present study, we attempted to improve the 
immunogenicity of the adenovirus-based vaccine by protecting it from neutralization by 
anti-Ad5 NAB by encapsulating the virus in Polyethylene glycol or PLGA.  We also tried 
to improve transduction efficiency and antigen expression by adding absorption 
enhancers to the final preparation.  The mucosal T cell response induced by the 
PEGylated and the PLGA encapsulated preparations was not compromised by PEI 
induced by the nasal route.  In addition, formulations significantly blunted anti-vector 
immunity.  These data support the notion that shielding of virus capsid proteins facilitates 
the immune response against the encoded antigen by preventing neutralization.  Despite 
the fact that the memory T cell response induced by these preparations were not 
compromised by PEI, protection was incomplete.  This suggests that additional studies in 
which the PEGylation chemistry and density on our adenovirus-based vaccine is 
optimized are necessary.  The size and surface chemistry of PLGA microspheres must 
also be adjusted to enhance immune responses for complete protection.   
Interestingly, the immune response generated by formulation #16 fulfills two 
important requirements that we originally aimed to achieve.  This formulation restored 
the antigen-specific multifunctional CD8+ T cell and antibody responses compromised by 
PEI.  Although this formulation protected only 20% of immunized animals, it is 
important to note that the amount of vaccine used for the challenge study was a 10-fold 
lower dose than what was used in the previous mouse challenge studies [100].  Currently, 
we are testing the protective efficacy of higher vaccine doses formulated with F16 to 
identify an optimal preparation that affords complete protection.  Formulation #16 
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consists of an amphiphilic polymer with alternating hydrophilic and hydrophobic side 
chains.  A series of compounds that differed by length of molecule in an in vitro study, 
only this compound significantly increased the in vitro transduction efficiency without 
causing cytotoxicity (Figure 4.9).  To our knowledge, this is the first report to incorporate 
this type of compound in an rAd5-based vaccine.  The exact mechanism how this 
formulation enhances transduction efficiency in the presence of anti-Ad5 NAB is not 
completely understood.  Amphiphilic polymers have been widely used for solubilizing 
integral membrane proteins and delivering biomolecules across lipid bilayers of the cell 
membrane [362-365].  Unlike detergent-based micelles, the polymer forms a belt around 
the trans-membrane domain of proteins in the cell membrane.  At neutral pH, the overall 
surface charge of the polymer is highly positive, which allows immobilization of 
negatively charged biomolecules and promotes interaction with the negatively charged 
cell surface [366].  Even though these characteristics of the polymer partly explain the 
enhanced transduction efficiency of rAd5-based vector formulated in F16, additional 
studies are required to further determine whether this polymer prevents anti-Ad5 NAB 
binding to the vector, or how this formulation reinvigorate the antigen-specific adaptive 
immune responses through enhanced interaction with antigen-presenting cells.   
Optimization of the immunogenicity of viral vectors for vaccine applications is an 
important research priority.  Elucidating the contribution of innate immunity to 
adenovirus to the overall, potency of rAd-based vaccines could potentially assist in the 
rational design of improved vectors and adjuvants.  There have been few reports 
describing methods to improve the immunogenicity of rAd-based vaccines.  Combining 
alum with rAd35 elicited improved antibody responses to a malaria antigen [358].  The 
addition of toll like receptor (TLR) 9 agonists (CpGs) paradoxically diminished immune 
responses elicited by a rAd5 vector but improved protection against a cancer antigen 
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[359].  Most recently, Appledorn et al. reported enhanced antigen-specific T lymphocyte 
responses with the co-administration of a rAd vector engineered to express a novel TLR5 
agonist in mice [360].  It is important to note that none of these reports examined the 
utility of these novel adjuvants in any model of PEI and failed to evaluate how these 
agents affected anti-Ad5 immunity.  Addition of TLR ligands to activate the innate 
immune system is an agreeable approach in animals/humans without prior exposure to 
the vector.  However, these approaches have strong possibility to enhance 
immunogenicity towards the vector itself not the vector-encoded transgene.  Therefore, 
these types approaches were excluded in this study.  
In summary, we have identified novel excipient that substantially augments the 
transduction efficiency, immunogenicity and protective efficacy of rAd5-based Ebola 
vaccine.  Although it failed to achieve complete protection in its present format, this 
opens up a new possibility that formulations consisting of pharmaceutically acceptable 
ingredients can prime multiple-arms of the immune response and can increase protective 
efficacy upon lethal challenge with Zaire Ebola virus in animals with mucosal PEI. 
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CHAPTER FIVE 
CONCLUSION 
The primary focus of this project was to develop a safe and effective recombinant 
adenovirus serotype 5 (rAd5)-based mucosal vaccine for Zaire Ebola infection that can 
override the effects of pre-existing immunity (PEI) to the vector.  Experiments were 
designed to test the hypothesis that non-traditional methods of mucosal immunization and 
development of formulations that strengthen certain arms of the immune response 
compromised by prior exposure to adenovirus will greatly enhance the potency of rAd5-
based vaccines.  Mucosal administration of rAd vaccines can significantly reduce 
widespread systemic vector-induced toxicity observed after intramuscular (IM) injection 
of the vaccine.  Despite this benefit, mucosal administration of rAd-based vaccines is 
currently under-developed due to the relatively low T cell-mediated immune responses 
generated against the encoded antigen.  In the studies described in this document, I have 
shown that sublingual administration of the vaccine induces rapid migration of MHCII+, 
CD11c+, antigen-presenting cells to the delivery site and elicits antigen-specific T and B 
cell-mediated immune responses in naïve mice and those with PEI to rAd5 at a level 
higher than that achieved by oral immunization.  Ebola challenge studies revealed that a 
single sublingual (SL) dose of the vaccine is sufficient to protect naïve animals from 
lethal Ebola infection in a manner similar to the vaccine given by the traditional IM route.  
More importantly, this strategy improved protection of animals with PEI to Ad in contrast 
to poor protection after IM injection.  Unlike other vaccine platforms currently under 
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development for Ebola, SL delivery minimizes medical waste associated with 
immunization and promotes rapid self-administration in outbreak situations.  However, 
incomplete survival upon EBOV challenge in rodents strongly suggests that further 
studies with the emphasis in the development of formulations that improve transduction 
efficiency of rAd5-based EBOV vaccine across the sublingual mucosa and strengthen 
immunogenicity of the vector are needed to improve the utility of this novel 
immunization method.      
Early studies to evaluate methods to bypass the effects of adenovirus PEI for gene 
delivery and vaccine applications established PEI in various animal models with a single 
IM injection of an irrelevant rAd 30 days prior to administration of the therapeutic vector.  
It has been argued that since Ad is a respiratory pathogen, IM injection of the virus may 
not accurately induce immune responses similar to those associated with natural 
infection.  To address this issue, in the second phase of my research, I established a 
method of PEI induction (intranasal administration: IN) and compared immunological 
parameters of this approach with the standard IM protocol.  When the vaccine was given 
by the same route in which PEI was induced, the antigen-specific multi-functional CD8+ 
T cell cytokine and antibody responses were significantly compromised.  This correlated 
with poor survival after challenge with a lethal dose of Ebola Zaire in rodents.  The 
studies outlined here allowed us to make two conclusions before developing formulations 
to improve vaccine potency in those with PEI to Ad, a) establishment of PEI by the same 
route used for immunization is the most stringent test for a novel formulation designed to 
be effective in those with PEI, b) for a formulation for an Ebola vaccine to be effective in 
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those with PEI, it must be capable of restoring antigen-specific multi-functional CD8+ T 
cell and antibody responses, both compromised by PEI. 
The last phase of this project involved screening formulation candidates that 
could protect the virus from neutralization and enhance transgene expression in a manner 
that induces potent immune responses in naïve animals and those with PEI.  Numerous 
reports have suggested strategies to circumvent PEI by creating novel vectors from rare 
adenovirus (Ad) serotypes, genetic modification of capsid proteins and mucosal 
immunization protocols.  Although each of these could induce significantly more antigen 
expression than unmodified vector alone in those with pre-existing immunity (PEI), the 
overall immunogenicity of these vaccines is low.  Therefore, identification of alternative 
strategies to improve the performance of rAd5-based vaccines in those with PEI is of 
importance for continued clinical utility of this otherwise potent vaccine candidate.  Here 
we provide the first evidence that data generated by in vitro assays that evaluated the 
ability of a formulation to improve transduction efficiency of airway epithelial cells 
(Calu-3) in the presence of anti-Ad5 NAB generally correlate with in vivo performance of 
the formulated vaccine.  Formulations consisting of pharmaceutically acceptable, non-
immunogenic excipients that do not have overt adjuvant properties or toxic profiles can 
facilitate priming of multiple arms of the immune responses by increasing the uptake and 
processing of rAd vectors.  Additional studies are currently in progress to determine if 
these results are applicable to non-human primates.  Encouraging preliminary results 
suggest that additional studies to modify formulation candidates to improve 
immunogenicity of our vaccine in terms of the antibody response can afford complete 
protection upon lethal challenge with EBOV.  
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APPENDIX 
Method for gating/data analysis of flow cytometry data 
 
 
 
Figure A. 1 General study design for in vivo CTL assay (A) and gating strategies for 
data generated from isolated splenocytes (B, C).  A detailed procedure for this assay 
can be found on page 59 in Chapter 2 and in the material and method section of reference 
100.  Note: Single cell populations isolated from various tissue compartments do not 
require surface or intracellular cytokine staining for this assay.  In order to obtain reliable 
results, at least 1,000,000 total events should be captured per sample. 
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A detailed description of experimental method for this assay can be found in the 
Croyle lab protocol binder titled “In vivo CTL Assay protocol” (prepared by Ross 
T. Phan) 
 
Gating strategies: You should always have unstained, CFSEhigh and CFSElow cells 
before you run samples from immunized animals for correct adjustment of 
fluorescent intensity. 
 
1. Open FlowJo program and load the data by dragging raw data files to the 
program, more detailed about for this program can be found: 
(http://www.flowjo.com/home/tutorials). 
2. Double click on data from a control sample (this is a sample that contains a 1:1 
ratio of CFSEhigh and CFSElow stained cells).  A light scattering plot under 
parameters forward-scattered light (FSC-H, x-axis) and side-scattered light (SSC-
H, y-axis) much like that in the first panel of Figure A1.B will show up in a new 
window.  
3. Click the gate tool in the program and define the lymphocyte population under 
study be marking it as shown in panel B in the Figure A1.  If you are not sure how 
to gate the lymphocyte population correctly, you can use the auto-gate tool in the 
program.  Note: To identify and gate the correct populations, samples should be 
run under appropriate fluorescent intensities.  If you ran samples under incorrect 
fluorescent intensities, you can edit the intensities using compensation function on 
the FlowJo program, however this is not recommended since it may skew the 
results by losing the real populations.  
4. Once you have properly identified the cell population under study, double click 
on the newly gated lymphocyte population.  A new light scattering plot will show 
up in a separate window.   
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5. Select “FL-1 (CFSE)” for the x-axis and “histogram” for the y-axis parameters, 
respectively.  
6. Gate CFSEhigh and CFSElow populations using gate tools and apply the CFSEhigh 
and CFSElow gate to all samples.  If you mix the cells to 1:1 ratio for adaptive 
transfer the percentage of each CFSEhigh and CFSElow populations should be 50 %.  
Also, the sum of both populations should be 100%.  Note: Always gate these 
populations with a sample that contains a 1:1 ratio of CFSEhigh and CFSElow 
stained cells and apply these gates to all samples.  If you move the gate for some 
reason, apply the new gates to all samples.  
7. Lastly, perform the following calculations to determine the lysis of CFSEhigh 
population: 
o Percent lysis = [1 – (ratio control mice/ratio vaccinated mice)] × 100  
o Ratio = percent CFSElow/percent CFSEhigh. 
 
Example (Data from Figure A1.C) 
Ratio control mice : 50.97 %/49.03 % = 1.0396 
Ratio vaccinated mice : 86.38 %/13.62 % = 6.3421 
Percent lysis of Naïve/IM group: [1 – (1.0396/6.3421)] × 100 = 83.607 % 
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Figure A.2 Gating strategy for antigen-specific CD8+ T cell quality analysis.  A 
detailed procedure for this assay can be found on page 92 in the materials and methods 
section of Chapter 3, material and method section.  A gating tree first identifies CD8+ T 
cells based on the fluorescence staining of surface marker CD8.  Within the CD8+ T cell 
population, the subset of cells that express each functional marker (for example, IFN-γ, 
TNF-α and IL-2) is entered into a Boolean gating analysis that separately identifies the 
seven subsets that express each possible combination of functions.  The frequency of 
each functional subset within the Zaire GP-specific CD8+ T cell population is shown in 
the bar chart; the representation can also be shown as a fraction of the total response in a 
pie chart.  Over 500,000 total events should be captured per sample for this assay.  
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A detailed description of the experiment method for this assay can be found in the 
Croyle lab protocol binder under the title “T cell assay staining - for FACS” 
(prepared by Ross T. Phan) 
Gating strategies: You should always have unstained cells before you run samples 
from immunized animals for correct adjustment of fluorescent intensities. 
1. Open FlowJo program and load the data by dragging raw data files to the 
program. 
2. First, open control sample that contains unstained splenocytes obtained from 
animals given saline by double clicking the data on the FlowJo program.  A light 
scattering plot under parameters forward-scattered light (FSC-H, x-axis) and side-
scattered light (SSC-H, y-axis) much like that in the first panel of Figure A2 will 
show up in a new window. 
3. Using the gate tool in the program and draw a line around the cell population as 
shown in gate lymphocyte population with the highest cell density in the light 
scattering plot as shown in Figure A2 (red/yellow, lymphocytes).  If you are not 
sure how to gate the lymphocyte population correctly, use the auto-gate tool in the 
program and adjust the gate size to encompass all of the red/yellow populations.  
Note: The red/yellow area in the light scattering plot represents the high-density 
monocytes.  
4. Once you are satisfied that you have correctly identified the population you want 
to study, double click on the newly gated lymphocyte population.  A new scatter 
plot with the same axis as above will show up in a separate window.   
5. In this new plot, select “FL-1” (anti-mouse-CD8-FITC) for x-axis and 
“histogram” for y-axis parameters, respectively.  Change the x-axis label to CD8+ 
cells.  Note: Analysis of using unstained cells allows you to easily identify CD8 
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negative or positive populations in the newly gated lymphocyte population as 
seen in Figure A2.    
6. To determine the number of IFN-γ producing CD8+ T cells in population, double 
click the CD8+ T cell populations and select FL-1 for the x-axis (anti-mouse CD8-
FITC) and FL-2 for the y-axis (anti-mouse IFN-γ-PE) parameters, respectively.  
As shown in Figure A2, the number in top right in the quadrant (Q2) represents 
IFN-γ secreting CD8+ T cells.  Change the label of Q2 to read IFN-γ+ cells.  Note: 
If you just want to analyze the of IFN-γ producing CD8+ T cell responses from 
vaccinated animals, then, apply the gate parameters to all samples and report the 
results.  However, if you want to analyze the multifunctional CD8+ T cell 
responses go to the next step. 
7. To determine the number of TNF-α producing CD8+ T cells in population, change 
the y-axis parameter from FL-2 (anti-mouse IFN-γ-PE) to FL-3 (anti-mouse TNF-
α-PerCP-Cy5.5).  Now, the number in top right in the quadrant (Q6) represents 
the percentage of TNF-α secreting CD8+ T cells.  Change the label of Q6 to read 
TNF-α + cells.  Note: It is very important that these parameters should not change 
by opening new scatter plots as was done in steps 2 to 4.  Failure to do so will 
result in inability to process Boolean gate analysis.    
8. To identify IL-2 producing CD8+ T cells in the population, change the y-axis 
parameter from FL-3 (anti-TNF-α-PerCP-Cy5.5) to FL-4 (anti-mouse IL-2-APC).  
The number in top right in the quadrant (Q10) now represents IL-2 secreting 
CD8+ T cells in the population.  Change the label of Q 10 to read IL-2 + cells.   
9. To identify the number of triple producers in a sample, highlight each gate labeled 
to IFN-γ+ (Q2), TNF-α+ (Q6) and IL-2+ (Q10) within a single sample by and click 
on the Boolean gate icon located in the workspace ribbon.    
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10. To identify single, double and triple producers in each sample, select combination 
gates using AND and NOT logic selections in the FlowJo program.  You should 
have total eight combinations based on the percentage of cytokine expression in 
CD8+ T cells as follows: 1) IFN-γ+ TNF-α+IL-2+ (triple producers), 2) IFN-
γ+TNF-α-IL-2+, 3) IFN-γ+TNF-α+IL-2-, 4) IFN-γ-TNF-α+IL-2+, 5) IFN-γ+TNF-α-
IL-2-, 6) IFN-γ-TNF-α+IL-2-, 7) IFN-γ-TNF-α-IL-2+ and 8) IFN-γ-TNF-α-IL-2-. 
11. Select all gate parameters that you have generated in steps 1 to 10, including 
combination gates, and apply to all samples.  Note: This type of data analysis 
generates large files and it may take a while to get this job done.  
12. Export the data to a spread sheet in Excel and rearrange the data as follows 
(Figure A2.B): 
1) Triple producers: IFN-γ+ TNF-α+IL-2+ 
2) Dual producers: IFN-γ+TNF-α+IL-2-, IFN-γ+TNF-α-IL-2+, IFN-γ-TNF-α+IL-2+ 
3) Single producers: IFN-γ+TNF-α-IL-2-, IFN-γ-TNF-α+IL-2-, IFN-γ-TNF-α-IL-2+ 
13. Plot the data in two different formats (bar graph, pie graph) using Kaleidagraph 
software.  Note: Bar graph shows the absolute number of the positive cells 
present in each population.  The pie graph shows the percentage of each 
individual population as part of the whole population under study.    
 
 
 173 
 
 
Figure A.3 General gating strategy for CD8+ T cell proliferation assay (CFSE 
dilution assay).  A detailed procedure for this assay can be found on page 58 in Chapter 
2 and in the material and method section of reference 100.  Negative controls (CFSE 
stained cells without TELRTFSI peptide stimulation, CFSE stained cells with irrelevant 
peptide i.e. YPYDVPDYA and unstained cells without peptide stimulation) should be 
included in the analysis of each sample. At least 1,000,000 total events should be 
captured per sample for this assay.   Note: It is also important to note that since this assay 
does not require a cytoperm/fixation step, they must be run right after antibody staining.  
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A detailed description of the experimental method for this assay can be found in the 
Croyle lab protocol binder under the title “T cell Memory (CFSE) Assay” (prepared 
by Ross T. Phan) 
Gating strategies: 
1. Open FlowJo program and load the data by dragging raw data files to the 
program. 
2. Double click to open data obtained from a sample that contains unstained 
splenocytes (CFSE-ve) from animals given saline.  A light scattering plot under 
parameters forward-scattered light (FSC-H, x-axis) and side-scattered light (SSC-
H, y-axis) much like that in the first panel of Figure A3 will show up in a new 
window. 
3. Using the gate tool in the program and draw a line around the cell population as 
shown in gate lymphocyte population with the highest cell density in the light 
scattering plot as shown in Figure A3 (red/yellow, lymphocytes).  If you are not 
sure how to gate the lymphocyte population correctly, use the auto-gate tool in the 
program and adjust the gate size to encompass all of the red/yellow populations.  
Note: The red/yellow area in the light scattering plot represents the high-density 
monocytes.  
4. Select FL-3 (anti-mouse-CD8-PerCP-Cy5.5) for the x-axis and histogram for the 
y-axis parameters, respectively.  Change the label of the x-axis to CD8+ cells as 
shown in panel B (Figure A3).  Note: using unstained cells you can gate CD8 
negative populations in the lymphocyte.    
5. Once you are satisfied that you have correctly identified the population you want 
to study, double click on the newly gated lymphocyte population.  A new scatter 
plot with the same axis as above will show up in a separate window.   
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6. In this new plot, select “FL-2” for x-axis (anti-mouse CD44-PE) and “FL-4” for 
y-axis (anti-mouse CD62L-APC) parameters, respectively.  Then, apply these 
gated parameters to each sample.  As shown in Panel C (Figure A3), the number 
in bottom right of quadrant (Q3) on the panel C represents the percentage of 
CD44HICD62LLoCD8+ T cells in the population under study.  Change the label to 
effector/effector memory CD8+ T cells to provide a figure for presentation and 
publication. 
7. Gate the entire Q3 population as seen Panel C (Figure A3) and generate a new 
scatter plot by double clicking on the newly selected population.  Change the y-
axis parameter to “FL-1 (CFSE)” and x-axis to forward-scattered light (FSC-H). 
8. Select the cluster of cells located right below the major CFSE population (Q5) 
The number in the gated area (Q5) represents the percentage of effector/effector 
memory CD8+ T cells that have proliferated in response to antigen.   
9. Select all gate parameters and apply to all samples for analysis. 
10. Plot the data (bar graph) using Kaleidagraph software.  Note: Bar graph shows the 
absolute number of the proliferated effector/effector memory CD8+ T cells present 
in each population.  
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